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Blood-brain barrier (BBB) dysfunction is an early feature of several central nervous 
system (CNS) pathologies and is characterised by increased leukocyte migration to the 
CNS and increased paracellular permeability of brain endothelial cells (BECs). The 
mechanisms by which the BBB actively participates in the inflammatory events that 
contribute to the progression of many CNS diseases is still poorly understood. 
Extracellular vesicles (EVs) are a novel mechanism of cell-to-cell communication. 
Endothelial cell-derived EVs are upregulated in circulating blood in different pathologies 
(e.g. multiple sclerosis) and systemic inflammation. TNFα-stimulated BECs secrete a 
higher number of EVs, which carry a pro-inflammatory cargo. However, the role of 
cerebrovascular EVs modulating inflammation at the BBB is still unclear. 
In this project, EVs secreted from BECs were characterised based on number, size and 
RNA cargo. Indeed, BECs secreted higher number of EVs in inflammation that carried 
pro-inflammatory modulators (e.g. miRNA-155). Uptake of EVs by NVU cells and their 
role in BEC function was investigated. Interestingly, EVs decreased transendothelial 
resistance and increased T cell adhesion to BECs via up-regulation of adhesion molecules.  
TNFα/IFNγ–mediated BECs dysfunction is partially modulated by miRNA-155. 
However, the mechanism by which miRNA-155 modulates T cell adhesion remains to be 
elucidated. WNK1 was identified as possible target of miRNA-155 and shown to 
modulate T cell adhesion.  
Finally, unexpected increased polydipsia in female aged miRNA-155 knock-out mice was 




Results from this work constitute the first evidence that BEC-derived EVs modulate BBB 
function in inflammation, which is likely to be a mechanism of the cells to amplify pro-
inflammatory cytokine signalling in the vasculature. Additionally, this work has 
demonstrated endothelial WNK1 as a modulator of T cell adhesion. Genotyping tissue 
from miRNA-155 KO mice will serve for future identification of novel modulators of 
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CHAPTER 1: Introduction 
 
1.1. Clinical significance of brain barriers research 
 
The central nervous system (CNS) is highly protected from changes in the 
systemic blood circulation due to the presence of the brain barriers. There are different 
types of brain barriers that differ in their location, cellular origin and function (Redzic, 
2011). In addition to the blood-brain barrier (BBB), which is associated with the 
endothelium, there is the blood-cerebrospinal fluid (CSF) barrier (BCSFB), which is 
located on the choroid plexus epithelial cells (Table 1.1.) (Redzic, 2011). Lastly, the 
arachnoid barrier is a tight barrier located at the subarachnoid space (Weller et al., 2018). 
The brain barriers contribute to the fine modulation of the CNS microenviroment. These 
barriers form different types of tight junctions between cells to create a physical barrier 
and prevent the passive diffusion of molecules into the CNS (Table 1.1). Furthermore, 
specific expression of membrane proteins (e.g. specific solute carriers) contribute to the 
metabolic function of the CNS barriers by selectively exchanging the nutrients needed by 
the CNS and removing the waste. Finally, the CNS barriers also express a series of protein 
transporters (e.g. ATP-binding cassette (ABC) transporters) to exclude the entrance of 









Table 1.1. Physical and molecular characteristics between the blood-brain barrier 
and the blood-CSF barrier 
 
 Blood-Brain Barrier Blood-CSF Barrier Reference 
Location Brain Microvessel Choroid Plexus 
epithelial cells 
(Abbott, Adjanie A.K. 
Patabendige, et al., 2010) 
Physical barrier  
TEER 1500 Ω cm2 
 (pial vessels) 
150 Ω cm2 
(bull frog fourth 
CP) 
(Crone and Christensen, 
1981; Saito and Wright, 
1984) 
Tight Junctions  
Ocluddin Yes Yes (Redzic, 2011) 
JAMs A, -B, -C Yes Yes (Redzic, 2011) 
Claudins 3, 5, 12 1,2, 3, 11 (Wolburg et al., 2001; 
Redzic, 2011) 





(Williams et al., 2005; 
Redzic, 2011) 
Catenins α, β, χ, ρ120 α, β (Lippoldt et al., 2000; 




GLUT1 Yes Yes (Redzic, 2011) 
Aminoacid transporter  
LAT1 Yes Yes (Redzic, 2011) 





MCT MTC1, MTC7, MTC8 MTC1, MTC8 (Leino, Gerhart and 
Drewes, 1999; Enerson 
and Drewes, 2006; Roberts 
et al., 2008) 
Synthesis of TTR No Yes (Power et al., 2000; 
Redzic, 2011) 
ABC-transporters  




(Gazzin et al., 2008; 
Redzic, 2011) 
Mrp1 + +++ (Gazzin et al., 2008; 
Redzic, 2011) 
Ion Transporters  
NKCC1 Blood-facing side CSF-facing side (Redzic, 2011) 
    
 
Abbreviations: CSF, cerebrospinal fluid; TEER, transendothelial resistance; JAM, 
junctional adhesion molecules; GLU1, glucose transporter 1; LAT1, system-L amino acid 
transporter 1; EAAT1, excitatory amino acid transporters; MCT, proton-linked 
monocarboxylate transporters; TTR, transthyretin; ABC, ATP-binding cassette; P-gp, P-
glycoproteins; Mrp1, multidrug resistance-related protein; NKCC1, Na+-K+-2Cl-- 




Dysfunction of the brain barriers is associated with cerebrovascular diseases, 
which includes a range of pathologies that affect the blood vessels of the brain. The most 
common examples of disorders affecting the vasculature are ischemic and haemorrhagic 
strokes (Ferrer and Vidal, 2018). However, the pathogenesis of other types of 
neurological disorders is strongly affected by the vasculature, which includes diseases 
such as Multiple Sclerosis (MS) or Alzheimer´s disease (Minagar and Alexander, 2003; 
Kalaria, 2018).  For this reason, investigating the function of the cerebral vasculature and 
the contribution of the brain barriers in disease is of utmost importance to further 
understand unmet clinical goals in these neurological disorders. In particular, this project 
focuses specifically on investigating the BBB in disease and the remainder of the sections 
in the Introduction will be focused on this barrier. 
 
1.2. The Blood-Brain barrier as a component of the neurovascular unit 
 
The cerebral vasculature is a complex and specialised structure, whose length if 
unfolded has been estimated to be around 600 to 700 km (Begley and Brightman, 2003). 
The vasculature tree is composed of arteries, arterioles, capillaries, venules and veins 
(Abbott et al., 2018). The brain vasculature is initially formed by the penetration of 
arteries that originate in the Circle of Willis into the brain through the subarachnoid space. 
A progressive decrease of the vessel lumen of the penetrating arteries leads to the 
formation of arterioles (lumen diameter ranges from 10 to 100 µm). As penetrating 
arterioles branch into the brain parenchyma, their lumen diameter further decreases to 
form capillaries (lumen diameter ranges from 5 to 10 µm). Blood returns to the heart 
along post-capillary venules (up to 100 µm of lumen diameter) that feed into the veins 
that are situated on the surface of the brain (Figure 1.1) (Abbott et al., 2018). As described 
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in the previous section, the cerebral endothelium presents barrier properties that varies 
along the vascular tree. The BBB was a classical term used to refer to an endothelial 
centred barrier. Nowadays, it is clear that the BBB is an active structure influenced by the 
action of vascular-associated cells such as pericytes and CNS cells including astrocytes, 
microglia or neurons (Keaney and Campbell, 2015). This new concept of interactive BBB 
is known as the neurovascular unit (NVU). In the next section, the historical research into 
the BBB will be discussed to understand the experiments that marked the beginning of 
brain research in the CNS.  
 
1.3. Historical overview of the blood-brain barrier  
The first evidence of brain barriers was published in the late 1800s. In 1885, Paul 
Ehrilch observed that aniline dyes injected into the peritoneum of rats failed to stain the 
brain, which was attributed to differences in dye affinity to specific tissues (Ehrlich, 1885; 
Ribatti et al., 2006). His student, Edwin Goldmann extended these findings by injecting 
trypan blue (molecular weight, MW, 960 KDa) directly into the CSF or the peripheral 
bloodstream (Goldmann, 1909, 1913; Ribatti et al., 2006). He observed that dye injected 
into the CSF only stained the CNS whereas peripheral administration of trypan blue 
excluded the whole brain except from the chorus plexus and the pineal gland suggesting 
the presence of a barrier between the brain and the periphery. 
The presence of a physical barrier and the concept of “blood-brain barrier” was 
first hypothesised by Max Lewandowsky (1876-1918) after he demonstrated that 
intravenous injection of sodium ferrocyanide or cholic acids had no pharmaceutical effect 
in the CNS whereas cerebro-ventrical injection did (Lewandwsky, 1909; Ribatti et al., 
2006). Further data supporting the hypothesis of a physical barrier between the brain and 
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the blood was provided by Lina Stern (1878-1968), who observed that intravenous 
injection of anti-tetanus failed to protect the brain after the pathogen had already reached 
the CNS (Stern and Gautier, 1921; Ribatti et al., 2006). 
Advances in electron microscopy (EM) techniques enabled scientists to examine 
ultrastructural brain morphology (Ribatti et al., 2006). Using this technique, Reese and 
Karnovsky showed for the first time that the endothelium in mouse cerebral capillaries 
constituted a physical barrier to peroxidase extravasation (Reese and Karnovsky, 1967).  
The authors described the presence of specific and highly expressed tight junctions in 
brain endothelial cells (BECs) when compared to other endothelia (e.g. blood vessels of 
the skeletal muscle). The presence of tight junctions between brain endothelium greatly 
limits the paracellular flux of solutes and leads to the formation of polarised cells with 
distinct luminal and abluminal membrane compartments (Obermeier, Verma and 
Ransohoff, 2016).  
Later research developed the understanding of the influence of other CNS cell 
types on modulating BBB function (Janzer and Raff, 1987; Hayashi et al., 1997; 
Pardridge, 1999). However, it was not until 2001 when the first Stroke Progress Review 
Group meeting of the National Institute of Neurological Disorders and Stroke of the 
National Institutes of Health took place, that the concept of the NVU was emphasised 
(Iadecola, 2017). Traditionally, scientists had considered CNS and vascular cells as 
distinct entities, but the view of the scientific community evolved into an interactive 
relationship between CNS-resident cells and vascular cells, which is known now as the 
NVU. One evidence of this change on perspective is the exponential increased on 





1.4. Composition of the neurovascular unit 
The composition of the NVU varies significantly across the cerebrovascular 
network (Figure 1.1).  Morphologically, pial arterioles are larger vessels whose 
endothelium is separated from several layers of smooth muscle cells (SMCs) by a 
prominent elastic basal lamina (Figure 1.1). Functionally, pial arterioles are surrounded 
by perivascular nerves, which play an important role in controlling vessel contraction and 
blood flow (Iadecola, 2017). Pial arterioles branch into smaller arterioles that penetrate 
the brain parenchyma. In comparison to pial arterioles, penetrating arterioles are 
composed by a thinner layer of SMCs. Penetrating arterioles are surrounded by the 
perivascular space which contains perivascular macrophages, pial cells, and mast cells 
among others, as well as nerve and collagen fibres (Figure 1.1.). Emerging data suggest 
that the perivascular space contributes to the immune surveillance of the CNS as well as 
a waste clearance (Abbott et al., 2018). When arterioles penetrate deeper into the brain, 
the perivascular space is minimised. These intra-parenchyma arterioles are characterised 
by having a single or discontinuous layer of SMCs and they are surrounded by astrocyte 
end-feet.  Finally, cerebral capillaries are characterised by the presence of pericytes, 
which replaces SMCs, covering approximately 30% of the endothelial cells surface. 




Figure 2.1. Schematic representation of the neurovascular unit at the different 
parts of the cerebrovascular network. The neurovascular unit changes across the 
vascular tree: 1) pial arteriole, 2) penetrating arterioles, 3) intra-parenchymal arteriole 
and 4) capillary. Abbreviations: PVM, perivascular macrophage; SMC, smooth muscle 
cell. Image adapted from (Iadecola, 2017) 
 
Understanding the characteristics of the NVU cellular components as well as their 
inter-cellular interactions is a highly attractive topic in the field of vascular biology both 
in physiology and pathology. In this project, there will be a special focus on the NVU in 
brain microvessels, with specific focus given to the endothelium at the capillary level. 
 
1.4.1. Astrocytes 
Astrocytes are polarised glial cells, whose morphology varies depending of their 
location and association with other cell types (Reichenbach and Wolburg, 2013). 
Astrocytes are known to interact between blood vessels and neighbouring cells. Indeed, 
astrocyte-end feet is shown to surround the microvessel wall and express high levels of 
specialised proteins that are relevant for the induction of BBB properties (Abbott, 
Rönnbäck and Hansson, 2006). 
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Strong in vitro data have demonstrated that astrocytes are necessary to promote 
the BBB phenotype on BECs. Indeed, astrocytes can induce the formation of tight 
junctions in BECs, hence increasing their trans-endothelial resistance (TEER) (for a 
review see (Abbott, 2002)). Mechanistically, astrocytes are able to secrete specific soluble 
factors which include transforming growth factor-β (TGFβ), glial-derived  neurotrophic  
factor (GDFN) or basic  fibroblast growth factor (bFGF) among others (Abbott, 
Rönnbäck and Hansson, 2006). These factors have already been demonstrated to promote 
BBB tightness. For instance, supplementation of BEC culture media with GDFN resulted 
in a dose-dependent increase of the endothelial TEER (Igarashi et al., 1999). 
Astrocyte-end feet contain high levels of specific proteins such as Aquaporin 4 
(AQP4), dystroclycan and dystrophin (Tait et al., 2008; Keaney and Campbell, 2015). 
The complex dystroglycan-dystrophin interacts with agrin to facilitate anchoring of the 
astrocyte-end feet to the vascular basal membrane. Agrin is located in brain microvessels 
and its expression is increased in areas of BBB tightening (Abbott, Rönnbäck and 
Hansson, 2006; Obermeier, Verma and Ransohoff, 2016).  
Astrocytes act as an interface between neurons and blood vessels by releasing 
signals to control blood flow in response to neuronal changes. Therefore, astrocytes can 
modulate the contraction and dilation of SMCs on larger arterioles and pericytes in 
capillaries.  Indeed, it has been shown that astrocytes can detect the level of glutamate-
dependent synaptic activity, then signal to adjacent cerebral vessels, causing vasodilation 






Pericytes are specialised perivascular cells with mesodermal origin and are located 
within the capillary wall. Pericytes are embedded via integrins within a basal membrane 
(BM) shared with BEC. Furthermore, pericytes´ elongated processes cover the capillary 
walls (Winkler, Bell and Zlokovic, 2011). Interestingly, the CNS vasculature presents a 
higher pericyte coverage than peripheral organs. Indeed, pericytes are present in the 
microvessels at a 1:3 ratio with respect to BECs (Shepro and Morel, 1993). Endothelial 
cell to pericytes ratio is reported to be lower in other vascular beds such as that in liver 
(10:1) or skeletal muscle (100:1) (Zhang et al., 2020). Occasionally, pericytes and BECs 
show also direct contact via the formation of peg-and-socket structures containing cell-
to-cell junction and gap proteins, structures that are considered to contribute to the 
transfer of nutrients, metabolites, secondary messengers and ions between the two cell 
types (Bobbie et al., 2010; Winkler, Bell and Zlokovic, 2011) 
Pericyte recruitment to endothelium during development is a critical step for 
vessel formation and involves different signalling pathways such as platelet-derived 
growth factor B (PDGF-B) and TGF-β (Winkler, Bell and Zlokovic, 2011). Different 
studies have shown that homozygous deletion of Pdgfb gene or some genes involved in 
TGF-β signalling were embryonic lethal in mice and resulted in a loss of CNS pericytes 
(Levéen et al., 1994; Gaengel et al., 2009; Bell et al., 2010). In adulthood, pericytes are 
also critical in regulating BBB integrity and this has been demonstrated using mouse 
models with deletions in the pdgf-B signalling. For instance, aged pericyte-deficient mice 
show reduced levels of important endothelial tight junctions such as occludin and claudin-
5 (Bell et al., 2010). 
It is suggested that pericytes are also important for processing toxic cellular 
compounds. Indeed, deposition of blood-borne macromolecules (e.g. fibrin or plasmin) 
29 
 
is considered to be responsible for the BBB breakdown and CNS impairment shown in 
aged pericyte-deficient mice (Chen and Strickland, 1997; Paul, Strickland and Melchor, 
2007; Winkler et al., 2012).  
Pericytes are contractile cells, which can modulate the blood flow and capillary 
diameter. Recent studies have shown that pericytes express receptors for vasoactive 
mediators such as endothelin-1, angiotensin II or vasopressin (Winkler, Bell and 
Zlokovic, 2011). This is in accordance with an organotypic slice study where stimulation 
with different neurotransmitters resulted in dilation and contraction of pericytes (Peppiatt 
et al., 2006). However, validation of these results in vivo is controversial and need further 
investigation (Bell et al., 2010; Fernández-Klett et al., 2010).  
Research into pericyte biology is still needed as there are other pericyte functions 
that are not well understood such as their involvement in T cell transmigration to the CNS 
(Zachariah and Cyster, 2010). Pericytes and BECs share a common BM and the secretion 
of extracellular matrix (ECM) proteins as well as metalloproteinases might play an 
important role in T cell transmigration. 
 
1.4.3. Basal or basement membrane 
The BM is an extracellular structure composed by a multitude of ECM proteins 
the main types being collagen type IV, nidogen, laminin and heparan sulfate 
proteoglycans (HSPGs). In the brain, the BM is mainly associated with blood vessels and 
both number and localisation of BMs is dependent on the associated vessel type (Figure 
1.1) (Lecrux and Hamel, 2011). Larger arterioles present several layers of BM between 
SMCs whereas the BM of capillaries is thinner. Capillary BMs are classified into two 
different types of BMs: an endothelial BM and a parenchymal BM. BECs are the primary 
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source for ECM proteins for the endothelial BM, whereas astrocytes secrete most of the 
ECM proteins comprising the parenchymal BM (Table 1.2). These two membranes are 
observed to be physically separated by pericytes but appear as one BM in areas with no 
pericytes (Yao, 2019).  
Table 1.2. List of the source of several laminin isoforms and their location in 
the endothelial and/or parenchymal BM. 
 Astrocytes Endothelial Cells Pericytes 
Endothelial BM - Laminin-411 and -
511 
Laminin α4 and α5 
Parenchymal BM Laminin-211 - Laminin α4 and α5 
 
Abbreviations: BM, basal membrane  
 
In physiology, the BM serves as a supporting structure for the NVU cells and 
facilitates the assembly of the different components (Xu, Nirwane and Yao, 2019). Under 
pathological conditions, the BM is considered to act as a physical barrier to protect the 
CNS from the peripheral circulation. This function is supported by the experimental 
measurement of the migration of T cells into the CNS. Interestingly, the time for T cell 
migration across endothelium is shorter than the time needed to cross the BM 
(Bartholomäus et al., 2009; Yao, 2019). Furthermore, the cells of the NVU express 
specific receptors that can be activated by the ECM proteins composing the BM. Genetic 
deletion of ECM receptors or ECM proteins in animal models have demonstrated how 
important these proteins are for BBB integrity (Chen et al., 2013; Nirwane and Yao, 2019; 
Yao, 2019). Furthermore, changes in ECM proteins have been observed in both 
haemorrhagic and ischemic stroke (Yao, 2019). 
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1.4.4. Brain endothelial cells 
BECs are the main cellular component of the cerebral blood vessels. For arteries 
and venules, dozens of BECs may attach to form the vessel lumen, whereas a single BEC 
is sufficient to cover the lumen for capillaries (Aird, 2007). BECs are organised 
continuously across the capillary whereas other peripheral endothelial cells might be 
fenestrated or form a discontinuous layer too. Indeed, BECs are typically morphologically 
different from endothelial cells of other peripheral organs (Table 1.3) (Potente and 
Mäkinen, 2017). For instance, transmission EM (TEM) experiments reported that BECs 
have a lower number of pinocytotic vesicles. Indeed, BECs have a low rate of 
transcytosis, which results in a reduced vesicle-mediated transport of molecules 
(Obermeier, Verma and Ransohoff, 2016). Furthermore, the number and volume of 
mitochondria is higher in BECs than other endothelial cells, which suggest BECs have an 
increased metabolic activity.  
Table 1.3. Organ-specific characteristics of endothelial cells. 
Type of EC Location Organisation Enriched Molecular 
Markers 
Reference 
BBB ECs CNS Continuous MFSD2A GLUT1, 
SLC7A5, others 
(Ben-Zvi et al., 2014; 




Heart Continuous CD36, LPL, PPARγ (Potente and Mäkinen, 2017) 
Liver 
sinusoidal ECs 





Kidney Fenestrated ND (Aird, 2007; Potente and 
Mäkinen, 2017) 
 
Abbreviations:  EC, endothelial cells; Mol., molecular; BBB, Blood-brain barrier; 
CNS, central nervous system; MFSD2A, sodium-dependent lysophosphatidylcholine 
symporter 1; GLUT1, glucose transporter 1; ; SLC7A5, solute carrier family 7 member 
5; PL, lipoprotein lipase; PPARγ, peroxisome proliferator-activated receptor-γ; ; HGF, 




One of the most characteristic functions of BEC monolayers is the formation of a 
physical barrier that prevents the passive diffusion of larger molecules into the CNS via 
the arrangement of specialised tight junctions (TJs) (Figure 1.2). The TJ complex 
contributes to limit the diffusion of polar solutes through the paracellular space as well as 
preventing larger macromolecules from penetrating into the brain. Tight junctional 
proteins are classified into claudins, occludin and junctional adhesion molecules (JAM) 
(Abbott, Adjanie A.K. Patabendige, et al., 2010). 
 Claudins are essential proteins for the formation of the tight junctions and there are 
at least 24 different claudins (Redzic, 2011). These proteins are composed by four 
membrane-spanning regions, two extracellular loops and two cytoplasmic domains, a 
short N-terminal sequence and a long C-terminal sequence. BECs highly express 
claudin-5 but also claudin-3 and claudin-12 (Redzic, 2011). Indeed, genetic ablation 
of claudin-5 resulted in brain damage causing early death in a murine model (Nitta et 
al., 2003).   
 Occludin is a protein responsible for sealing the tight junctions thereby leading to 
high TEER between the blood and the CNS parenchyma (Bamforth et al., 1999; Li et 
al., 2005). This protein is formed by two extracellular loops, four trans-membrane 
domains and three cytoplasmic domains; the cytoplasmic domains include one 
intracellular short turn, N-terminal domain and a 150 amino-acids long carboxyl (C-
) -terminal domain (Redzic, 2011). This latest domain is associated with zonula 
occludens proteins (ZO-1, ZO-2 and ZO-3), a set of regulatory proteins that anchor 
occludin to the cytoskeleton (Li et al., 2005). 
 JAMs are members of the immunoglobulin-like family and include JAM-A, B and C 
in BECs (Redzic, 2011). These proteins have a membrane-spanning domain, an 
extracellular domain, an extracellular N-terminus and a cytoplasmic C-terminus. 
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JAMs form homophilic and heterophilic interactions with other JAMs at the 
intracellular junction of BECs to contribute to the structure of tight junctions (Bazzoni 
et al., 2000; Redzic, 2011).  
BECs also form adherens junctions to support a tight endothelial monolayer. 
This complex is formed by cadherins and associated proteins into which actin filaments 
are linked (Redzic, 2011). Vascular endothelial (VE) cadherin (cadherin-5) and cadherin-
10 are the two main cadherins expressed in BECs. However, recent evidence suggests 
cadherin-10 is highly expressed in BECs with BBB properties whereas VE-cadherin 
expression is subtler. Indeed, VE-cadherin, but not cadherin-10, was highly expressed in 
microvessels with loose BBB properties isolated from glioblastoma (Williams et al., 
2005).  Cadherins associate with a series of catenins, proteins that include β, α, χ and p120 
at the BBB, which are believed to associate with actin filaments to support endothelial 




Figure 1.2. Structure of brain endothelial cell tight junctions. Tight junctional 
proteins include occludin and claudins (mostly 3 and 5). These proteins are linked to 
scaffolding proteins zonula occludens (ZO-1, ZO-2 and ZO-3), which are associated to 
the actin cytoskeleton. Junctional adhesion molecules (JAMs) are believed to contribute 
to leukocyte cell-adhesion. Adherens junctions are crucial for the formation of tight 
junctions. Drawn by David Roig via adaptation from Abbott, Adjanie A K Patabendige, 
et al., 2010 
 
Apart from the formation of tight junctions and adherens junctions to prevent the 
passive diffusion of solutes into the CNS, BECs also express specific transporters on the 
luminal side, some facilitating the passage of their substrates onto the brain parenchyma 
whereas other transporters function as neuroprotective and detoxifying barriers to blood-
borne agents (Mahringer and Fricker, 2016). These latter proteins are known as ABC 
transporters and are composed by a large superfamily of membrane proteins of 
approximately 48 different types. BECs are known to predominately express P-
glycoprotein (P-gp) but also multidrug resistance-related proteins MRPs and the breast 
cancer resistance protein (BCRP) (Redzic, 2011). Although these transporters play a 
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protective role in physiology, treatment of CNS disorders is limited due to the exclusion 
of many therapeutic molecules by ABC transporters (Mahringer and Fricker, 2016). 
To accommodate the nutritional needs of the CNS, BECs express specific and 
high levels of membrane proteins such as specific solute carriers to transport ions, nutrient 
and macromolecules to the CNS (Redzic, 2011). Indeed, BECs highly express the 
ubiquitous glucose transporter 1 (GLUT-1) to efficiently provide glucose to the CNS 
cells. Indeed, a transcriptomic study on the rat BBB showed GLUT-1 as one of the most 
abundant transcripts in the brain microvessels (Enerson and Drewes, 2006). 
Genetic and epigenetic modifications leading to changes in the function of the 
NVU as discussed above have been associated with a multitude of neurological disorders. 
In the next section, the implications of BBB dysfunction in CNS pathologies will be 
addressed. 
 
1.5. The blood-brain barrier as a central feature in neurological 
disorders 
Growing evidence suggest that the loss of BBB normal function is a key step in the 
development and progression of several CNS disorders (Daneman, 2012). This BBB 
dysfunction is predominantly characterised by the loss of BBB integrity (e.g. BBB 
breakdown or increased paracellular permeability) (Jiang et al., 2018) or the increased of 
immune cell extravasation into the CNS (Lopes Pinheiro et al., 2016). Other phenotypes 
might include effects on membrane transporter function or expression (e.g. GLUT-1 
deficiency) or loss of pericytes. However, the causes and consequences of the disruption 
in the BBB are poorly understood, although knowledge of the contribution of the BBB to 
the pathogenesis of neurodegenerative disorders appears to differ widely (Table 1.4). 




Table 1.4. List of characteristics involved in blood-brain barrier dysfunction in 
three different neurodegenerative disorders. 





Genetic Mutations* APP, PSEN1, PSEN2, 
APOE, SOR1 etc 












(Fibrin in developing 
lesions) 
RBC extravasation Yes Yes ND 
Reduced tight 
juntions proteins 




Loss of pericytes Yes (confirmed by EM 
and IHC) 




Yes (GLUT1, LRP1) Possibly LRP1  






Yes Yes Yes 
Pro-inflammatory 
cytokines 
Yes (IL-1, IL-6,TNFα) Yes (IL-1, IL-6, TNFα, 
TGF-β) 
Yes (IL-17,IL-22, IL-1, 
IL-12, TNFα, IFNy) 
References (Horwood and Davies, 
1994; Deane et al., 
2004; Cullen, Kócsi 
and Stone, 2005; 
Zipser et al., 2007; 
Cortes-Canteli et al., 
2010; Su, Bai and 
Zhang, 2016; Sweeney 
et al., 2019) 
(Sui et al., 2014; Gray 
and Woulfe, 2015; 
Pienaar et al., 2015; 
Alam et al., 2016; Lee 
et al., 2019; Sweeney 
et al., 2019) 
(Kirk et al., 2003; 
Cramer et al., 2015; 
Lopes Pinheiro et al., 
2016; Wang et al., 
2018; Rivera, 
Hinrichsen and Silva, 
2019; Sweeney et al., 
2019) 
 
*Detection of inherited genetic mutations with associated cerebrovascular pathology 
within the specific neurodegenerative disorder 
Abbreviations: CNS, central nervous system; BBB, blood-brain barrier; RBC, red-
blood cell; EC, endothelial cells; BM, basal membrane; APP, PSEN1, PSEN2, APOE, 
SOR IRRK2, MDR1; IgG, inmunoglobin G; EM, electron microscopy; IHC, 
immunohistochemistry; GLUT1, glucose transporter 1; IL-, interleukin; TNFα, tumour 





1.5.1. Loss of BBB integrity in CNS pathologies 
As summarised in Table 1.4, the loss of integrity of the BBB is a common feature 
of neurodegenerative disorders, including Alzheimer’s disease (Zlokovic, 2005), MS 
(Minagar and Alexander, 2003), Parkinson’s disease (Cabezas et al., 2014) but also acute 
neurological pathologies such as stroke or traumatic brain injury (Sweeney et al., 2019). 
Indeed, BBB disruption is critical for assessing the outcome of both ischemic and 
haemorrhagic stroke (Jiang et al., 2018). Increased permeability and disruption of TJs 
promote the extravasation of blood-borne molecules and cells to the brain (Jiang et al., 
2018). For instance, Knowland and colleagues observed decreased endothelial occludin 
and ZO-1 staining in a mouse model of stroke, and this deregulated expression correlated 
with parenchymal depositions of IgG (Knowland et al., 2014).  
This vascular “leakiness” observed in BBB dysfunction can be exacerbated by 
pro-inflammatory CNS modulators such a tumour necrosis factor alpha (TNFα) in MS, 
lipopolysaccharide (LPS) in systemic infection or β-amyloid in Alzheimer’s disease, 
which can alter the formation or/and organization of TJ proteins, thereby increasing 
paracellular permeability (Varatharaj and Galea, 2017). Indeed, the organisation of 
occludin appears discontinuous in MS lesions when compared to normal appearing white 
matter (NAWM). Additionally, loss of BBB integrity exacerbates infiltration by 








1.5.2. Leukocyte transmigration into the brain in CNS pathologies 
As described above, inflammation induced either locally or via systemic cytokines 
and chemokines, is a principal component of many neurodegenerative conditions. For 
example, analysis of post-mortem MS tissue revealed CNS-immune infiltrates as well as 
BBB disruption as an early feature of MS (Alvarez, Cayrol and Prat, 2011).  Although 
most studies in MS have researched BBB alterations after immune infiltration, growing 
evidence suggests that there is an earlier immune cell-independent disruption of the BBB. 
In fact, conversion of optic neuritis to MS has been predicted according to the state of the 
general BBB disruption in the CNS (Cramer et al., 2015). In the following paragraph, the 
mechanism of migration of immune cells into the CNS and the importance of the BBB in 
this process will be discussed. 
During neuroinflammation, peripheral immune cells are able to cross the BBB and 
enter into the brain parenchyma following a multistep process (Figure 1.3.) (Lopes 
Pinheiro et al., 2016). For example, experimental autoimmune encephalomyelitis (EAE) 
in mice (a widely accepted model for demyelinating diseases) develops only after immune 
cells enter the CNS (Engelhardt and Ransohoff, 2012), whereas no clinical signs develop 
if immune cells are only detected in the perivascular or leptomeningeal spaces (Toft-




Figure 1.3 Cascade of steps for lymphocyte diapedesis to brain parenchyma. 
Transendothelial migration of lymphocytes is a multistep process that involves capture, 
rolling, activation, adhesion and crawling of the leukocyte. Then, leukocyte might 
migrate either across the brain endothelial cells (BECs), transcellular diapedesis, or 
between BECs, paracellular diapedesis. Once in the basal membrane (BM), leukocytes 
need to cross both the BM and astrocytes to enter to the brain. Figure drawn by David 
Roig-Carles. 
 
Before blood-derived leukocytes migrate into the brain, it is hypothesised that a 
first wave of immune cells reach the CNS via the choroid plexus, although the molecular 
mechanisms are poorly understood (for a review see Lopes Pinheiro et al., 2016). After 
overcoming the BCSFB, these immune cells can release pro-inflammatory mediators 
such as cytokines, which can diffuse into the brain parenchyma and activate the brain 
endothelium thereby facilitating the entry of blood-derived leukocyte into the CNS as a 
second wave of immune cell migration. These events promote the formation of 
inflammatory lesions typically observed in MS (Raine CS1, Cannella B, Duijvestijn AM, 
1990; Reboldi et al., 2009b). 
Blood-derived leukocyte migration into the brain is a specialised and multistep 
process that involve the rolling, capture, activation, arrest, crawling and finally diapedesis 
across the brain endothelium (Engelhardt and Ransohoff, 2012) (Figure 1.4.). The process 
of leukocyte migration across brain endothelium is tightly controlled by the expression 
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and release of specific proteins from both endothelial cells and leukocytes (Muller, 2011) 
(Table 1.5).  
 
Table 1.5. Proteins involved in the process of transmigration of leukocytes 
into the brain and their cell of origin. 







































Abbreviations: ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular 
cell adhesion molecules 1; ICAM-2, intercellular adhesion molecule 2; JAM-A, 
junctional adhesion molecule A; PECAM, platelet endothelial cell adhesion molecule; 
VE-cadherin, vascular endothelial cadherin; ESAM; endothelial cell-selective adhesion 
molecule; PSGL1, P-selectin glycoprotein 1; LFA-1, lymphocyte function-associated 
antigen1; very late activation antigen 4; MAC-1, macrophage-1 antigen. 
 
 
 Capture & rolling. When a neuro-antigen-specific T cell crosses one of the brain 
barriers and recognise its specific antigen on the antigen-presenting cells (APCs), it 
will initiate the inflammatory cascade responsible for the expression of inflammatory 
mediators that will support the rolling and capture of immune cells (Bartholomäus et 
al., 2009). Mechanistically, up-regulation of endothelial molecules of the selectin 
family interact with leukocyte-expressing selectin-ligand proteins, such as P-selectin 
glycoprotein ligand-1 (PSGL-1) to facilitate T cell tethering and rolling (Battistini, 
2003). Indeed, PSGL-1 expression is increased in CD4+ T cells in MS when 
compared to healthy donor’s cells (Bahbouhi et al., 2009). PSGL-1-mediated T cell 
interactions promote leukocyte tethering, slowing the movement of leukocyte along 
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the vascular wall and promoting them to roll onto the endothelium (Engelhardt and 
Ransohoff, 2012).  
 
 Activation. Brain endothelia release chemokines that can bind to lymphocytes and 
activate them. In EAE, encephalitogenic T cell adhesion to brain meningeal 
microvessels is dependent on G protein-coupled receptor (GPCR) signalling. 
Therefore, chemokines or eicosanoids need to be up-regulated in order to enhance T 
cell adhesion to BEC. The concentration of chemokines CCL19 and CCL21 are 
increased in the cerebral endothelium of EAE mice, thus mediating firm Th1 adhesion 
to frozen section of brain microvessels in situ (Alt, Laschinger and Engelhardt, 2002). 
However, many other chemokines and their respective receptors have been proposed 
to mediate lymphocyte adhesion to brain microvessels (McCandless et al., 2006; 
Shulman et al., 2012). 
  
 Adhesion. Chemokine activation is also important because it promotes clustering of 
leukocyte integrins as well as conformational changes in the integrin proteins that 
increase their affinity and avidity for ligands on brain endothelium (Engelhardt and 
Ransohoff, 2012). Integrin activation is a crucial step for lymphocyte arrest to CNS 
microvessels, which occurs at the post-capillary venule. Increased levels of integrin 
α4β1 (VLA-4) and αLβ2 (LFA-1) ligands, vascular cell adhesion molecule 1 
(VCAM1) and intercellular cell adhesion molecule -1 (ICAM1) respectively, are 
found to be up-regulated in the endothelium of the BBB as well as in the BCSFB in 
EAE (Engelhardt and Ransohoff, 2012). LFA-1 positive cells are observed to locate 
and accumulate on ICAM1+ venules of MS and EAE tissue samples, whereas VLA-
4+ cells not always are found to accumulate in MS lesions but they do in EAE samples 
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(Sobel, Mitchell and Fondren, 1990; Peterson et al., 2002). Additionally, VCAM1 
and ICAM1 role in modulating T cell adhesion to inflamed endothelium has been 
extensively proven in vitro using both static and flow-based assays (Steiner et al., 
2010).  
 
 Crawling. Sophisticated in vitro time lapse imaging techniques in a system that 
include shear stress and primary mouse endothelial cell showed ICAM1/2-LFA-1 was 
the only interaction needed for T cells to polarize and crawl across the endothelium 
(Steiner et al., 2010). T cells can crawl against the flow in order to find an optimal 
site for diapedesis. Crawling long distances is also a unique characteristic to CNS 
endothelium, since it has been shown that leukocytes crawl significantly lower 
distances on peripheral endothelium compared to CNS endothelium (Engelhardt and 
Ransohoff, 2012).  
 
 Diapedesis. In the absence of ICAM1 and ICAM2, fewer T cells migrate across the 
endothelium (Steiner et al., 2010). These results suggested that T cell diapedesis may 
be both dependent and independent of ICAM1/2-mediated crawling. In peripheral 
tissues, T cells prefer to migrate via a paracellular route, which involves crossing 
between endothelial junctions. Because the TJs of the BECs are tighter and more 
complex than those in the periphery, transcellular diapedesis is hypothesised to be the 
preferential route of lymphocyte entry into the brain because this does not require TJ 
opening and re-sealing (Engelhardt and Ransohoff, 2012). The route of T cell entry is 
dependent on ICAM1 levels. ICAM1-deficient endothelial cells lead to paracellular 
diapedesis whereas high levels of ICAM1 result in transcellular diapedesis across a 
pore formed in a single endothelial cell (Steiner et al., 2010; Engelhardt and 
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Ransohoff, 2012). Recently evidence suggest that activated leukocyte cell adhesion 
molecule (ALCAM) also plays a role in leukocyte extravasation (Cayrol et al., 2008). 
ALCAM can form homophile interactions between endothelial and leukocyte-
expressing ALCAM (Marchetti and Engelhardt, 2020). Recently, Engelhardt´s group 
demonstrated ALCAM play a lesser role in T cell transmigration and shown antibody-
inhibition of ALCAM reduced CD4+ Th1 but not Th17 under unstimulated condition. 
No effect was observed under inflammatory conditions. In contract, it was observed 
inhibition of ALCAM highly affected the different steps of monocyte extravasation 
(arrest, adhesion, crawling and diapedesis) in vitro (Lyck et al., 2017). These 
processes are still poorly understood and more research is needed to elucidate which 
molecules decide the fate of the leukocytes. 
 
 Migration across the BM. Finally, T cells migrate through the endothelial basal 
membrane. It has been shown that leukocytes prefer to cross in areas of basal 
membrane where there is laminin isoform α4 and little or none of laminin α5 (Wu et 
al., 2009). Metalloproteinases (MMPs) are endopeptidases whose function is to 
degrade different proteins of the extracellular matrix (Cui, Hu and Khalil, 2017). 
MMPs are constitutively expressed or induced by pro-inflammatory cytokines and 
chemokines in leukocytes and CNS-resident cells. In EAE, it was shown that CD4+ 
T cell migrating to the brain parenchyma required of focal activation of MMP2 and 
MMP9 (Agrawal et al., 2006). Mechanistically, MMP2 and MMP9 has been shown 
to cleave dystroglycan, an astrocyte-feet-specific receptor, to facilitate leukocyte 
infiltration through the parenchymal BM (Agrawal et al., 2006). Chemokines are 
substrates of MMPs and help to activate and modify the extracellular environment to 
enhance T cell transmigration into the brain (Engelhardt and Ransohoff, 2012). 
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Furthermore, disruption of the BM has been linked to NVU dysfunction resulting in 
an increase of leukocyte extravasation to the brain parenchyma, which is a main 
hallmark of many neuroinflammatory pathologies (Obermeier, Verma and Ransohoff, 
2016). 
 
As described in the sections above, pro-inflammatory modulators can induce the 
activation of BECs that lead to different aspects of BBB dysfunction. Activated 
signalling pathways affect gene expression via canonical routes (e.g. transcription 
factors) or non-canonical routes, which may include epigenetic changes (Wei et al., 
2017). In the next section, the definition and role of non-coding RNAs (ncRNAs) in 
modulating BBB function in inflammation will be discussed. 
 
1.6. Non-coding RNAs and cell function 
 
Sequencing of the human genome revealed that although two thirds of the genome 
is transcribed, less than 2% encodes for regions of protein-coding genes (Djebali et al., 
2012). Part of that “extra DNA” plays an important role in the maintenance of DNA 
structures as well as modulating the expression of messenger RNA (mRNA) (e.g. 
promoters, transcription binding sites and enhancer regions) (Wang and Chang, 2011). 
However, the rest of non-coding DNA was traditionally considered “junk DNA”. For the 
past two decades, many studies have showed evidence that a significant proportion of this 
“junk DNA” is transcribed into ncRNAs. Therefore, currently, it is estimated that around 
80% of the genome is functional and that 62% is transcribed into ncRNAs. NcRNAs can 
be classified as housekeeping and regulatory ncRNAs. This last subtype can further be 
divided based on their size including long ncRNA (lncRNAs) (>200 nucleotides) or short 
ncRNA (<200 nucleotides) (Matera, Terns and Terns, 2007). Short ncRNAs include small 
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inhibitory RNAs (siRNAs), P-element Induced WImpy testis (PIWI)-interacting RNAs 
(piRNAs) and microRNAs (miRNAs) (for a review see (Wei et al., 2017)).  
MiRNAs have widely been described to regulate cell function both in physiology 
and pathology. In fact, many miRNAs are deregulated in disease, hence, understanding 
miRNAs is a promising approach for novel therapeutic target development. This project 
will focus in miRNAs and a more extensive description is given in the following sections. 
 
1.7. Discovery and definition of miRNAs 
MiRNAs are highly conserved, small ncRNA oligonucleotides of 20-25 
nucleotides in length that influence gene expression by post-transcriptional regulation at 
the mRNA level (R W Carthew and Sontheimer, 2009). Although miRNAs constitute a 
novel field of research, the discovery of the first miRNA, lin-4, was achieved in 1993 by 
two independent groups studying the nematode Caenorhabditis elegans (C. elegans) 
(Lee, Feinbaum and Ambros, 1993; Wightman, Ha and Ruvkun, 1993). A few years later, 
another miRNA, let-7, was identified in C. elegans (Pasquinelli et al., 2000; Reinhart et 
al., 2000). However, the concept of miRNAs was not fully addressed until the early 
2000s, when three independent research groups contributed to define miRNAs as a novel 
and abundant group of gene expression regulators (Lagos-Quintana et al., 2001; Lau et 
al., 2001; Lee and Ambros, 2001). From those early discoveries up to today, the field of 
miRNAs has grown exponentially.  
According to the miRNA database (miRbase, www.mirbase.org) more than 2,500 
miRNAs have been annotated in the human genome (release March 2018) (Kozomara, 
Birgaoanu and Griffiths-Jones, 2019). MiRNAs play a crucial role in regulating many 
physiological functions, which include cell cycle, cell development, differentiation and 
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apoptosis as well as contributing to the progression and regulation of diseases in various 
model organisms and in humans (Friedman and Jones, 2009). 
 
1.8. MicroRNA biogenesis  
 
In humans, miRNA genes are defined to be either intergenic (between two genes) 
and/or within genes, currently described as either intronic or exonic (Griffiths-Jones et 
al., 2006). The majority of miRNAs follow a similar canonical biogenesis pathway, but 
there are exemptions in which the process differs at some point (non-canonical pathway) 
(Graves and Zeng, 2012). 
In the canonical pathway, the host miRNA gene is transcribed by RNA 
polymerase II (Pol II) into the primary miRNA transcript (pri-miRNA) following 
transcriptional mechanisms, which are similar to the ones used for protein-coding 
mRNAs. Pri-miRNAs are large RNAs that contain at least one hairpin structure and are 
capped, spliced and polyadenylated (Han et al., 2004) (Figure .4).  
In the nucleus, the process to convert the structure of a pri-miRNA into a mature 
miRNA requires two endonuclease processing steps (Richard W. Carthew and 
Sontheimer, 2009) Firstly, the microprocessor complex, which includes the nuclear 
enzyme DROSHA (Rnase III type endonuclease) and a RNA-binding protein DGCR8 
(DiGeorge syndrome critical region gene 8), recognizes and cleaves the pri-miRNA 
releasing the stem-loop precursor (pre-miRNA) from the flanking pri-miRNA sequences 
(Gregory et al., 2004; Han et al., 2004). The pre-miRNA is a 70 nucleotide structure that 
is actively transported to the cytoplasm by the nuclear export receptor exportin-5 (Yi et 
al., 2003; Kim, 2004; Lund et al., 2004). 
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In the cytoplasm, exportin-5 releases the cargo into the cytosol (Bohnsack, 
Czaplinski and Gorlich, 2004; Lund et al., 2004). Subsequently, the pre-miRNA is 
cleaved to generate the double stranded mature miRNA. This process is carried out by 
the DICER protein (RNase III endonuclease enzyme) associated with TAR RNA-binding 
protein (TRBP) and releasing the terminal loop of the pre-miRNA (Bernstein et al., 2001). 
The double stranded miRNA is loaded into the RISC. The RISC complex is formed by 
the union of DICER with the AGO proteins mediated by TRBP. The loading of the 
miRNA duplex into the AGO protein is process requiring high energy that alters AGO 
conformation. When AGO protein returns to its original form, one strand of the miRNA 
(passenger strand) duplex exits the complex leaving the mature single stranded miRNA 
(this mature microRNA can be either the -5p or -3p strand, also known as leading strand). 
This mature miRNA is now guided to its target mRNA through base pairing (Zealy et al., 
2017). Then, together with the RISC complex recruit proteins of the TNRC6 family in 
order to mediate the post-transcriptional regulation of the target gene (Jabri, 2005; Parker 
and Sheth, 2007). 
Fully mature miRNAs can regulate gene expression and affect both physiological 
and pathological signalling pathways (Bartel, 2009). In the following section, the 








Figure 1.4.Overview of microRNA biogenesis. MicroRNA biogenesis starts in the 
nucleus (purple) with the transcription of either intergenic, intronic or exonic microRNA 
gene by the RNA pol II to generate pri-miRNAs or mirtrons. Subsequently, they are 
cleaved by DROSHA-DGCR8 complex and the spliceasome respectively in order to 
produce a 60-80 nucleotide pre-microRNA. This pre-microRNA is transported to the 
cytoplasm by association with exportin-5 protein. Then, the hairpin structure of the pre-
microRNA is cleaved by the complex TRBP-DICER. The resulting mature microRNA 
(either the leading or passenger strand) is loaded into the RISC complex to regulate post-
transcriptional gene expression by either inhibiting the translation or degrading the target 





1.9. Molecular mechanisms underlying miRNA function 
MiRNAs are powerful and complex regulators of gene expression at the post-
transcriptional level  (Berezikov, 2011). The interaction between mRNAs and miRNAs 
is very versatile and one single miRNA can potentially target hundreds of different 
mRNAs. Similarly, one mRNA can be regulated by many miRNAs. Indeed, it has been 
suggested that 60% of all protein-coding genes can be regulated by miRNAs in mammals 
(Friedman and Jones, 2009). 
The microRNA-mRNA duplex is mediated by the binding of the miRNA´s 
seeding region to the complementary sequence at the 3’ untranslated region (3’UTR) 
following Watson-Crick base pairing (Saugstad, 2010). The complementarity between 
the seed region and the sequence in the target mRNA influences the mechanism by which 
gene silencing occurs (Bartel, 2018). In humans, perfect matching is not required for 
microRNA/mRNA interactions. Mismatched base pairing leads to different methods of 
mRNA repression. The supporting proteins recruited by AGO complexes can induce 
deadenylation of the target mRNA to decrease the length of the poly(A) tail, which results 
in mRNA destabilization. Furthermore, miRNAs can also interfere with protein 
expression by inhibiting the initiation step for mRNA translation (Filipowicz, 
Bhattacharyya and Sonenberg, 2008). 
The cellular environment as well as the subcellular location of the RISC-miRNA 
complex can influence the mechanism of action of miRNA-modulated mRNA 
expression.  Recent evidence suggest that the RISC complex accumulates inside P-bodies, 
which are cytoplasmic foci enriched with mRNA-degradation´s machinery and depleted 
of ribosomes (O’Brien et al., 2018) (Figure 1.9). In the nucleus, the RISC-miRNA 
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complex is enriched in the area where there is an active transcription of DNA whereas in 
the cytoplasm, the RISC-miRNA complex can diffuse across the cell, most likely 
associated to microtubules, and be located to different compartments where mRNA 
silencing is required (e.g. polysomes, endoplasmic reticulum) (O’Brien et al., 2018) 
In addition, mRNA turnover is highly variable within mammalian cells and can 
range from minutes to days, making it difficult to predict miRNA targets. MiRNA decay 
is specific of both cell conditions and the type of miRNA, which can be used by the cell 
in order to modulate the levels of gene expression (Bartel, 2018). 
1.10. MiRNAs in inflammation and vascular function 
 
As mentioned above, miRNAs play a crucial role both in the physiological and 
pathological function of any cellular type (Friedman et al., 2009). In the context of 
inflammation, both pro- and anti-inflammatory stimulus have been reported to alter 
mRNA and protein levels (Garavelli, De Rosa and de Candia, 2018). These changes can 
be partially explained by alterations at the miRNA profile. Therefore, many publications 
have sought to identify, understand and characterise the role of miRNAs in modulating 
inflammation in different areas, which include immune cell differentiation, cancer 
progression or vascular function among others (Garavelli, De Rosa and de Candia, 2018). 
 
1.10.1. MiRNA regulation of the immune cell response 
MiRNA levels are highly variable in different T lymphocyte subpopulations and 
contribute to normal functioning of immune cells (Neilson et al., 2007). The fate of T 
cells can be controlled by a single miRNA or a cluster of miRNAs based on the cellular 
context. For example, the levels of the miRNA-17-92 family are increased upon viral 
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infection weighting the balance of T cells toward a more pronounced pro-inflammatory 
type-1 phenotype, which results in increased interferon gamma production (IFNγ) 
(Ventura et al., 2008). 
1.10.2. MiRNAs in vascular function 
Chronic inflammation is associated with many vascular pathologies in which the 
presence of a pro-inflammatory stimulus increase the permeability to soluble compounds 
and migration of leukocytes across the blood vessel, which ultimately contribute to the 
inflammatory response (Reijerkerk et al., 2013). For example, miRNA-126 expression is 
down-regulated in atherosclerosis leading to increased levels of its direct target, VCAM1. 
Increased levels of VCAM1 are directly related with the number of leukocytes that adhere 
to the endothelium (Harris et al., 2008). Down-regulation of miRNA-21 in VSMCs has 
been shown to be associated with decreased proliferation and increased apoptosis in vitro 
(Ruirui et al., 2007).  Therefore, miRNA-21 is proposed to be a regulator of the formation 
of the neointimal lesion, a process in which VSMCs migrate primary in the tunica intima 
leading to increased blood vessel thickness (Ruirui et al., 2007).  . 
In the context of the BBB, miRNAs have recently emerged as potent modulators of 
the BBB phenotype, including paracellular permeability and extravasation of immune 
cells into the CNS, both in physiological and inflammatory conditions. MiRNAs have 
also shown to play a role in astrocytic function. Some of the best characterized miRNAs 








Table 1.6. Summary of inflammation-regulated miRNAs involved in 
modulating BBB function. 


















 BECs ↑ ↑T cell 
adhesion 
ND (Cerutti et al., 
2016) 
 Astrocytes ↑ ↑ MMP3 
expression 


















(Wu, et al., 
2015) 
Astrocytes ↑ ↓MMP and 
TIMPs 
expression 
ND (Broekaart et 
al., 2020) 




Abbreviations: BECs, brain endothelial cells; MMP, metalloproteinases; TIMP, 
tissue inhibitor of metalloproteinases; ND, not determined; CLDN1, claudin 1; SDCBP, 
syntentin-1; ANXA2, annexin A2; DOCK1, dedicator of cytokinesis 1; VCAM1, 
vascular cell-adhesion molecule 1; NFAT5, nuclear factor of activated T cells 5. 
 
In general, a single miRNA can regulate inflammation differently depending on the 
cell type or tissue in which the miRNA is expressed. For instance, miRNA-155-5p is well-
known for being a pleiotropic miRNA that regulates inflammation on three different 
biological functions, which include immunity, cancer biology and vascular function 
(Faraoni et al., 2009). Specifically, miRNA-155-5p has been described to be a negative 
regulator of BBB function (Lopez-Ramirez et al., 2014), up-regulated in neurological 
disorders and modulator of leukocyte adhesion . Therefore, the study of miRNA-155 is 
of utmost interest to understand novel mechanisms of cell function during inflammation 
at the BBB. 
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1.11. MicroRNA-155: a pleiotropic microRNA 
 
MiRNA-155 is a well-characterised miRNA, which is originated from the non-
coding gene B-cell Integration Cluster (BIC or also known as MIR155HG) (for a review 
see Elton, Selemon, Elton, & Parinandi, 2013). Human MIR155HG is located on 
chromosome 21q21 in humans and includes three exons that comprise a 13 Kb region 
(Tam, 2001). Pre-MiRNA-155 sequence is conserved among different species (Figure 
1.5.A). Cleavage of pre-miRNA-155 produces two single-stranded miRNA-155 
(miRNA-155-5p and miRNA-155-3p). Human and murine mature miRNA-155-5p 
differs only by one nucleotide (Figure 1.5.B). Experimentally, human miRNA-155 origin 
was validated in HL-60 leukaemia cells (Kasashima, Nakamura and Kozu, 2004) and 






Figure 1.5. Species conservation of miRNA-155. (A) Phylogenetic tree on the sequence 
alignment of miRNA-155 loop sequence among 6 species that included homo sapiens 
(hsa), mus musculus (mmu), gallus gallu (gga), xenopus tropicalis (xtr), dario rerio (dre) 
and ciona intestinalis (cin). (B) Sequence alignment for mature miRNA-155-5p from 
human and mouse species. Adapted from  Vigorito, Kohlhaas, Lu, & Leyland, 2013. 
 
1.11.1. MicroRNA-155 in health and disease 
 
Cleaved pre-miRNA products can differ in expression and function across cell 
types (Choo et al., 2014). MiRNA-155-5p is expressed by many tissues and different cell 
types although relative expression is the highest in the thymus (Martin et al., 2006). On 
the other hand, miRNA-155-3p expression is reported to be between 20 to 200 fold lower 
than microRNA-155-5p in a number of human tissues such as thymus or spleen (Elton et 
al., 2013). Therefore, the biological relevance of miRNA-155-3p is currently uncertain 
(Elton, Sansom and Martin, 2010). Recent reports showed that stimulation with Toll-like 
receptor 7 (TLR7) agonist on human plasmacytoid dendritic cells (PDCs) increased levels 
of both miRNA-155-5p and -3p. Transcription kinetics studies demonstrated that 
miRNA-155-3p up-regulation occurred at an earlier stage than miRNA-155-5p, 
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suggesting a cooperative role among both variants (Zhou et al., 2010). Therefore, more 
research is needed to understand how the two strands of miRNA-155 interact. However, 
for the rest of this work, the focus will be given to miRNA-155-5p, which will hereafter 
be referred to as miRNA-155 unless otherwise specified. As mentioned above, miRNA-
155 has been related to a wide range of physiological and pathological conditions such as 
cancer, vascular pathologies, inflammatory and autoimmune diseases (e.g. rheumatoid 
arthritis) (Faraoni et al., 2009). In the following section, focus will be given to miRNA-
155 function in modulating inflammation.  
 
1.11.2. MiRNA-155 in inflammation 
 
Expression of miRNA-155 has been widely investigated in both in vitro and in 
vivo models of inflammation. Different studies relate inflammatory cytokines, such as 
TNFα or IFNγ, and inflammatory mediators (e.g. LPS) as modulators of miRNA-155 
expression in monocytes, macrophages and various different endothelial cells (O’Connell 
et al., 2007; Sun et al., 2012). Under basal conditions, levels of miRNA-155 are relatively 
low but upon stimulation with TNFα, miRNA-155 levels are highly up-regulated and 
sustained over time in brain endothelial cells, macrophages and monocytes (Faraoni et 
al., 2009; Lopez-Ramirez et al., 2013). Furthermore, activation of pro-inflammatory 
pathways such as nuclear factor (NF)-κB and activator protein-1 (AP-1) promote 
miRNA-155 expression (Gatto et al., 2008; Yin et al., 2008). Thompson et al., 
demonstrated the presence of a promoter at 178 nucleotides up-stream of MIR155HG 
transcription start site that is regulated by NF-kB p50/65 (Thompson, Vardinogiannis and 
Gilmore, 2013).  
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The first clinical evidence of miRNA-155 association with a neurological disorder 
such as MS was demonstrated in 2009 by miRNA profiling of active MS lesions (Junker 
et al., 2009). The role of miRNA-155 in MS pathology is complex and diverse regarding 
the context of the BBB function, peripheral inflammation and CNS injury (¡Error! No s
e encuentra el origen de la referencia.1.12.) (Wu and Chen, 2016). MiRNA-155 is 
crucial for DC to acquire a mature phenotype and helps producing inflammatory Th1 and 
Th17 cells. Th1 and Th17 cells (two distinct subsets of T cells) regulate the adaptive 
immune response (Chalovich and Eisenberg, 2005). In EAE, Th1-derived cytokines 
promote Th17 invasion into the CNS (Reboldi et al., 2009a). Furthermore, miRNA-155 
promotes production of cytokines such as IFNy and IL-6. Low levels of these cytokines 
in miRNA-155 KO mice leads to decreased levels of inflammation in the periphery and 
CNS, which results in a less severe phenotype in EAE (Wu and Chen, 2016). In addition 
to this, miRNA-155 has been found to supress anti-inflammatory proteins such as 
suppressor of cytokine signalling (SOCS1) in microglia (Wu and Chen, 2016). The 
suppression of SOCS1 leads to an increased production of inflammatory cytokines. 
Moreover, miRNA-155 targets SMAD2, CEBPbeta and CD206 thereby increasing 
phagocytic activity in microglia (Wu and Chen, 2016). MiRNA-155 has also been 
reported to be increased in CSF samples from patients with Alzheimer’s disease 
(Alexandrov et al., 2012) and regulate Japanese Encephalitis Virus-Induced 
Inflammatory (Thounaojam et al., 2014). 
Due to many observations such as those described above, miRNA-155 is 
classically defined as a pro-inflammatory miRNA. However, recent studies point to a dual 
role for microRNA-155 in inflammation.  A negative feedback role was described for 
miRNA-155 in human vein umbilical cell line (HUVECs) (Wu et al., 2014). After 
exposure to TNFα, expression of miRNA-155 was increased and led to decreased levels 
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of VCAM1, which reduced the pro-inflammatory status of the endothelial cells (Wu et 
al., 2014). 
 
1.11.3. MiRNA-155 in BBB function 
 
As mentioned above, miRNA-155 has been recently proposed to be a negative 
regulator of BBB function and levels changed in inflammation (MA. Lopez-Ramirez et 
al., 2014).  In vitro, inflammatory cytokines were shown to induce a rapid increase of 
miRNA-155 in the human brain endothelial cell line hCMEC/D3. Ex vivo, miRNA-155 
was demonstrated to be expressed at the NVU of MS patients as well as in EAE 
microvessels. In fact, it was reported that loss of miRNA-155 in EAE mice resulted in a 
reduced extravasation of systemic tracers into the CNS. Furthermore, it was shown that 
overexpression of miRNA-155 led to disorganisation of TJs and loss of focal adhesion 
plaques in hCEMC/D3 cells. Lopez-Ramirez identified that miRNA-155 was targeting 
molecules involved in focal adhesion components (DOCK1 and sysntenin-1) as well as 
in cell-cell complexes molecules (Annexin-2 and claudin-1).  
In addition, miRNA-155 has also been shown to contribute to shear-resistant 
leukocyte adhesion to human brain endothelium in vitro (Cerutti et al., 2016). In this 
study, overexpression of miRNA-155 led to an increase of monocyte and T cell line firm 
adhesion to human brain endothelium in vitro. Overexpression of miRNA-155 also led to 
an increase of BEC-adhesion molecules such as VCAM1 and ICAM1. These two 
molecules play a pivotal role in regulating leukocyte extravasation across the BBB. 
However, neither VCAM1 nor ICAM1 are direct targets of miRNA-155, therefore, the 
molecular pathway by which miRNA-155 stimulates the up-regulation of these two 
adhesion molecules is still unknown. A recent study has also identified a novel axis of 
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communication between the gut and the brain, where LPS released by the gut microbiome 
is transported via the systemic circulation to the brain and activated BECs through the 
NFκB pathway and expression of miRNA-155 (Alexandrov et al., 2019). 
In vivo miRNA-155 inhibition using antisense oligonucleotides was shown to 
promote recovery after experimental mouse stroke mediated by up-regulation of one of 
its target proteins, Rheb (Pena-Philippides et al., 2016). In this study, in vivo loss of 
miRNA-155 led to improved preservation of tight junctions in cerebral microvessels 
following stroke as assessed by EM techniques and by ZO-1 staining. 
Altogether, these studies indicated that inhibition of miRNA-155 may prove a suitable 
molecular target for supporting cerebral microvascular function in neuroinflammation. 
Furthermore, miRNAs can be transported and delivered from one cell to another via 
extracellular vesicles (EVs), which can then modulate the functions of the recipient cells 
(Howitt and Hill, 2016). In this next section, there will be a focus on understanding what 
EVs are, what role they play in inflammation and BBB and how their miRNA cargos are 
involved in this process. 
 
1.12. Extracellular Vesicles: a novel mechanism of cell-to-cell 
communication 
 
Cells can modify the cellular functions of neighbouring or distant cells by 
paracrine and endocrine pathways involving the secretion of soluble proteins, circulating 
RNAs and recently discovered EVs amongst other mechanisms (Ciardiello et al., 2016; 
Nava and Llorens, 2016). This last pathway is especially interesting because of the ability 
of EVs to carry both proteins and RNA species in order to regulate the function of 
recipient cells both in physiological and pathological conditions (Bayraktar, Van 
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Roosbroeck and Calin, 2017). Therefore, the study of EVs as carriers of RNA species 
such as miRNAs and how these affect cell function has become a very attractive research 
topic in the last years. 
EV is a generic term used to describe a type of cellular-secreted carrier, unable to 
replicate, that are formed by a lipid bilayer (Théry et al., 2018). Secretion of EVs is 
believed to be a highly evolutionary-conserved process (Colombo, Raposo and Théry, 
2014). In fact, both prokaryotic and eukaryote organisms are considered to secrete EVs 
into the extracellular environment. In mammals, EVs have been isolated from diverse 
body fluids, including blood (Crawford, 1971), urine, saliva, breastmilk, amniotic fluid, 
ascites, cerebrospinal fluid, bile and semen (Stegmayr and Ronquist, 1982).  
 
1.13. Historical point of view of EV research 
From a historical perspective, several independent studies reported evidence of 
EVs for the first time. For instance, Chargaff and West first reported the presence of 
“extracellular particles” derived from platelet cells in normal plasma (Chargaff and West, 
1946). In 1967, these platelet-derived particles were named “platelet dust” by Wolf (Wolf, 
1967). Furthermore, Anderson observed matrix vesicles during bone calcification 
(Anderson, 1969). In the following decade, independent research groups reported the 
presence of EVs in different contexts (Yáñez-Mó et al., 2015). Different studies showed 
that EVs were released by rectal adenoma microvillus cells. EV were also isolated and 
detected in seminal plasma (Crawford, 1971). It was also reported the presence of virus-
like particles in human cell culture supernatants, later termed proteasomes (Benz and 
Moses, 1974). In this decade, membrane fragments originating from tumours were 
identified in the extracellular space (Taylor, Homesley and Doellgast, 1980). 
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Until the 1980s, EVs were always described as membrane-enclosed vesicles 
generated by outward budding of the plasma membrane. In 1983, however, Harding et al. 
described a novel pathway of EV secretion when studying the differentiation of 
reticulocytes into erythrocytes (Harding, Heuser and Stahl, 1983). It was reported that 
reticulocytes released transferrin receptor (TfR) into the extracellular medium. 
Immunogold-labelled EM techniques were employed to follow the fate of endocytosed 
receptors across the cell. The authors found TfR to be enclosed within multivesicular 
endosomes and observed that the highest concentration of the staining was carried in 
small vesicles (~50nm) inside the multivesicular endosomes (Harding, Heuser and Stahl, 
1983). These studies promoted the idea that EVs were a mechanism by which cells 
removed cytosolic content. Furthermore, the discovery of an endosomal biogenesis 
pathway allowed researchers to differentiate shedding EVs from endosomal EVs, or also 
referred as exosomes (Yáñez-Mó et al., 2015). 
Research into EVs was considered not very relevant until the late 1990’s, when 
two publications highlighted the interesting role of EVs in the context of immunology 
(Raposo et al., 1996; Zitvogel et al., 1998). In 1996, Raposo et al., demonstrated that 
exosomes derived from Epstein-Barr virus (EBV)-transformed B cells were enriched in 
major histocompatibility complex (MHC) class II molecules. The specific endosomal 
origin of these vesicles was also shown by EM, ruling out the criticisms that these vesicles 
could have been generated by outward budding of the plasma membrane. In addition to 
these findings, Zitvogel et al. reported the suppression of growth of established tumours 
in vivo after treatment with human dendritic cell-derived exosomes (Zitvogel et al., 1998). 
Several studies investigated the role of traditional plasma membrane-derived vesicles, 
also referred as microvesicles, derived from immune cells (platelets, monocytes and 
neutrophils) to regulate blood coagulation (Sims et al., 1989; Satta et al., 1994). There 
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were also reports of vehicles for the transfer of inflammatory mediators (Mesri and 
Altieri, 1998; Gasser and Schifferli, 2004), regulation of  lipid metabolism (Sims et al., 
1989) as well as on regulating the endothelial or immune cell survival (Baj-Krzyworzeka 
et al., 2002). However, none of these studies using microvesicles reported the presence 
of MHC complexes.  
In 2007, Valadi revolutionised the field of EVs when they demonstrated that 
exosomes carry both mRNA and miRNAs (Valadi et al., 2007). The authors isolated 
exosomes from a mouse mast cell line (MC/9) and identified the presence of mouse-
specific mRNAs. Subsequently, exposure of human mast cells (HMC-1) to mouse 
exosomes led to the production of mouse-specific proteins, indicating the transfer of 
mouse mRNA and its ability to be translated by the human recipient cells (Valadi et al., 
2007). Moreover, presence of nucleic acids in microvesicles and their role in regulating 
gene expression in recipient cells was also demonstrated in tumour- and stem cell-derived 
EVs (Baj-Krzyworzeka et al., 2006; Ratajczak et al., 2006). Thanks to these studies, 
exosomes and other EVs have emerged as carriers of genetic information with the 
potential to regulate the gene expression in targeted cells. 
 
1.14. Classification of extracellular vesicles 
EV are classified according to both size and biogenesis which includes exosomes, 
microvesicles (also referred to as ectosome or shedding microvesicles) or apoptotic 
bodies (Kalra, Drummen and Mathivanan, 2016) (Figure 1.6). Exosomes are generated 
as a result of the inward budding of the endosomal membrane, with a size range between 
30 to 150 nm. Microvesicles are generated from outward budding of the plasma 
membrane and have a broader size range, ranging from 100 nm up to 1 µm. Apoptotic 
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bodies are also secreted following outward budding of the plasma membrane as a 
mechanism of cell debris removal during the later stages of apoptosis. Apoptotic bodies 
include vesicles from 40 up to 5000 nm (van der Pol et al., 2012). Interestingly, research 
in apoptotic bodies is normally independent of both exosome and microvesicle research. 
In fact, many publications define EVs as the mixture of both exosomes and microvesicles. 
This heterogeneous population of EVs is a consequence of the lack of specific markers 
and optimised methods of isolation to distinguish exosomes from microvesicles. In 
contrast, the experimental conditions as well as the wide size distribution of apoptotic 
bodies result in a higher confidence for researchers to claim a reasonable purity of this 
type of vesicles (Kalra, Drummen and Mathivanan, 2016).  
 
Figure 1.6. Schematic representation of extracellular vesicle subtypes. Cells can 
secrete mainly three types of vesicles. Exosomes (30-150nm) are originated by 
exocytosis, microvesicles (100-1000nm) are the result of outward budding of the plasma 
membrane and apoptotic bodies (50-5000nm) are secreted in the later stages of a cell 
dying through apoptosis to facilitate the removal of cell debris. Figure adapted from 




Although the classification of EV is clear, the nomenclature of the different EVs 
have been highly heterogenous. For this reason, in 2018 the International Society of 
Extracellular Vesicle (ISEV) released a report containing the criteria regarding EV 
research (MISEV2018, Théry et al., 2018). The authors recommended that researchers 
employ classical EV nomenclature (exosomes, microvesicles or apoptotic bodies) only if 
they could demonstrate specific cellular origin by, for example, showing stable 
expression of specific markers of subcellular origin. Théry et al., proposed an alternative 
nomenclature that is based on the different characteristics of the EV population (Table 
1.7). If the minimum information to describe the nature of the EV population is not 
reached, it is recommended that authors refer to the sample preparation as extracellular 
particles (EPs) (Théry et al., 2018).  
Table 1.7. List of different nomenclatures for extracellular vesicles. 
Property for classification Examples 





Density Low Middle High 





Cell or condition of origin Podocyte EVs Hypoxic EVs Large oncosomes 
Not a EV Extracellular Particles 
 
Abbreviations: EVs, extracellular vesicles. Information taken from (Théry et al., 
2018) 
 
1.15. Biogenesis of the different subpopulations of EVs 
 
In this section, the processes involved in the generation of exosomes and 




Exosomes are vesicles originated in a complex and regulated process, (Figure 1.7). 
Briefly, the secreting cell generates an early endosome, which is transported through the 
cytoplasm. Subsequently, there is a maturation from early endosomes to late endosomes. 
Then, changes in the endosomal microenvironment lead to alterations of the endosomal 
membrane resulting in the creation of intraluminal vesicles (ILV) within the endosome 
or, now referred to as multivesicular bodies (MVB). The reorganisation of the endosomal 
membrane into tetraspanins-enriched microdomains, involving both CD9 and CD63, 
initiates the process of ILV formation (Pols and Klumperman, 2009). The ILVs contained 
within the MVB carry part of the cytosol containing proteins and nucleic acids, which are 
believed to be selectively sorted into the ILVs. The MVB have now two different fates. 
It has been demonstrated that MVB normally fuse with lysosomes to mediate the 
degradation of their cargo. The MVBs trafficking and fusion to the plasma membrane is 
a coordinated and highly regulated mechanism. Both tetraspanins and small RAB 
GRPases have been described to regulate MVBs fusion to the plasma membrane (Savina, 
Vidal and Colombo, 2002; Simons and Raposo, 2009; Ostrowski et al., 2010). However, 
different in vitro studies revealed the different role and expression of some RAB proteins, 
suggesting the existence of alternate pathways for MVB fusion to the plasma membrane. 
When MVBs fuse with the plasma membrane of the cell and they release the cargo into 





Figure 1.7. Schematic representation of exosome biogenesis. Multivesicular bodies 
(MVB) are created from inward budding of the palsma membrane. Intraluminal vesicles 
within the MVB carried cytosolic proteins and RNAs. MVBs secrete their content to the 
extracellular space via exocytosis. Figure adapted from (Schorey et al., 2015) 
 
On the other hand, microvesicles follow a different pathway. Direct outward 
budding of the plasma membrane is required for the formation of microvesicles and is 
controlled by mechanisms different to those involved in the exosome´s biogenesis 
(Cocucci, Racchetti and Meldolesi, 2009). The process of microvesicle production 
includes the rearrangement of the cytoskeleton and membrane constituents as well as the 
recruitment of membrane abscission-related proteins (Kalra, Drummen and Mathivanan, 
2016). Cytosolic proteins and genetic material (e.g. mRNA and miRNAs) are loaded into 
the lumen of the future vesicle as a consequence of the gradual disassembly of the 
cytoskeleton. Budding and pinching off can occur by different mechanisms. On one hand, 
a high activity of translocases can produce a high enough plasma membrane curvature 
capable of turning the plasma membrane onto itself (Devaux et al., 2008). However, it is 
considered that the excision of the plasma membrane is generally mediated by proteins 
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that promote cytoskeleton contraction, which involves the activation of actin-myosin-
dependent contraction and pinching off the microvesicles (Filipowicz, Bhattacharyya and 
Sonenberg, 2008).  
Despite the investigation and elucidation of these mechanisms controlling 
microvesicle biogenesis, the reality is that this process is more dynamic and complex and 
can be altered depending on the cell type and conditions by which is activated (Kalra, 
Drummen and Mathivanan, 2016).  
 
1.16. Handling and isolation of extracellular vesicles 
EVs can be detected in a wide range of biofluids as well as in cell culture 
conditioned media (CCM). Therefore, handling the source of EVs prior to their isolation 
is of utmost importance to ensure reproducibility and the highest EV purity. Thus, the 
MISEV2018 proposed certain recommendations regarding preparation and collection of 
EVs (Théry et al., 2018). 
CCM was described as the most common source for the isolation of EVs (Théry 
et al., 2018). It is important that cell culture conditions (passage, seeding density, cell 
type) are identified for the EV-producing cells and that cultured cells are screened 
routinely for contamination (e.g. mycoplasma) because this can affect EV release. In 
addition, authors are recommended to report the volume of CCM, number of dead cells 
as well as cell culture surface area. Furthermore, researchers should describe the type of 
serum, if at all, that is present in the CCM. Most cells are unable to survive in serum-free 
media and serum is known to contain EVs, therefore, it is important to deplete serum from 
EVs prior to their use for the isolation of EVs (Beninson and Fleshner, 2015). For this 
purpose, serum can be manually depleted using ultracentrifugation at 120,000 x g for  at 
least 18 h, which was shown to efficiently eliminate the serum-associated EVs (van 
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Balkom et al., 2013). Alternatively, commercially available EV-depleted serum can be 
purchased. 
Once the source of EVs has properly been handled and collected, EVs can be 
isolated and purified. The isolation of EVs is a controversial topic because there is still 
no protocol that has reached worldwide use. This results in a lack of reproducibility of 
results across the different labs working on EVs. A survey carried out by ISEV 
interrogated the methods for isolating EVs across different research groups around the 
world (Gardiner, Vizio, et al., 2016). Ultracentrifugation resulted to be the preferred 
method, although a high number of researchers also preferred to use a combination of 
methods (Gardiner, Vizio, et al., 2016). Given that the selection of a protocol will 
influence the heterogeneity of the isolated EVs, it is important to take into account the 
different limitations and advantages that the available isolation methods offer.  
 
1.16.1. Ultracentrifugation 
 The first method was developed due to the need to purify exosomes secreted from 
reticulocytes into cultured medium (Johnstone et al., 1987), then adapted to isolate these 
vesicles from immune cells (Raposo et al., 1996; Zitvogel et al., 1998) (Figure 1.14). This 
protocol employs, first, a series of differential centrifugation steps with increasing speeds 
in order to remove bigger vesicles. Then, the remaining supernatant is centrifuged at 
higher speed (100,000 x g) allowing the sedimentation of smaller vesicles, both exosomes 
and small microvesicles. These differential centrifugation steps ruled out the possibility 
of artificially creating smaller vesicles from larger ones by applying high speed 
centrifugation straight to the raw sample. This method has been widely modified, by 
changing both speed and sedimentation times (Tauro et al., 2012), in order to improve 
yields or influence the type of isolated EVs. Many studies have demonstrated the 
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functional activity of EVs isolated by ultracentrifugation (Witwer et al., 2013). However, 
this protocol shows a low vesicle recovery as well as long experimental time. In addition, 
ultracentrifugation can isolate a wider size distribution of EV population as well as protein 
aggregates especially if the protocol is not optimized properly (Van Deun et al., 2014). 
1.16.2. Precipitation-based methods 
The lack of a universal isolation method as well as the technical problems associated with 
the traditional protocols were found to be an opportunity for many companies to develop 
quick and user-friendly kits for EV isolation (Witwer et al., 2013). ExoQuick (System 
Bioscience), Total Exosome Isolation (Invitrogen), miRCURY Exosome Isolation 
(Exiqon but now merged with Qiagen) are some examples of available products in the 
market (Winter et al., 2009).  
Most of these commercial kits are based on a volume-excluding polymer, such as 
poly ethylene glycol (PEG), dextrans or polyvinyls. PEG is a non-toxic and non-
denaturing water-soluble synthetic polymer that has been previously used as a method of 
plant virus isolation and protein complexes (Rider, Hurwitz and Meckes, 2016). Briefly, 
the biofluid (cell culture medium, urine, plasma, saliva etc.) is mixed with a specific 
volume of the precipitation buffer containing PEG. The mixture is incubated from 1 h and 
can be extended overnight at 4ºC. The incubation is followed by a low-speed 
centrifugation to pellet the EV’s and remove the PEG. The precipitation is the result of 
the retraction of solvent by the polymer resulting in a concentration of biological materials 
until its solubility is reached and precipitation occurs (Umezu et al., 2012). 
These methods have become popular due to their minimal experimental 
requirements and easy to perform. Furthermore, a high concentration of isolated vesicles 
has been reported, however, they might precipitate soluble and aggregate proteins 
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together with the vesicles. The presence of bulked protein results in a decreased purity of 
the isolated EV population (Rider, Hurwitz and Meckes, 2016).  
1.16.3. Size exclusion methods 
 Separation of EV based on the size and filtration through physical barriers may be 
achieved through the use of filters or chromatography. Usually, large particles can be 
removed through filtration across 0.8µm pore. If small vesicles are desired a filtration 
with 0.22 µm pore size will isolate both small MV and exosomes. However, protein 
contaminants are typical difficult to avoid, therefore, chromatography column presents 
an improved alternative for EV isolation. Column chromatography allows for sequential 
elution of EV size fractions from a single column (Witwer et al., 2013). The most popular 
type of column chromoatography is qEV, which has been designed by IZON (Oxford, 
UK).  
The qEV column isolates EVs in a process that typically takes less than 15 min, 
resulting in highly purified vesicles. Proteins and other contaminating molecules smaller 
than 75 nm enter the  pores  of  the  resin  and  are  delayed  in their passage through the 
column, eluting mainly in later fractions. However, EVs smaller than 75 nm in diameter 
also enter the resin and are delayed in their passage (Vogel et al., 2016). 
1.16.4. Other methods of isolation 
 EVs can be also isolated according to their density coefficient. Different methods used 
sucrose gradients to differ between high and low density EVs. After EVs have been 
separated in the gradient, they are usually washed and concentrated (e.g. 
ultracentrifugation). Iodixanol based density-gradient are an alternative to sucrose 
gradient and are reported to have a more accurate separate based on their buoyant density. 
On the other hand, some research group take advantage of common EV markers such as 
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CD63 or CD9 to isolate and enrich EVs that are carrying these markers using 
immunoaffinity assay. Furthermore, ultrafiltration has also been demonstrated to 
successfully isolated EVs from their source biofluid. 
In conclusion, the selection of the isolation method is important and should be 
optimized empirically. Combination of different methods have been showed to improve 
the isolation EVs. Furthermore, technical details relevant to the isolation of EVs are very 
important to be recorded and reported in order to ensure reproducibility of experiments. 
 
1.17. EVs in in inflammation and cerebrovascular function 
The discovery of a role for EVs in intercellular communication has resulted in an 
exponential growth of EV research in the last decade. In fact, many publications have 
described the role of EVs as mediators of physiological conditions with an important role 
in the pathogenesis of many conditions (Kalra, Drummen and Mathivanan, 2016). EVs 
have been described as regulators of a wide range of diseases such as cancer (Ciardiello 
et al., 2016), neurodegenerative conditions (Janas et al., 2016), cardiovascular diseases 
(Osteikoetxea et al., 2016) or inflammation (Momma, 2015). In this section, there will be 
a special focus on how EVs module inflammation and cerebrovascular function. 
 
1.17.1. EVs in inflammation 
In the context of inflammatory diseases, higher numbers of platelet-derived EVs 
were observed in patients with Crohns´ disease compared to healthy controls (Ardoin, 
Shanahan and Pisetsky, 2007). Similarly, endothelial, leukocyte and platelet EVs were 
shown to be increased in patients with progressive MS (Sáenz-Cuesta, Osorio-Querejeta 
and Otaegui, 2014). 
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EVs can stimulate the inflammatory response by carrying membrane-bound TNFα  
that interact with the acceptor cells (Olleros et al., 2012). Furthermore, EVs have been 
shown to promote the production of pro-inflammatory cytokines such as TNFα,  IL-6 and 
IL-8 (Withrow et al., 2016). Additionally, EVs can trigger toll-like receptor 4, hence, 
promoting the inflammatory cascade (Abdollahi-Roodsaz et al., 2007). Interestingly, EVs 
can also decreased the inflammatory response (for a review in the benefits of 
mesenchymal cell-derived EVs visit (Keshtkar, Azarpira and Ghahremani, 2018)).  
 
1.17.2. EVs in cerebrovascular function 
The first evidence of secretion of EVs by brain endothelia was reported in 2012 
(Virgintino et al., 2012). The authors observed an association of vesicles to the filopodia 
generated at the tip of endothelial cells from microvessels during brain development. The 
authors proposed that these vesicles might carry signalling molecules and, therefore may 
play a role in intercellular communication during vessel development (Virgintino et al., 
2012; András and Toborek, 2015). A year after, Haqqani et al., published a method of 
EV isolation for the immortalized human brain microvascular endothelial cell line 
hCMEC/D3 (Haqqani et al., 2013). The same study conducted a proteomic profile of 
hCMEC/D3-derived EVs and found that 58 proteins out of 65 described EV markers were 
expressed.  
In the context of inflammation, brain endothelial-derived EVs regulate and 
mediate many pro-inflammatory processes (Figure 1.10) (András and Toborek, 2015; De 
Rivero Vaccari et al., 2016). Indeed, inflammatory mediators such as cytokines (TNFα, 
IFN, IL1B) and LPS can activate BECs and, therefore significantly increase the release 
of EVs (Alexy et al., 2014). Furthermore, EVs released after activation of BECs have 
been found to regulate both communication with another components of the NVU 
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(Yamamoto et al., 2015) as well as vascular integrity of the endothelial monolayer 
(András and Toborek, 2015). Another study showed that EVs isolated from activated 
BEC transfer miRNAs to pericytes leading to an increase in vascular endothelial growth 
factor-B (VEGF-B) (Yamamoto et al., 2015). VEGF-B is a ligand of VEGFR-1, which is 
a receptor expressed in both endothelial cells and pericytes. The up-regulation of VEGFR-
1 has been linked to pericyte ablation and increased leaky endothelium (Cao et al., 2010). 
Furthermore, EVs derived from activated BECs can modulate leukocyte and monocyte 
migration across the endothelium. In fact, a recent study suggested the transfer of claudin-
5 from BECs to leukocytes through EVs (Paul et al., 2016). Claudin-5 is incorporated in 
the leukocyte membrane helping the leukocyte to cross the endothelium between two 
BECs. Briefly, claudin-5 expressed in the leukocyte plasma membrane bridges with the 
endogenous endothelial claudin-5 leading to decreased tight junction integrity which 
promotes leukocyte extravasation (Paul et al., 2016). A proteomic study of EV isolated 
from TNFα-activated hCMEC/D3 cells revealed that inflamed EVs carry pro-
inflammatory proteins such as ICAM1 or VCAM1 (Dozio and Sanchez, 2017) (Figure 
1.8). However, whether EVs derived from activated BECs can modulate neighbouring 
BECs is still largely unknown. 
In addition to the role of endothelial-derived EVs, BBB function is also modulated 
by the action of inflamed-derived EV released by other cellular types (Sáenz-Cuesta, 
Osorio-Querejeta and Otaegui, 2014). For instance, activated T cells release EVs that can 
upregulate the levels of ICAM-1 in endothelial cells (Barry et al., 1998). Astrocytes and 
neurons have been found to release EV containing both bGFG and VEGF (Proia et al., 
2008). However, the role of these EV on endothelium has not been described yet.  
The role of plasma-derived EVs have been investigated in the context of 
neuroinflammation (Sáenz-Cuesta, Osorio-Querejeta and Otaegui, 2014). EV derived 
73 
 
from plasma of patients with MS were cultured with naïve hCMEC/D3 cells resulting in 
a decrease of electric cell-substrate impedance sensing as well as subcellular altered 
localization of ZO-1 and VE-Cadherin. The authors suggest that plasma-derived EV can 
affect BBB function and contribute to the progression of MS. In another study, EVs were 
purified from serum of LPS-challenged mice. Injection of these EVs into naïve mice 
induced neuroinflammation and leaky BBB (Li et al., 2018). However, it is still not clear 
whether a type of EVs or combination of many types (e.g. platelet-, endothelial- or 
leukocyte-derived EVs) were responsible of the phenotypes observed in those articles. 
Furthermore, whether BEC-derived EVs modulate BBB function remains unknown as 













Figure 1.8 Summary of role of EVs in blood-brain barrier in inflammation. (1) Human brain endothelial cells (BECs) exposed to TNFα 
released EVs that carry pro-inflammatory proteins. Furthermore, (2) inflammation-induced brain endothelial-derived EV modulate pericyte 
expression of VEGF-B.  Activation of brain endothelium promotes release of endothelial-derived EVs, which can modulate cell migration by (5) 
activating monocytes and (3) transferring claudin-5 to lymphocytes. Claudin-5 from lymphocytes facilitate the paracellular migration of the T cells 
by bridging with endothelial claudin-5. (4) Activated circulating lymphocytes release EVs and inflammatory mediators leading to activation of 
brain endothelium and up-regulation of adhesion molecules such as VCAM-1, ICAM-1 and E-selectin. Furthermore, (5) Systemic inflammation 
or neuroinflammatory diseases such as multiple sclerosis (MS) increase the release of endothelial-derived EVs, which can disrupt the brain 
endothelium. (2). Cell-derived EV: pink (endothelial cell), blue (lymphocyte). Figure drawn by David Roig-Carles. 
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1.18. Aims and objectives 
 
For this PhD work, we set out to investigate how miRNAs and EVs modulate the role of 
BBB in inflammation, in an attempt to elucidate the link between endothelial miRNAs 
and EVs in BBB function. To address this overall goal, the following aims were carried 
out: 
1) Compare three common methods for the isolation of EVs based on number and 
size of isolated EVs as well as their protein purity (Chapter 3). 
2) Characterise the physical and molecular properties of brain endothelium-derived 
EVs in inflammation (Chapter 3) 
3) Investigate the uptake, effect and molecular changes of brain endothelium-
derived EVs in BBB function in inflammation. (Chapter 4) 
4) Study the mechanism of action by which miRNA-155 induced leukocyte 
adhesion to brain endothelium. (Chapter 5) 
Finally, an unexpected phenotype on miRNA-155 KO mice was observed in the animal 
facility. Hence, I spend part of my first two years, characterising this phenotype and 












CHAPTER 2: Material and Methods 
2.1. Materials 
 
Tissue culture consumables including flasks, plates, cryo-tubes, sterile serological 
pipettes and tips were obtained from Greiner Bio-One (Stonehouse, Gloucestershire, 
UK). General-use consumables, including Eppendorfs® tubes, RT-qPCR tubes and 
phosphate saline buffer (PBS) were purchased from Fisher Scientific/Thermofisher 
(Paisley, Renfrewshire, UK). All other consumables were purchased from Merck 
Millipore (Watford, Hertfordshire, UK), unless stated otherwise.  
 
2.2. Tissue Cell Cultures 
 
The immortalised hCMEC/D3 was previously obtained from a primary cell 
culture at passage 0 by co-expression of human telomerase reverse transcriptase (hTERT) 
and SV40 large T antigen using a high efficient DNA-flap lentiviral vector system 
(Weksler et al., 2005).  
hCMEC/D3 cells were grown in Endothelial Basal Medium-2 (EBM-2) and 
supplemented with the following supplements: 0.025 % (v/v) VEGF, insulin growth 
factor (IGF) and epithelial growth factor (EGF), 0.1 % (v/v) bFGF, gentamycin (GA-
1000) and ascorbic acid, 0.04 % (v/v) hydrocortisone and 2.5 % (v/v) foetal bovine serum 
(FBS), hereafter referred to as EBM-2 complete media (Lonza, Wilford, 
Nottinghamshire, UK). Prior to seeding the cells, tissue culture surfaces were coated with 
1/20 (v/v) collagen type I from calf skin (0.1 % (w/v) solution in 0.1 M acetic acid) (Merk 
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Millipore, Watford, Hertfordshire, UK) in Hank’s Balanced Salt Solution (HBSS) for 1 h 
at room temperature (RT). For all experiments, hCMEC/D3 cells (passage from 25 to 35) 
were grown on collagen-coated plates to sub-confluence unless otherwise specified. 
hCMEC/D3 medium was replaced every two days until cells were sub-confluent 
(approximately 90 % of confluent cells).  
The T cell line Jurkat from acute T cells was a kind gift from Dr. V Male (Imperial 
College London, UK). Jurkat T cells were grown in suspension in Roswell Park Memorial 
Institute (RPMI) 1640 with GLUTAMAX I (Gibco® Invitrogen, Paisley, Renfrewshire, 
UK) culture medium containing 10 % (v/v) FBS and 1 % (v/v) penicillin and streptomycin 
(P/S).  Cells were maintained at a concentration of 0.3 to 0.5x106 cells/ml and fresh media 
was added every two days. At the end of every week, cells were spun down at 190 x g for 
5 min, then pelleted cells were manually counted and cells were diluted in fresh medium 
at the concentration stated above. 
Human brain pericytes (HBMP) were a gift from Dr. Bread (Oxford University, 
UK) and were grown in Pericyte Medium (Science cell, Carlsbad, CA, USA) 
supplemented with 1 % (v/v) of pre-made and commercially available cocktail of pericyte 
growth factors´ solution, 2 % (v/v) FBS and 1 % (v/v) P/S.  HBMP were grown in tissue 
culture flasks/dishes that were pre-coated with poly-L-lysine solution for 1h at RT. 
Human primary cortical astrocytes (hA) (Science cell, Carlsbad, CA, USA) were 
grown in Astrocyte medium (Science cell, Carlsbad, CA, USA) supplemented with 1 % 
(v/v) astrocyte growth factor´s solution, 2 % (v/v) FBS and 1 % (v/v) P/S.  hAs were 
grown in tissue culture flasks/dished that have been pre-coated with 1/20 (v/v) calf-skin 
collagen diluted in HBSS for 1 h at RT. 
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Adherent cells were passaged at sub-confluence and were washed twice with 
HBSS without calcium and magnesium and de-attached using 0.25 % (w/v) porcine 
trypsin-EDTA (trypsin) for 3 min at 37 oC. Trypsin was inactivated by adding 10 % (v/v) 
of FBS, cells were spun at 300 x g for 5 min and pelleted cells were resuspended and sub-
cultured in a new tissue culture flask at a dilution of 1:5 unless specified otherwise.  
All spared cell passages were cryo-conserved by mixing 106 cells/ml with 10 % 
(v/v) dimethyl sulfoxide (DMSO) in complete cell culture medium (Merk Millipore, 
Watford, Hertfordshire, UK). Then, cells were kept for 24h in a cell-freezing chamber at 
-80 oC prior to transfer to liquid nitrogen for long-term storage. 
All cell lines were maintained in a 95 % (v/v) humidified air and 5 % (v/v) CO2 
incubator at 37 °C. Cells were routinely screened for the presence of mycoplasma using 
MycoAlert Mycoplasma kit (Lonza, Wilford, Nottinghamshire, UK). 
 
2.3. Isolation of brain endothelial cell-derived extracellular vesicles 
 
hCMEC/D3 cells were seeded in 175 cm2 collagen-coated tissue culture flasks. 
After 48 h, cells were washed with HBSS three times and EBM-2 complete medium was 
replaced with 15 ml of EBM-2 complete medium supplemented with 2.5 % (v/v) EV-
depleted FBS (Gibco®Invitrogen, Paisley, UK) instead of normal FBS, hereafter referred 
to as EV medium. Cells were treated with TNFα and IFNγ (R&D Systems, Abingdon, 
Oxfordshire, United Kingdom) at concentrations ranging from 1 to 100 ng/ml (see figure 
legends for specific doses) or EV medium only. CCM was collected 24 h after medium 
was exchanged, when cells had reached 95–100 % confluency (15 × 106 cells per 175 cm2 
tissue culture flask). CCM was centrifuged at 300 x g for 10 min to remove remaining 
live/dead cells and at 2000 x g for 20 min to remove cell debris and large vesicles such 
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as apoptotic bodies. Large EVs (L-EVs) were isolated by centrifugation at 10,000 x g for 
30 min and subsequently washed by resuspending the pellet in 30 ml of PBS. 
Resuspended L-EVs were filtered through a 0.8 µm filter unit (Merk Millipore, Watford, 
UK) and centrifuged at 10,000 × g for 30 min. Pelleted L-EVs were resuspended in either 
PBS, EV medium lacking IGF, EGF, VEGF and FBS or lysis buffer. L-EVs were 
aliquoted and stored at -80 oC for up to two months to minimise vesicle/RNA degradation 
(Wu, Deng and Klinke, 2015). Supernatant from the first separation of L-EVs was used 





Figure 2.1. Work-flow for the isolation of hCMEC/D3 cell-derived EVs. hCMEC/D3 
cells were seeded onto 175 cm2 tissue culture flask for 48h. Media was replaced for EV 
medium with or without combination of cytokines (10 ng/ml TNFα and IFNγ) and cell 
conditioned media (CCM) was collected 24h later. Small and large EV (sEVs and L-EVs) 
were concentrated by removal of large particles by differential centrifugation (300 x g for 






sEVs were isolated from remaining CCM supernatant following either of the three 
different method: precipitation-based method (A), size exclusion (B) and 




CCM supernatant from the first spin of L-EVs was used to isolate sEVs. CCM 
was centrifuged at 120,000 x g for 120 min, subsequently washed by resuspending and 
pooling the pellets together in 30 ml of PBS and centrifuged again at 120,000 x g for 120 
min. sEVs were resuspended and filtered through 0.22µm filter (Merk Millipore, 
Watford, UK). EVs were aliquoted and stored at – 80 oC for up to two months to minimise 
vesicle/RNA degradation (Wu, Deng and Klinke, 2015). All ultracentrifugation steps 
were performed using the Sorvall Discovery (Brea, CA, USA) Superspin 630 Sorvall 
rotor (k factor 226.3) at 4 °C. 
 
2.3.2. Precipitation-based method  
Cold CCM was concentrated using Amicon Ultra-15 filters of 100K (CAR, Merk 
Milipore, UK) by centrifuging at 4,000 x g for 20 min at 4 ºC. If CCM was greater than 
15 ml, the concentration procedure was repeated until 1 ml or less of CCM was obtained. 
CCM was brought to a final volume of 1 ml with fresh PBS and filtered with a 0.22 µm 
filter. Then, sEVs were isolated using miRCURYTM Exosome Isolation Kit (Exiqon, 
Vedbæk, Denmark) according to manufacturer’s instructions. Briefly, 1 ml of CCM was 
transferred to a 2 ml Eppendorf tube, mixed with 400 µl of Precipitation Buffer B and the 
tube was inverted and vortexed thoroughly. CCM was incubated overnight (~18 h) at 4 
ºC. Then, sEVs were isolated by centrifuging the CCM at 10,000 x g for 30 min at 20 ºC. 
Supernatant was removed and a quick spin was applied to remove excess of supernatant. 
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EV pellet was resuspended in 100 µl of Exiqon resuspension buffer. Samples were 
aliquoted and kept at -80 ºC. 
 
2.3.3. Size exclusion  
Cold CCM was concentrated using Amicon Ultra-15 filters with 100K (CAR, 
Merk Milipore, UK) by centrifuging at 4,000 x g for 20 min at 4 ºC. If CCM was greater 
than 15 ml, the concentration procedure was repeated until 1 ml or less of CCM was 
obtained. CCM was brought to a final volume of 1 ml with fresh PBS filtered with a 0.22 
µm filter. Size exclusion columns, qEV, purchased from IZON (Oxford, Oxfordshire, 
United Kingdom) were used to separate sEVs from non-vesicular components. CCM was 
layered on top of the column and was eluted in PBS. After 3 ml of void volume, 0.5 ml 
fractions were collected to a final volume of 8 to 9 ml. Fractions were aliquoted and stored 
at -80oC.  
 
2.4. Nanoparticle tracking analysis 
 
The size and concentration of the EVs were measured using nanoparticle tracking 
analysis (NTA). The Nanosight LM10 (Malvern, Worcestershire, UK) was used to 
compare EVs generated by the different methods of isolation. Prior to analysis, Nanosight 
LM10 was calibrated using synthetic silica microspheres of 100 nm diameter 
(Polyscience Inc, Warrington, PA, USA). LM10 was set to capture videos during 30 
seconds (s) with a camera level of 11; these settings were kept across all samples. Briefly, 
after calibration of LM10, the chamber was washed three times in PBS and samples were 
loaded manually using a Luer-lock disposable 1 ml syringe (Fisher Scientific, Paisley, 
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Renfrewshire, UK). The injected sample was allowed to equilibrate in the chamber for 60 
s and followed by 30 s video capture. Five technical replicates were recorded for each 
sample and the specific temperatures of the LM10 system at each time were annotated. 
Quantification of both size and concentration of sample was assessed using NTA 1.5 
software (Malvern, UK). The NTA software tracks the Brownian motion of each particle 
and calculates particle size and concentration using the Stokes–Einstein equation 
(Equation 1). This equation measures the diffusion coefficient of each particle (Dt) and 
the sphere-equivalent, hydrodynamic radius (rn).  
Equation 1 Strokes-Einstein equation 




Where the KB is Boltzmann’s constant, T is temperature and η is viscosity. 
The chamber was washed three times with PBS between samples in order to remove 
remaining vesicles. 
LM10 Nanosight was used to select the method of isolation of EVs. 
Characterisation of EV size and number was carried out using the NS500 Nanosight, an 
upgraded version of LM10 after an unexpected equipment failure of the LM10. The 
mechanism by which EVs are quantified on the NS500 is the same as LM10 although 
handling of the instrument was less user-dependent. Briefly, the fluidics of the system 
were primed and flushed with PBS prior loading of EVs. Camera focus was adjusted to 
ensure that individual particles could be distinguished and camera level was set at 14 for 
all recordings. Three 30-second videos were recorded for each sample with a delay of 5 s 
between each recording. The accuracy of size detection was calibrated with 100 nm 
diameter silica nanoparticles. NS500 operates with NTA 2.3 software, which followed 
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the same principle of Brownian motion and quantification described above for LM10. 
The NTA system used in individual experiments is indicated in specific figure legends.  
 
2.5. Transmission electron microscopy 
 
Uranyl-oxalate solution (pH 7): 4 % (w/v) uranyl acetate, pH 4 was mixed with 
0.15 M solution of oxalic acid (0.945 g in 50 ml distilled water), at a 1:1 ratio. Then, pH 
was adjusted to 7 by adding 25 % (w/v) NH4OH in drops to prevent formation of insoluble 
precipitates.  
Isolated EVs were resuspended in an equal volume of 4% (w/v) of p-formaldehyde 
(PFA) diluted in PBS. EVs in 2% (w/v) PFA were stored up to 1 week at 4 ºC before 
proceeding further. A drop of 10 µl of EV suspension was placed on a clean parafilm and 
Formvar-carbon coated EM grids (AgarScientific, Stansted, Essex, UK) were placed on 
the surface. Three grids were placed per sample and incubated for 20 min at RT. Grids 
were transferred into 100 µl PBS with clean forceps being careful not to wet the EV-free 
side of the grid. Then, the grids were transferred to a 50 μl drop of 1 % (v/v) 
glutaraldehyde for 5 min. To wash grids with EVs, eight drops of 100 µl of PBS were 
sequentially added to grids for 2 min each wash step. Grids containing the same EV 
sample were placed in the same drops. Grids were transferred to a 50 µl drop of uranyl-
oxalate solution (pH 7) for 5 min. Grids containing EV samples were embedded in a drop 
of 50 µl of a mixture of 2 % (w/v) methyl cellulose and 4 % uranyl acetate at a ratio of 
1:9 and incubated with the embedding solution for 10 min on ice. Grids were removed 
with stainless steel loops and, excess fluid was blotted and discarded by gently pushing 
the loop sideways on Whatman no. 1 filter paper so that a thin film was left behind over 
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the sEV side of the grid. Grids were air-dried for 5 to 10 min in the steel loop. After the 




For Western blot analysis, different buffers were prepared as described below: 
 10 x Tris-buffered saline (TBS-T): 24.22 g/l of Tris-HCl (pH 8.0), 80 g/l of NaCl and 
0.2% (v/v) Tween-20 were mixed. 
 2 x Tris glycine sample buffer (pH 6.8): 0.151 g/l Tris-HCl (pH 8.0), 20 % (v/v) 
Glicerol, 1 % (w/v) of bromophenol blue with 2 mercaptoethanol in a 1:250 
proportion were mixed in 80 ml of distilled water. 
 1 x Tris Glycine running buffer for reducing conditions: 3.038 g/l Tris-HCl (pH 8.0), 
14 g/l glycine, 1 g/l SDS were mixed with distilled water. 
 1x Tris-glycine transfer buffer (reducing conditions): 20 % (v/v) 1 X tris-glycine 
running buffer, 20% (v/v) methanol were mixed with distilled water. 
 RIPA buffer: 20 mM Tris base (pH = 8), 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 
1 mM EDTA, 0.1% (w/v) SDS, 1% (v/v) Igepal, 50 mM NaF, and 1 mM NaVO3 were 
mixed with distilled water. 
 Stripping buffer: 3.91 mM Tris buff (pH 6.8), 20 % (v/v) of 10 % (w/v) SDS and 0.8 
% (v/v) β-mercaptoethanol. 
Isolated EVs or cells were lysed in 1x RIPA Buffer supplemented with protease 
inhibitor cocktail (Merk Millipore, Watford, Hertfordshire, UK). Samples were sonicated 
twice at 20% of amplitude for 10 s on ice (Fisherbrand™ Model 120 Sonic Dismembrator, 
Fisher Scientific, Paisley, Renfrewshire, UK). Protein concentration was measured using 
a DC™ Protein Assay kit (Bio-Rad, Watford, UK). Samples were mixed with 2x Tris 
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glycine sample buffer in a 1:1 ratio and protein were denatured by heating the sample at 
75 ºC for 5 min. Then, pre-cast gel of 4-20 % (w/v) Tris-Glycine (Invitrogen, Paisley, 
Renfrewshire, UK) were loaded with 5 µg of EV sample or 20 µg of cell lysates and run 
at 120 V for 2 h using Superlock western blot system (Thermofisher, Paisley, 
Renfrewshire, UK).  Proteins were transferred onto a nitrocellulose membrane at 300 mA 
for 2 h at RT using Superlock western blot system (Thermofisher, Paisley, Renfrewshire, 
UK). Then, the membrane was blocked with 8 % (w/v) of skimmed milk (Marvel, Premier 
Foods,  St. Albans, Hertfordshire, UK) diluted in TBS-T. Each membrane was incubated 
overnight at 4 ºC with the appropriated antibody diluted in 8 % (w/v) skimmed milk 
diluted in TBS-T (Table 2.1). Subsequently, membranes were washed 3 times with TSB-
T for 10 min and then incubated with their corresponding secondary antibody, goat anti-
rabbit or anti-mouse HRP (System Bioscience Palo Alto, CA, USA), at 1:5000 diluted in 
8% (w/v) of skimmed milk diluted in TBS-T for 60 min at RT (Table 2.1). Subsequently, 
the secondary antibody was removed and the membrane was washed 6 times with TBS-
T for 10 min per wash. After the final wash, enhanced chemiluminescence (ECL) (GE 
Healthcare, Amersham, UK) was used to visualize the immunoblot at 2, 10 and 30 min 
of exposure using G:Box (Syngene, Cambridge, UK).  
To ensure equal protein loading, membranes were stripped by incubating them in 
Stripping buffer at 65 oC for 20 min with continuous stirring. Stripped membranes were 
washed 6 times in TBS-T for 10 min per wash at RT. Then, membranes were blocked, 
stained and imaged for Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
described in the paragraph above.  
Protein quantification was carried out using Image J Software. Images were converted 
to 8 bit and pixel intensity of a defined section surrounding the band of interest was 
measured. Protein expression is calculated by normalised protein expression of the 
86 
 
investigated protein over internal control, GAPDH. Relative expression to the control is 
represented. 
Snap-frozen kidneys were used to isolated protein content from cortex using RIPA 
buffer. Immunoblotting was carried out as described above using specific antibodies for 
NCC (1:500), NKCC2 (1:500) at (1:1000 diluted in 8% (w/v) of skimmed milk diluted in 
TBS-T overnight at 4oC. GADPH (1:50000 diluted in 8% (w/v) of skimmed milk diluted 




Table 2.1. List of primary antibodies used for Western Blotting analysis 
Primary antibody Host Dilution Company 
Anti-human CD63 Rabbit 1:1000 System Bioscience, USA 
Anti-human CD9 Rabbit 1:1000 System Bioscience, USA 
Anti-human HSP70 Rabbit 1:1000 System Bioscience, USA 
Anti-human Ocluddin Rabbit 1:150 Life technology, UK 
Anti-human Claudin-5 Rabbit 1:150 Life technology, UK 
Anti-human VCAM1 Mouse 1:300 R&D Systems, UK 
Anti-human ICAM1 Mouse 1:300 R&D Systems, UK 
Anti-human/mouse GAPDH Rabbit 1:50,000 Life technology, UK 
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Anti-mouse NCC Rabbit 1:500 Sigma-Aldrich, UK 
Anti-mouse KNCC2 Rabbit 1:500 Sigma-Aldrich, UK 
 
2.7. TNFα and IFNγ sandwich ELISA 
 
Enzyme-linked immunosorbent assay (ELISA) kit from DuoSet® (R&D Systems, 
Abingdon, United Kingdom) was used to measure residual levels of TNFα and IFNγ in 
sEVs following manufacturer’s instructions. Capture antibodies for TNFα and IFNγ were 
diluted to working concentrations (4 or 2 µg/ml respectively) in PBS. Then, 100 µl was 
pipetted per well, and the plate was sealed and incubated overnight at RT. Capture 
antibodies were then aspirated, washed three times with 1x wash buffer (0.05% (v/v) 
Tween® 20 in PBS) and wells were thoroughly dried between washes by tapping the plate 
on a clean paper. Subsequently, blocking buffer (1 % (w/v) bovine serum albumin (BSA) 
in PBS) was pipetted in each well and incubated for 1 h at RT in order to block unspecific 
binding. Then, wells were washed as described above. 
On the day of the experiment, fresh standard dilutions from purified TNFα and 
IFNγ were prepared by diluting stocks to a working concentration in reagent diluent (1% 
(w/v) bovine serum albumin (BSA) in PBS). Working concentration was further diluted 
by 2-fold dilution for eight times to prepare the standard curve. 100 µl of standards or 
sample (sEVs diluted in PBS to 108 sEVs/µl) were pipetted in each well. Plates were 
sealed and incubated at RT for 2 h. Then, samples were washed as described above and 
streptavidin-horseradish peroxidase solution, which was diluted to the working 
concentration specified on the vial label using reagent diluent, was added for one h. 
Subsequently, the plate was washed again, the substrate solution added and the plate was 
incubated for 20 min before the reaction was stopped. The plate was read using FLUOstar 
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Optima fluorescence plate reader (BMG Labtech, Aylesbury, UK) at 450 nm and 
background measures taken at 570 nm were subtracted. 
Standard curves were generated for each cytokine by applying the regression to 
the curve with the best fit (Figure 2.2). TNFα standard curve was calculated with a second 
order polynomial (quadratic) equation (Figure 2.2A), whereas IFNy standard curve was 
calculated with a linear regression (Figure 2.2B). Values were inferred using GraphPad 
Prism version 7.1 to draw the best fit curve (GraphPad Software, San Diego, CA, USA).  
 
 
Figure 2.2. Standard curves for measuring TNFα and IFNγ. DuoSet® kit ELISA kit 
was used to determine residual levels of TNFα and IFNγ in small EVs. Standard curves 
were generated to infer the values for the concentration of the cytokines. TNFα standard 
curved was calculated with a second order polynomial (quadratic) equation (A), whereas 
IFNγ standard curve was calculated with a linear regression (B). Graphs are representative 
of two technical replicates. Absorbance is shown as arbitrary units (AU). 
 
2.8. Extraction of RNA from EVs and hCMEC/D3 cells. 
 
RNA was isolated from either cultured cells or sEVs using miRCURY RNA 
isolation kit (Exiqon, Vedbæk, Denmark which is now part of Qiagen, Manchester, UK) 
following manufacturer’s instructions. Briefly, cells or sEVs were incubated with lysis 
buffer, homogenised using a vortex mixer and precipitated by adding an equal volume of 
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pure ethanol. Samples were concentrated using miRCURY columns, washed and eluted 
in 50 µl of elution buffer. RNA concentration and quality (absorbance ratio of 260/280 
and 260/230) was measured using Nanodrop ONE (Thermofisher, Paisley, Renfrewshire, 
UK). 
 
2.9. RT-qPCR analysis for microRNAs and mRNAs. 
 
The reverse transcription for miRNAs was performed using Taqman miRNA 
transcription kit (ThermoFisher, Paisley, Renfrewshire, UK) with specific pre-design 
Taqman primers for miRNA-155-5p (000479-4427975), 126-5p (000451-4427975), 126-
3p (000419-4427975), 24-3p (000402-4427975), 146a-5p (000468-4427975) and 146b-
5p (001097-4427975) following manufacturer’s instructions. Small nuclear U6 RNA 
(U6; 001093-4440887) was used as internal control for cellular miRNAs levels whereas 
let-7g (002282-4440887) was used as control of miRNAs levels in sEVs. Levels of 
miRNAs were analysed using Taqman Universal Master mix with 1.7 ng of cDNA per 
reaction, loaded in Optima thermocycler (Bio-Rad Laboratories Ltd., Watford, 
Hertfordshire UK) and probes were amplified and analysed. 
For mRNA analysis, total cDNA was generated using TaqMan High Capacity 
cDNA Reverse Transcription kit (Applied Biosystem, Life Technologies, Warrington, 
UK) using random primers. QuantiTect Syber® Green master mix (Qiagen, Manchester, 
UK) was used to study the relative levels of mRNAs with 10 ng of cDNA. Pre-designed 
primers for ICAM1, VCAM1, lysine deficient protein kinase 1 (WNK1), annexin A2 
(ANXA2), Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), 
occludin (OCLN) and claudin-5 (CLDN5) were tested whereas β-actin primers were used 
as a housekeeping control of cDNA loading (Merk Millipore, Watford, UK). Gene 
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expression was detected using an Optima thermocycler (Bio-Rad Laboratories Ltd., 
Watford, Hertfordshire UK). 
The relative levels of miRNA or mRNA was calculated using the 2−ΔΔCt (delta-delta Ct) 
method and normalised with β-actin for mRNA and U6 or let-7g for miRNAs. 
Equation 2. Relative RNA expression. 
ΔCt = Ctg-Cti 
ΔΔCt = ΔCtt-ΔCtc 
Relative expression = 2−ΔΔCt 
Where Ct = threshold cycle, Ctg = gene of interest Ct, Cti = internal control Ct, Ctt = 
treated samples Ct and Ctc = control sample Ct. 
The results of microRNA/mRNA relative levels in treated hCMEC/D3 cells, 
cytokine-treated hCMEC/D3 cell-derived small EVs (cytokine-sEVs) or transfected 
hCMEC/D3 cells were expressed as microRNA/mRNA relative expression to 
unstimulated hCMEC/D3 cells, quiescent small EVs (quiescent sEVs) or scramble-
transfected hCMEC/D3 cells, respectively (refer to specific figure legends for more 
detail). 
2.10. Uptake of sEVs by cells of the neurovascular unit. 
 
sEVs were isolated using ultracentrifugation as described above with a 
modification in the final washing step. After the first 120,000 x g centrifugation spin, 
sEVs were resuspended in 5 ml of PBS and labelled with 10 % (v/v) Vybrant-DiO (Life 
technology, Paisley, UK) for 30 min at 37 oC. Same volume of PBS with no sEVs was 
labelled and treated in the same manner in order to control for any free Vybrant-DiO dye 
left in the solution.  Samples were then diluted further with 25 ml of PBS, isolated as 
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described above, resuspended in PBS and stored at -80 oC. sEVs were then quantified 
using the Nanosight S500 as described above. 
hCMEC/D3, HBMP and hA cells were grown in 24-well plates until they reached 
sub-confluency (~95%). Then, cells were washed twice in HBSS and incubated with DiO-
labelled sEVs at concentrations and times specified in figure legends. At the end of the 
incubation time, cells were washed with HBSS, collected using trypsin/EDTA and 
washed twice with HBSS prior to flow cytometry analysis. Washed cells were analysed 
on a Becton-Dickinson FACScalibur (Reading, UK) with a FL1 detector set at 530 V and 
results are reported as the mean±SEM (n=3/4) of the median fluorescence of the analysed 
cells unless stated otherwise in the figure legend.  
For qualitative analysis of the uptake of sEVs, hCMECD3 cells were grown in 
collagen- and fibronectin-coated Nunc® Labteck chamber slides (Merk Millipore, 
Watford, UK). Briefly, Nunc® Labteck chamber slides were first incubated with 1/20 
(v/v) calf skin I collagen diluted in HBSS for 1h at RT. Then coating was replaced by 
1:100 (v/v) bovine fibronectin solution (Merk Millipore, Watford, UK) diluted in HBSS 
for 1h at RT. Cells were cultured with DiO-labelled sEVs for 6, 24 and 48h prior they 
were fixed in 4% PFA for 10 min at RT. PFA was removed and washed three times with 
PBS and once with double-distilled water (ddH2O) prior to addition of the mounting 
media containing DAPI dye (Vector Laboratories, Burlingame, USA) for nuclear 
staining. Images were analysed using confocal laser scanning microscopy (Leica TCS 
SP5, Leica Microsystems, Milton Keynes, UK) and showed as the maximum projection 
of a z-stack of images. images of ten Z stacks of 2.5 μm in depth were acquired using a 




2.11. Electric cell-impedance sensing method 
 
Electric cell-impedance sensing method (ECIS) Z-Theta (Applied BioPhysics, 
Troy, NY, USA) was used to measure the TEER (Ωcm2) of the hCMEC/D3 cell 
monolayers in real time as described previously (Keese et al., 2004).  
Approximately 20,000 cells were seeded onto each well of an array (model 
96W10E+ Applied BioPhysics, Troy, NY, USA) previously coated with calf skin 
collagen type I (as described in section 2.2). Cells were grown to confluency and TEER 
monitored prior to treatment via ECIS. When cells formed a complete monolayer, they 
were treated with sEVs (0.1 to 1x108 sEVs/µl) alone and/or in combination of cytokines 
(TNFα and IFNγ, 1 ng/ml) at doses and times described in specific figure legends. TEER 
was monitored for up to 60 h after cells were treated with cytokines and impedance data 
were collected at different frequencies (250, 500, 1000, 2000, 4000, 8000, 16000, 32000, 
64000 Hz) and at intervals of 12 min through the extension of the experiment. 
To further investigate the effect of sEVs in cytokine-activated cells, confluent 
hCMEC/D3 cells were pre-activated with 1 ng/ml TNFα and IFNy for 18 h and sEVs 
were then added in the presence or absence of cytokines.  
The  ECIS  measurements  were  further  analysed  and  subjected  to  a  
mathematical modelling to calculate the TEER at each time point (Giaever and Keese, 
1991). Experimental differences were analysed every 5 h since beginning of the treatment 
and Rb data are shown as percentage of control at each time point.  
 




T cell adhesion was measured using a flow-based adhesion assay adapted from 
previously published data (Wu, Cerutti, Miguel A Lopez-Ramirez, et al., 2015; Cerutti et 
al., 2017). The system is based on a multi-channel plate specifically designed for 
experiments including shear stress (Ibidi® μ-Slide VI0.4, Ibidi® GmbH, Martinstreid, 
Germany).  
hCMEC/D3 cells were collected, centrifuged and counted in order to dilute 20,000 
cells in 30 µl of EBM2 complete medium. Diluted cells were seeded per channel of 
collagen-coated Ibidi® μ-Slide VI0.4. Twenty minmin after seeding, channels were 
topped-up with EBM2 complete medium and cells were kept in culture until confluence 
unless stated otherwise.  
After reaching confluence, hCMEC/D3 cells were incubated with sEVs (0.1 to 
1x108 sEVs/µl) alone or in combination with cytokines (TNFα and IFNy, 1ng/ml for 24 
h) at times (0 to 48h) described in specific figure legends. At the end of the incubation 
time, cells were washed twice with HBSS and kept in EBM2 complete media. Incubation 
with 1 ng/ml TNFα and IFNy for 24h was used as positive control for the experiment 
(Cerutti et al., 2016). 2 × 106 cells/ml Jurkat T cells were labelled with 5 µM 5–
chloromethylfluoresceindiacetate (CMFDA, Life Technologies, Eugene, USA) for 30 
min in RPMI basal media at 37 oC. Cells were washed in complete RPMI media for 45 
min, centrifuged and resuspended in EBM2 complete media at 2 × 106 cells/ml Jurkat T 
cells. Then, cells were flowed through the channel containing endothelial monolayers at 
0.5 dyn/cm2 for 5 min. After that, the flow was increased to 1.5 dyn/cm2 to mimic venular 
vessel wall shear stress for 1 min to remove non-adhered leukocytes. Interactions between 
leukocyte and endothelial cells were recorded for 6 min and firm leukocyte adhesion was 
quantified. Eight to ten different fields of vision (FOV, 640 × 480 μm) along the centre 
of the channel were imaged and firmed adhered leukocytes were manually counted. Image 
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acquisition was carried using inverted fluorescence microscope (Olympus IX70, Tokyo, 
Japan) with an X10 objective. Microscope was controlled by the Image Pro Plus software 
(Media Cybernetics Inc. Bethesda, USA).  
To study the role of VCAM1 and ICAM1 in sEV-induced leukocyte adhesion, 
hCMEC/D3 cells were washed and incubated with 30 µg/ml neutralising antibodies 
against ICAM1, VCAM1 or mouse IgG (R&D Systems, Abingdon, United Kingdom) for 
1 h at 37 oC in EBM-2 basal media. After incubation, cells were washed and experiment 
carried as described above. Firmly adhered Jurkat T cells were counted and expressed as 
fold change of sEVs treated cells over the corresponding untreated control. 
 
2.13. Transfection of hCMEC/D3 cells 
 
hCMEC/D3 cells were transfected using lipofection techniques with two different 
reagents: SiportTM (Life Technologies, Paisley, Renfrewshire, UK) for pre-miRNA-155 
and Lipofectamine 2000 (Thermofisher, Paisley, Renfrewshire, UK) for siRNAs and anti-
miRNAs. 
hCMEC/D3 cells were seeded at 25,000 cells/cm2 and 8 h after, cell culture 
medium was replaced with complete EBM2 media without GA-1000. Twenty-four hh 
after seeding, cells were transfected with either SiportTM or Lipofectamine 2000 following 
manufacturer’s instructions. Briefly, lipofection reagent was mixed with OptiMEM I 
reduced serum  medium and incubated for 10 min (SiportTM) or 5 min (Lipofectamine 
2000). Next, the mix was diluted with the desired oligonucleotides (Table 2.2) and 
incubated for 10 min (SiportTM) and 20 min (Lipofectamine 2000) at RT. Finally, the 
transfection reaction was diluted in complete EBM2 lacking GA-1000 to obtain a final 
concentration of the oligonucleotides of 30 nM (SiportTM) or 60 nM (Lipofectamine). 
95 
 
Media was replaced 6h (SiportTM) or 24 h (Lipofectamine) after transfection. Cells were 
kept in culture from 0 to 48h post-transfection.  
 
Table 2.2. List of oligonucleotides used for transfection of hCMEC/D3 cells. 
Oligonucleotide Target Company 
miRNA precursor miRNA-155-5p Thermofisher, UK 
miRNA precursor Scramble control 1 Thermofisher, UK 
siRNA pool WNK1 Dharmacon, USA 
siRNA pool Scramble control Dharmacon, USA 
 
 
In order to assess the efficacy of transfection of hCMEC/D3 cells with SiportTM 
reagent, hCMEC/D3 cells were transfected as described above but using Cy3-labelled 
oligonucleotide as a negative control (Thermorefisher, Paisley, UK). Both 
immunofluorescent microscopy using inverted fluorescence microscope (Olympus IX70, 
Tokyo, Japan) and flow cytometry analysis, using a Becton-Dickinson FACScalibur 




hCMEC/D3 cells were seeded onto collagen- and fibronectin-coated (1:100) Lab-
TekTM multiwell chamber slides (Sigma, UK), transfected as described above or treated 
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with 1 ng/ml TNFα and IFNy for 24 h. At the end of the experiment, hCMEC/D3 cells 
were washed twice in HBSS and incubated with 4 % (w/v) PFA in PBS for 20 min at RT. 
Subsequently, cells were washed with PBS three times and permeabilised with 0.5 % (v/v) 
Triton-X100 (Merck Millipore, Watford, Hertfordshire, UK) in PBS for 10 min at RT. 
Cells were blocked with 10% (v/v) FBS for 1 h. Primary antibody rabbit anti-human 
WNK1 was incubated overnight at 4 oC (1:50). Cells were washed with PBS three times 
and twice with PBS containing 0.025 % (v/v) Tween-20 at pH 7.4 (Merk Millipore, 
Watford, Hertfordshire, UK) and incubated for 1h at RT with a corresponding secondary 
goat anti-rabbit or anti-mouse antibody conjugated to Alexa Fluor 488 (Zymed, Life 
Technologies Ltd. Invitrogen division, Paisley, UK). Cell nuclei were stained using Dapi 
Fluoromount-G obtained from SouthernBiotech (Alabama, USA). Slides were viewed 
with a fluorescent microscope (Olympus BX61,Olympus, Hertfordshire, UK). Signal was 
quantified by pixel intensity and normalised by DAPI signal using Image J software. 
 
2.15. Databases for putative mRNA targets of miRNAs 
 
Open-access database for target identification was HumanTargetScan 7.2 
(http://www.targetscan.org/vert_72/, last access on September 2020). Tarbase v.8 
(http://carolina.imis.athena-
innovation.gr/diana_tools/web/index.php?r=tarbasev8%2Findex, last access on 
September 2020) was used to obtain the list of validated targets for miRNA-155. 
Comparisons among databases and mRNA/protein expression data was carried out with 






2.16. Animal husbandry  
 
C57bl/6 (wild-type (WT)) and B6.Cg-miR-155 (miRNA-155 knock-out (KO)) 
mice (Charles River, Kent, UK) were used in this study. All genetic modified strains had 
a C57bl/6 genetic background. All animal work was approved by The Open University 
Animal Welfare and Ethics Research Board and the UK Home Office (PPL 80/2612). 
Animals were housed on a 12 h light/dark cycle at temperature range from 19 to 22 °C, 
relative humidity 55±10% (v/v). Mice were housed in groups of 3 or 4 mice per 
polypropylene mouse (NPK, Selbitz, Germany) stored in ventilated cabinet (Scanteiners; 
Scanbur, Karlslune, Denmark). Diet (SDS Rat and Mouse No. 3), bedding (Enviro-Dri® 
and Sizzle-Pet, Paper Wool and Shavings), nesting (LBS Gold Aspen Midi 8/20), 
woodblocks (Aspen Blocks) and fun tunnels (GLP Fun Tunnels) were obtained from LBS 
Biotechnology (UK). Food and water was provided ad libitum. 
 
2.17. Genotyping miRNA-155 KO mice 
 
Ear punches were collected from each mouse and stored at -21 oC until tissue was 
processed. Digestion solution was prepared by mixing protenease K (final concentration 
0.52 mg/ml; Sigma-Aldrich, Watford, Hertfordshire, UK ) and tail buffer (0.05 M Tris 
pH 7.5, 0.1M EDTA and 2.5 % (v/v) of 20 % (v/v) SDS). Ear punches were resuspended 
in 100 µl of digestion buffer and incubate at 55 oC in a heat block overnight. Proteinase 
K was deactivated by heating the sample at 85 oC for 1 h. Samples were centrifuged at 
13,000 rpm for 1 min. Subsequently, DNA concentration was measured by Nanodrop 
ONE (Thermofisher, Paisley, Renfrewshire, UK). Samples were diluted to 10 ng/µl and 
stored at -21 oC.  
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Master Mix was prepared according to manufacter´s instructions. Briefly, 1x Taq 
Red Master Mix Kit (1.5 mM MgCl2, Genesee Scientific, El Cajon, USA), 1 µM primer 
WT forward (GTGCTGCAAACCAGGAAGG), primer WT Reverse 
(CTGGTTGAATCATTGAAGATG) and primer mutant 
(CGGCAAACGACTGTCCTGGCCG). Master mix was mixed with 20 ng of DNA 
material in a reaction with a total volume of 25 µl. Samples were run in a thermocycle at 
94 oC for 5 min, then 35 cycles of 94 oC/30 sec, 61.8 oC/1 min and 72 oC/1 min, followed 
by 72 oC for 2 min. PCR reactions were separated based on size using E-gel pre-cast 2% 
(w/v) agarose (Thermofisher, Paisley, Renfrewshire, UK) and 100 bp DNA loading 
control (15628-019, Invitrogen, Paisley, Renfrewshire, UK). Gels were revealed and 
imaged using the G:Box (Syngene, Cambridge, UK). 
 
2.18. Water and food intake 
 
Both miRNA-155 KO and WT mice were housed in cages with three to four 
animals each according to both genotype and sex. Water and diet intake was measured 
for seven days every four weeks from the time of weaning. On day 1, the bottle of water, 
the food pellets and the mice themselves were weighed in the morning. Every day 
thereafter and at the same time, the bottle of water was weighed and refilled. On day 7, 
food pellets remaining in the cage, mice as well as the bottle of water were weighed. Daily 
water and food intake were calculated as the average over the period of measurement 
divided by the number of mice housed in a cage. Both water and diet intake are expressed 




2.19. Urine and Blood analysis 
 
Urine specific gravity was used to assess the extent of urine concentration. Briefly, 
a drop of urine was collected from each mouse after finishing the measurement of the 
water and diet intake by gently grabbing the mice over a Parafilm-coated surface. Urine 
concentration was measured during three consecutive days at the same time of the day 
using a refractometer for urine and serum specific gravity (Burtons, Kent, UK). 
Blood was collected by intracardiac puncture in 18-month female miRNA-155 
KO and WT mice. Blood was transferred to a heparinised tube (serum- or plasma-
specific) and inverted once. Tubes were incubated at RT for 30 min followed by 
centrifugation at 8,000 x g for 10 min at 4 ºC. Supernatants, containing either plasma or 
serum, were transferred to a clean Eppendorf tube. 
Osmolality and electrolytes of serum and urine were analysed by an external 
laboratory managed by IDEXX BioResearch (Ludwigsburg, Germany).  
In addition to this protocol, blood was also collected after fasting 18 month female 
B6.Cg-miR155 mice for 8 h. Subsequently, glucose levels in blood were measured using 
a glucometer (Accu check-meter, Roche, Germany). 
 
2.20. Arg8-Vasopressin ELISA assay 
 
Standards for AVP ELISA assay kit (Abcam, Cambridgeshire, UK) were made 
following manufacturer’s instructions. Briefly, a stock solution of AVP was serially 
diluted to obtain standards ranging from 10.24 pg/ml to 10,000 pg/ml. For analysis, 
plasma samples were thawed and AVP was concentrated using the manufacturer’s 
extraction protocol. Two volumes of cold acetone were added to each sample, followed 
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by vortex mixing and centrifugation at 3,000 x g for 20 min at 4 ºC. Then, the supernatant 
was transferred into a clean Eppendorf tube and 5 volumes of petroleum ether were added. 
The mix was vortex mix and centrifuged at 3,000 x g for 10 min at 4 ºC. Subsequently, 
the top layer was discarded and the aqueous phase was transferred into a clean glass tube. 
Then, the tube was dried down under oxygen. The remaining pellet was reconstituted 
using Assay buffer, provided by the ELISA assay kit. 
Once standards and samples were ready, the ELISA plate was prepared following 
manufacturer’s instructions. Briefly, 100 µl of each standard, sample and blank solution 
were loaded onto their corresponding wells. Then, 50 µl of vasopressin biotin conjugate 
was added to each well, except for the blank wells, followed by 50 µl of vasopressin 
polyclonal rabbit antibody. The plate was then incubated at 4 ºC for 24 h. After 
incubation, the plate was washed three times with wash solution (provided by the kit) and 
finally 200 µl of streptavidin-conjugated HRP were added to each well, except for the 
blank wells. The plate was sealed and incubate at RT on a plate shaker for 30 min at 500 
rpm.  
After incubation of the plate for 30 min, the plate was washed as described above. 
Then, 200 µl of the 3,3',5,5'-Tetramethylbenzidine substrate was added to every well. The 
plate was sealed again with parafilm and incubated at RT for 30 min on a plate shaker. 
Finally, the reaction was stopped by adding 100 µl of Stop solution and the optical density 
of each well was read at 450 nm using a FluoStart Optima plate reader (BMG Labtech, 





2.21. Desmopressin challenge 
 
To study kidney response to AVP, 18-month female miRNA-155 mice were injected 
with 0.04 µg/Kg of desmopressin (DDAVP) (Sigma, Poole, Dorset, UK) diluted in saline 
solution (0.9 NaCl % (w/v)) subcutaneously. Urine was collected prior to injection and 1 
and 2 h after. Urine collection was carried out with a Pasteur pipette and mice were placed 
over a para-film sheet. Water availability was restricted during the period of the 
experiment. Experiment was carried twice in each animal with a period of 48 h between 
injections. Urine was analysed for osmolality as described above. 
 
2.22. RT-qPCR of animal tissue 
 
For hypothalamus, PBS-perfused brain was collected in RNAlater solution 
(ThermoFisher, Paisley, Renfrewshire, UK) and incubated for 24 h at 4 ºC. A brain slicer 
(Zivic Instruments, Pittsburgh, USA) was used to dissect the tissue into slices and the 
hypothalamus was separated under a microscope. Morphological identification of the 
hypothalamus was used following the mouse Allen brain atlas (https://mouse.brain-
map.org/static/atlas). Briefly, 1 cm from the third ventricle was used to dissect the area of 
the hypothalamus. The hypothalamus was disrupted in Qiazol® (Qiagen, Manchester, 
Greater Manchester, UK) solution using a tissue homogenizer pestle (Fisher Scientific, 
Paisley, Renfrewshire, UK). RNA was isolated with miRNesy kit (Qiagen, Manchester, 
Greater Manchester, UK) following manufacturer’s instructions. For kidney, the cortex 
was dissected manually and stored in RNAlater solution overnight at 4oC. Renal cortex 
was manually disrupted with a scalpel prior Qiazol® solution was added. Then, tissue 
homogenizer was used to further disrupt the tissue. One seventh of the kidney solution 
was further diluted with Qiazol® and RNA isolated following miRNesy isolation kit´s 
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instructions. RNA was measured by Nanodrop ONE (Thermofisher, Paisley, 
Renfrewshire, UK). 
Reverse transcription was carried out using high capacity reverse transcription kit 
as described in 2.1.9. (Thermofisher, Paisley, Renfrewshire, UK). Taqman chemistry was 
used for interrogating hypothalamus mRNAs using specific primers for AVP and 
oxytocin (OXC) and β-actin as housekeeping internal control. Sybr green chemistry (Sybr 
Green Master Mix, Qiagen Manchester, Greater Manchester, UK) was used for measuring 
levels of WNK1 using specific primers (Kickstart pre-designed primers, Merk Sigma, 




Mice were deeply anesthetised with an overdose of sodium pentobarbitone (20% 
(w/v) via intraperitoneal injection (IP), Animalcare, York, UK) and perfused 
intracardially with PBS followed by 4 % (w/v) PFA in PBS at a rate of 5 ml/min. Isolated 
organs were post-fixed in 4 % (w/v) PFA overnight at 4oC. To prepare brains for slicing, 
PFA was replaced with 30 % (w/v) sucrose solution in PBS at 4oC until the brain sunk to 
the bottom of the tube. Brains were mounted on a slicing platform and embedded with 
optimal cutting temperature (OCT) solution at -21 oC. Frozen OCT-embedded brains 
were cut into coronal slices of 20 µm thickness using a cryostat. Brain slides were 
collected into wells from a 24-well plate containing freezing media (30 % (v/v) glycerol, 
30 % (v/v) ethylene glycol, 40 % (v/v) PBS).   
Sections were transferred onto a new plate containing PBS and washed 3 times in 
PBS for 5 min each on a 100 rpm on lab bench shaker (Twist Shaker TW3, FINEPCR, 
Korea). Slides were cultured in 3 % (v/v) H2O2 diluted in PBS for 15 min on a shaker. 
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Slides were then washed three times in PBS for 5 min each time in a shaker. Slides were 
blocked using 15 % (v/v) Normal Donkey Serum (NDS) in PBS for 15 min on a shaker 
at RT.  Subsequently, NDS solution was removed and slides were cultured with primary 
antibody (1:1000 rabbit anti- mouse AVP was diluted in PBS + 0.1 % (v/v) Triton-x100) 
(AVP antibody, Abcam, Cambridge, UK) overnight at 4 oC on shaker. Next day, slides 
were washed three timeswith PBS for 5 min on shaker and then incubated in a biotinylated 
secondary antibody against rabbit diluted in PBS + 0.1 – 0.5% Triton-x100 at 1:400 for 
1 h. Sections were washed in PBS for 5 min during three cycles and subsequently 
incubated in Vectastain™ ABC kit (Vector Laboratories Ltd, Peterborough, UK) (1:200) 
diluted in PBS+0.01 % (v/v) Triton-x100 for 1 h. Staining was developed using DAB 
chromagen (Merk Millipore, Dorset, UK) with glucose oxidase enhancement, which was 
followed by slide mounting and dehydration through a series of alcohols and xylenes. 
Coverslips were then placed on slides using DPX (Fisher Scientific, Loughborough, UK). 
Photomicrographs from DAB-stained tissue were obtained using a Nikon Eclipse 80i 
light microscope and Picture Frame Software.  
 
2.25. Statistical analysis 
 
All data are presented as mean ± SEM (standard error of the mean) from a number 
of independent experiments (n) with replicates specified in each figure legend. Normality 
of data was assessed with Shapiro-Wilk test. P values were calculated using one-way 
ANOVA and Tukey’s multiple comparisons test when all groups were compared or 
Dunnet´s post hoc when groups were compared only to control group. Two-way ANOVA 
was used to compare experiments where two independent variables were compared 
followed by Tukey´s post hoc test. Paired two-tailed t-test was used when one comparison 
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between only two groups was designed in the experiment. Statistically significant 
differences are presented as P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) P < 0.0001 
(****). Statistical calculations and graphic figures were performed using the statistical 


















CHAPTER 3: Isolation and characterisation of 




In recent years, pioneering research on the biology of EVs has demonstrated that 
these lipid membrane-enclosed carriers can carry inflammatory mediators such as 
miRNAs and mRNAs to modulate the inflammatory response in both the vasculature and 
immune system (Ramirez et al., 2018). However, one of the challenges faced to achieve 
reproducible results across experiments is the optimisation of the method of isolation for 
EVs (Théry et al., 2018).  
Because there is no definitive isolation method, the ISEV released a collection of 
guidelines (MISEV2014 and MISEV2018) to help researchers to select an isolation 
method that is best suited to their experimental design (Lötvall et al., 2014; Théry et al., 
2018). Currently, methods are categorised in four groups based on the degree of recovery 
(proportion of EV isolated in comparison to the source fluid of EVs) and specificity 
(isolation of EV components from non-EV components or other EV subtypes). These 
categories are: 1) high recovery and low specificity (e.g. precipitation-based method), 2) 
intermediate recovery and intermediate specificity (e.g. differential centrifugation), 3) 
low recovery and high specificity (e.g. size exclusion), and 4) high recovery and high 
specificity. This latest group is unachievable with the current methodologies (Théry et 
al., 2018).   
A world-wide survey of EV research revealed that the majority of studies opted 
for ultracentrifugation as their preferred method for isolation of EVs in an attempt to 
balance recovery and specificity (Gardiner, Di Vizio, et al., 2016). Many researchers also 
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routinely use a combinatorial approach for EV isolation  such as density gradient isolation 
followed by size exclusion (Gardiner, Vizio, et al., 2016; Onódi et al., 2018). Once 
selected, it is important that the method is then tested and optimised for the conditions 
and cellular source used within the experimental design (Théry et al., 2018).  
Only few reports have attempted to characterise the different EVs derived from 
cells comprising the NVU, in particular, BECs. Haqqani et al. described an 
ultracentrifugation-based method for separating sEVs from CCM of cultured human 
BECs (hCMEC/D3 cells) under naïve conditions (Haqqani et al., 2013). Treatment of 
hCMEC/D3 cells with TNFα increased the number of EVs as well as the amount of pro-
inflammatory proteins carried within such as VCAM1, ICAM1 or pentraxin 3 (PTX3) 
(Dozio & Sanchez, 2017). This study showed for the first time a proteomic 
characterisation of human BEC-derived EVs in inflammation. However, characterisation 
of pro-inflammatory RNAs (miRNAs and mRNAs) carried by human BEC-derived EVs 
is still poorly understood. Interestingly, Yamamoto et al., investigated the miRNome of 
EVs derived from murine BECs after treatment with a cocktail of inflammatory 
modulators (pro-inflammatory cytokines and LPS) and identified mmu-miR-328-3p, 
mmu-miR-211-5p and mmu-let-7d-3p as the highest up-regulated miRNAs within the 
EVs (Yamamoto et al., 2015). Indeed, mmu-let-7d-3p was proposed to target Yin and 
yang 1 mRNA (YY1) to regulate YY1´s downstream gene vascular endothelial growth 
factor B (VEGFB) in mouse pericytes (Yamamoto et al., 2015). Unfortunately, it is 
possible that the cargo of BEC-derived sEV differs across species. 
Lastly, it is very likely that the effect of secreted EVs and their cargo contents are 
both treatment- and target cell-dependent. Different pro-inflammatory modulators (e.g. 
LPS, TNFα or IFNγ) have been previously shown to affect endothelial function and 
mimic phenotypes observed in neuroinflammatory disorders (Lopez-Ramirez et al., 2013; 
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Liang et al., 2014; Ni et al., 2017). LPS is a lipopolysaccharide protein from Gram-
negative bacteria normally used to study the effect of bacterial infection and general 
systemic inflammation in cells (Liang et al., 2014). However, the study of systemic 
inflammation can also be approached by investigating the single or combinatory effect of 
pro-inflammatory cytokines relevant to neuroinflammatory disorders. Previously, TNFα 
and IFNγ have been reported to modulate the function of human BECs via the modulation 
of miRNAs including hsa-miRNA-155, hsa-miRNA-126-3p or hsa-miRNA-146a-5p 
(MA. Lopez-Ramirez et al., 2016). Whether these intracellular changes are reflected in 
the secreted EVs by BECs is still poorly understood. 
The aim of this chapter was to determine an EV isolation method that yielded the 
most concentrated EV population with a suitable purity (e.g. enriched EV markers) from 
human BECs under naïve and inflamed conditions. To achieve this aim, a systematic 
comparison of the number of isolated sEVs by ultracentrifugation, precipitation-based 
and size exclusion methods for the separation of sEVs were carried out. Subsequently, 
determination of the specificity of sEVs isolated via the two methods that generated the 
greatest yield of sEVs following isolation was analysed by western blot. 
The physical properties of EVs isolated from hCMEC/D3 cells were studied. For 
this purpose, a comparison of the number, diameter size and morphology of sEVs and L-
EVs isolated from CCM of hCMEC/D3 cells treated with pro-inflammatory cytokines 
was carried out. Based on these results, RNA cargo of one subset of EVs (either sEVs or 
L-EVs) was also analysed. Therefore, measurement of the levels of pro- or anti- 
inflammatory miRNAs and mRNAs in the cargo of EVs isolated from cytokine-






3.2.1. Dose-dependent effect of cytokines on the yield of sEVs isolated 
from hCMEC/D3 cells. 
 
Prior to selecting the standard method to isolate sEVs, the impact of the 
combination of cytokines (TNFα and IFNγ) on the number of isolated sEVs from 
hCMEC/D3 cells was investigated using the precipitation-based method. Under 
basal/unstimulated conditions, the hCMEC/D3 cells secreted 1.4±0.2x107 sEVs/cm2 of 
confluent cells (n=4) (Figure 3.1.A). Low doses of TNFα and IFNγ (1 ng/ml) did not 
significantly increase the secretion of sEVs (2.7±0.7x107 sEVs/ cm2 of confluent cells, 
P>0.05 and n=4) (Figure 3.1.A). However, treatment with medium and high doses of 
TNFα and IFNγ (10 and 100 ng/ml) significantly increased the number of sEVs recovered 
from the CCM of hCMEC/D3 cells compared to untreated cells (6.7±0.8x107, P<0.05, 
and 8.0±1.4x107 sEVs/cm2 of confluent cells, P<0.05 and n=4, respectively). No 
differences were observed in the number of isolated sEVs from hCMEC/D3 cells treated 





Figure 3.1. Effect of the combination of cytokines in the diameter size and number 
of sEVs isolated from hCMEC/D3 cells. hCMEC/D3 cells were treated with increasing 
doses of a combination of TNFα and IFNγ (0, 1, 10 and 100 ng/ml) for 24 h following 
small EVs (sEVs) isolation by the precipitation method. (A) Number of sEVs recovered 
after treatment with pro-inflammatory cytokines as measured by nanoparticle tracking 
analysis using an LM10 Nanosight. (B) Histogram of the distribution in diameter of sEVs. 
Data are showed as mean±SEM of n = 4 independent replicates with 5 technical 
replicates, P*<0.05. Differences were measured by one-way ANOVA with Tukey’s 
multiple comparisons test. 
 
The histogram distribution for the diameter size of the isolated sEVs secreted by 
hCMEC/D3 cells remained similar regardless of the treatment with the combination of 
cytokines (TNFα and IFNγ) (Figure 3.8.B). Indeed, both mean and mode diameter size 
of sEVs were not significantly altered with treatment of pro-inflammatory cytokines 
(Table 3.1.). 
Table 3.1. Average data on hCMEC/D3 cell-derived sEVs after treatment with 






Control 177±6 159±9 
1 ng/ml TNFα & IFNγ 187±8 170±9 
10 ng/ml TNFα & IFNγ 191±5 165±6 
100 ng/ml TNFα & IFNγ 179±4 169±7 
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3.2.2. Comparison of the methods of isolation of BEC-derived sEVs on 
vesicle number and size by NTA 
 
To determine which of three well-known methods for the isolation of sEVs – 
ultracentrifugation, precipitation-based and size exclusion – yielded the purest and most 
concentrated fraction of sEVs from hCMEC/D3 cells, a systematic comparison was 
carried out. Based on Figure 3.1., hCMEC/D3 cells were treated with 10 ng/ml TNFα and 
IFNγ for 24 h to stimulate a high recovery of sEVs. Using cytokine-treated hCMEC/D3 
cells was a decision made for practical reasons to reduce the quantity of cultured 
hCMEC/D3 cells needed to harvest a greater number of sEVs to carry the comparison of 
these three methods of EV isolation.   
Before carrying out a systematic comparison of the isolation methods, the 
concentration of sEVs and protein content across the fractions collected using size 
exclusion were screened. Seventeen fractions of 0.5 ml were generated from the CMM. 
Fractions two and three were observed to contain the highest concentration of sEVs with 
the lowest amount of protein content (Figure 3.2). Fractions five and higher were enriched 
in soluble proteins and showed very low concentration of sEVs (Figure 3.2). Based on 







Figure 3.2. qEV histrogram of EV number and protein content. Size exclusion 
method provided by Izon Science (Oxford, UK) was used to separate small EVs (sEVs) 
from pre-treated conditioned cell media (CCM) of hCMEC/D3 cells. Fractions were 
measured for protein content (black line) and sEVs concentration (sEVs/ml, green line). 
Data are the raw value of one experiment. 
 
Next, the number and size of particles isolated using the three EV isolation 
methods were compared using NTA with an LM10 Nanosight (Malvern, Worcestershire, 
UK). As shown in Figure 3.3.A, the calibrated instrument detected nanoparticles in 
between 7 to 617 nm in diameter size, with a mode of 107±1 nm diameter.  
Systematic comparison of sEVs isolated from all three methods revealed that the 
precipitation-based method and ultracentrifugation isolated 3.7±0.8x107 and 3.2±0.1x107 
sEVs/cm2, respectively, whereas size exclusion recovered 1.02±0.07x107 sEVs/cm2 from 
the CCM of confluent hCMEC/D3 cells (Figure 3.4.B).  Indeed, precipitation-based and 
ultracentrifugation techniques isolated significantly higher number of sEVs than size 
exclusion (P<0.01 and P<0.05, respectively; n=3).  
Then, whether there were any differences in the diameter size distribution of the 
sEVs isolated from each method was investigated. All three methods isolated vesicles 
ranging mostly from 0 to 250 nm in size. The mode for the diameter of sEVs isolated by 
size exclusion was 160±5 nm whereas mode for the diameter of sEVs isolated using 
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precipitation and ultracentrifugation were 170±16 and 173±14 nm respectively (Figure 
3.3.C). However, there was no significant difference in the size distribution of all three 
methods.  
 
Figure 3.3. Systematic comparison of three methods for the isolation of sEVs. (A) 
Histogram of particles size distribution with a representative image of the video recorded. 
LM10 Nanosight was calibrated using 100 nm silica nanoparticles prior measurements 
and size of the nanoparticles were confirmed (mode=107±1 cm), (B) Number of small 
EVs (sEVs) recovered per cm2 of confluent hCMEC/D3 cells by each method: 
precipitation, ultracentrifugation and size exclusion as measured using nanoparticle 
tracking analysis via an LM10 Nanosight. (C) Representative video images of particle 
recordings and histograms of the size distribution of vesicles recovered by each method. 
Data are shown as mean±SEM of n=3 of independent replicates with 3 technical 
replicates, P*<0.05, P**<0.01. Results were analysed using one-way ANOVA with post-
hoc Tukey's multiple comparisons test. 
 
These results revealed that both the ultracentrifugation and precipitation-based 
method recovered a significantly higher number of vesicles than size exclusion without 
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affecting the general size of sEVs. Therefore, the size exclusion method was not pursued 
further.  
3.2.3. Effect of the method of isolation on markers for sEVs. 
 
To compare the purity of sEVs between the precipitation or ultracentrifugation 
methods, samples isolated from both methods were analysed for protein and RNA content 
per vesicle as well as expression of specific protein markers for sEVs (Figure 3.4). No 
significant differences were observed between both isolation methods regarding the ratio 
of ng of RNA per vesicle (6.6±1.4x10-8 and 4.7±1.5x10-8 ng RNA/sEVs respectively, 
P>0.05, n=3) (Figure 3.4.A). Conversely, sEVs recovered using the precipitation-based 
method contained significantly higher amount of protein per vesicle than sEVs isolated 
by ultracentrifugation (2.3±0.4x10-8 and 0.8±0.2x10-8 µg/sEVs, respectively and P<0.05; 
n=3) (Figure 3.4.B). This observation suggested an increased extracellular protein 
contamination in the precipitation-based method-isolated sEVs. 
The expression of sEV markers, tetraspanins CD63 and CD9 as well as heat shock 
protein HSP70, were evaluated by Western blotting.  Following standard guidelines for 
immunoblotting, equal amounts of protein were loaded and semi-quantitative comparison 
of protein expression was carried out. The immunoblot revealed stronger intensity in the 
bands for all three markers in the samples isolated by ultracentrifugation when compared 
to the precipitation-based method (Figure 3.4.C). Equal protein amounts of cell lysates 
were used as positive controls for the detection of sEV markers by immunoblotting. 






Figure 3.4. Analysis of the purity of the sEVs. (A) Quantification of total RNA per 
small EVs (sEVs), separated from the same cell culture supernatant and isolated by 
ultracentrifugation or precipitation method. (B) Quantification of total protein per sEVs 
measured by DC protein assay (Bio-Rad, Watford, UK). Differences were analysed by 
paired two-tailed t-test. Data presented as mean ± SEM (n =3), P*<0.05. (C) Cropped 
images from western blot analysis of EV markers (CD9, CD63 and HSP70) from sEVs 
isolated using precipitation method or ultracentrifugation. Equal amount of protein from 
cell lysates (CL) was used as positive controls. 
 
Taking all these results together, ultracentrifugation appeared to be the optimal 
method to isolate sEVs from hCMEC/D3 cells as it provided the highest yield combined 
with low extracellular protein contamination. However, ultracentrifugation may also pull 
down some of the soluble TNFα and IFNγ remaining in the CCM following treatment 
thereby impacting on downstream applications. Therefore, the concentration of residual 
TNFα and IFNγ in the CCM following 24 h of cytokine incubation with BECs was 
measured by ELISA. TNFα and INFγ residual concentration in the CCM was 
115 
 
117.52±19.82 and 142.25±32.43 ng, respectively. In isolated EVs, concentrations of 
TNFα and IFNγ were 0.012±0.008 and 0.015±0.005 ng respectively (Figure 3.5), 
suggesting that less than 1% of residual exogenously added TNF and IFN was 
contained within the EV mixture.  
 
Figure 3.5. Residual quantity of pro-inflammatory cytokines TNFα and IFNγ. 
Measurement of soluble TNFα and IFNγ in cell conditioned media (60 ml, CCM) and 
intact small EVs (1 ml, sEVs) with DuoSet ELISA. Data are showed as mean ± SEM of 
n= 3 P*<0.05. Differences were measured by paired two-tailed t-test. 
 
3.2.4. hCMEC/D3 cells secrete higher number of sEVs than L-EVs  
 
Conventional methods for the isolation of EVs enrich for two fractions of EVs: 
sEVs (<200nm) or L-EVs (>200nm) (Théry et al., 2018), which have different functional 
roles (Tkach et al., 2017). To determine the proportion of L-EVs and sEVs isolated 
following ultracentrifugation, the number, size and morphology of EVs under basal 
(quiescent sEVs and quiescent L-EVs) and inflammatory conditions (10 ng/ml of TNFα 
























and IFNγ, therefore, cytokine-sEVs and cytokine-L-EVs) was measured using NTA via 
a Nanosight S500 and TEM (Figure 3.7). 
A high degree of overlap was noted in the size distribution of sEVs and L-EVs 
(Figure 3.7A). Indeed, mean diameter size was not changed among the four groups (Table 
3.2.).  These results were consistent with the measurement of the most frequent diameter 
size of isolated EVs represented by the mode. The mode of isolated EVs was not 
significantly different in any group and highlight the heterogeneity of the sample (Table 
3.2). A percentile analysis of the low population (10%, D10), middle/median population 
(50%, D50) and high population (90%, D90) based on diameter size was studied. The 
range in diameters of EVs was similar to both subtypes for smaller particles (D10) and 
medium size particles among four studies groups (Table 3.2). However, the diameter size 
for the top percentage of EVs was significantly higher in cytokine-L-EVs (Table 3.2). 
D90 for quiescent, cytokine-sEVs and quiescent-L-EVs were 223±20, 268±25 and 
238±24 nm, respectively, whereas cytokine-L-EVs´ D90 was 330±29 nm. 











Quiescent sEVs 166 ± 14 129 ± 16 97 ± 8 141 ± 12 223 ± 20 **** 
Cytokine-sEVs 177 ± 12 135 ± 12 98 ± 7 148 ± 10 268 ± 25 * 
Quiescent L-EVs 164 ± 10 134 ± 5 84 ± 5 149 ± 6 238 ± 24 *** 
Cytokine-L-EVs 206 ± 13 144 ± 17 97 ± 8 178 ± 13 330 ± 29 
 
Abbreviations: EVs, extracellular vesicles; sEVs, small EVs; L-EVs, large EVs; NTA, 
NanoSight particle tracking analysis; *P values <0.05, ***P values <0.001, ****P 
values <0.0001 cytokine-sEVs vs. cytokine-L-EVs. Data are shown as mean±SEM with 
n=4 of independent replicates. Repeated measures, two-way ANOVA with Tukey´s post 




In accordance with Figure 3.1, number of isolated cytokine-sEVs (6.21±0.77x107 
sEVs/cm2 of confluent cells) was significantly higher than isolated quiescent sEVs 
(1.43±0.70x107 sEVs/cm2 of confluent cells, P<0.001; n=4). Under basal condition, 
number of isolated L-EVs was 0.11±0.02x107 L-EVs/cm2 of confluent cells, which 
showed a trend but no-significant decrease of number of EVs when compared to quiescent 
sEVs. Similarly, the effect of 10 ng/ml of TNFα and IFNγ did not significantly increase 
the number of cytokine-L-EVs when compared to quiescent L-EVs. However, analysis 
of the number of cytokine-EVs isolated from hCMEC/D3 cells showed that the number 
of sEVs was significantly higher than the number of L-EVs (sEVs = 6.21±0.77x107 vs. 







Figure 3.7. Characterisation of both sEVs and L-EVs isolated from hCMEC/D3 cells 
under inflammatory conditions. hCMEC/D3 cells were treated with 10 ng/ml of TNFα 
and IFNγ or left untreated for 24h. Cell conditioned media was then collected and small 
and large EVs (sEVs and L-EVs) were separated by differential centrifugation. (A) 
Histogram of size distribution of EVs isolated under basal conditions (quiescent sEVs 
and quiescent L-EVs) and after treatment with pro-inflammatory cytokines (cytokine-
sEVs and cytokine-L-EVs), which was analysed by nanoparticle tracking analysis (NTA, 
NS500). (B) Measurement of number of sEVs and L-EVs with NS500. Data are showed 
as mean ± SEM of n=4 (A and B), Two-way ANOVA using Tukey´s post hoc test for 
multiple comparison with *** P<0.001 to quiescent sEVs and #### P<0.0001 to 
cytokine-sEVs. (C) Transmission electron microscopy (TEM) images of cytokine-L-EVs 
(left panel) and cytokine-sEVs (right panel) stained with uranyl acetate. Images are 
representative of two biological experiments with two technical replicates each. Scale bar 
= 500 nm  
 
 
The morphology of both types of EVs (sEVs and L-EVs) was confirmed using 
TEM (Figure 3.7C). TEM images of cytokine-L-EVs (right panel of figure 3.7.C) showed 
lipid bilayer round vesicles ranging from 40 to 600 nm whereas TEM images of cytokine-
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sEVs (left panel of figure 3.7.C) was enriched for cup-shaped and lipid bilayer vesicles 
smaller than 250 nm. 
These results suggested that the isolation of the number of sEVs from hCMEC/D3 
cells under inflammatory conditions was greater than the number of L-EVs. As such, the 
remainder of the characterisation studies were focused on sEVs. 
 
3.2.5.  Profile of miRNAs and mRNAs in sEVs after treatment with 
pro-inflammatory cytokines 
 
sEVs can carry both proteins and nucleic acids (including DNA, mRNA and 
miRNAs) (Kalra, Drummen and Mathivanan, 2016). The expression of miRNAs within 
sEVs is dependent on the stimulus used to activate secreting cells (Geis-Asteggiante et 
al., 2018). Consequently, the expression of TNFα/IFNγ-related miRNAs in hCMEC/D3-
derived sEVs was investigated by RT-qPCR. For this purpose, six miRNAs whose 
expression under inflammatory conditions had been previously described in hCMEC/D3 
cells, were selected (Lopez-Ramirez et al., 2014; Wu, et al., 2015; Cerutti et al., 2017). 
These miRNAs have been previously observed to be either up-regulated (miRNA-155-
5p, miRNA-146b-5p and miRNA-146a-5p), down-regulated (miRNA-126-5p and 
miRNA-126-3p) or unchanged (miRNA-24-5p) in hCMEC/D3 cells during conditions of 
inflammation (Reijerkerk et al., 2013).   
 RT-qPCR revealed that miRNA-155 expression was increased in the cargo of 
cytokine-sEVs when compared to quiescent sEVs. Interestingly, miRNA-155 levels 
showed maximal expression after treatment with 10 ng/ml of pro-inflammatory cytokines 
(8.2±1.2 fold change over unstimulated, P<0.001; n=3) (Figure 3.9). No changes were 




Figure 3.9. Expression of inflammation-related microRNAs in sEVs. MiRNAs 
expression in the cargo of small EVs (sEVs) isolated from cytokine-treated (TNFα and 
IFNγ at 1, 10 or 100 ng/ml) hCMEC/D3 cells or untreated cells. Data were normalised to 
miRNA-let7g as internal control. Data is showed as mean±SEM of n = 3 of independent 
replicates (A), P**<0.01 and P***<0.001 to control/unstimulated sEVs. One-way 
ANOVA with Dunnet´s post hoc. 
 
To determine whether sEVs also contained mRNAs associated with cerebral 
endothelial inflammation, cargo levels of adhesion molecules CEACAM1, ICAM1 and 
VCAM1 were measured by RT-qPCR (Figure 3.10). Levels of both ICAM1 and VCAM1 
mRNA were significantly increased in the cargo of sEVs derived from inflamed 
hCMEC/D3 cells compared to those sEVs isolated from naïve hCMEC/D3 cells. VCAM1 
levels were significantly greater at 10 and 100 ng/ml of TNFα and IFNγ (10 ng/ml = 
3.76±0.93 whereas control levels were 1.09±0.33, P<0.05; n=5) (Figure 3.10). On the 
other hand, ICAM1 levels were increased at all three doses investigated but only 
significantly at 10 and 100 ng/ml (1.01±0.08, 2.91±0.44, 6.21±1.33 and 10.10±0.355, 
P>0.05, P<0.01 and P<0.001, respectively; n=3) (Figure 3.10). No differences in 
CEACAM1 mRNA levels were noted between quiescent sEVs and those from TNFα and 



































Figure 3.9. Expression of inflammation-related mRNAs in sEVs. Analysis of 
inflammation-related mRNAs in sEVs (CEACAM, VCAM1 and ICAM1) by RT-qPCR. 
Data was normalized to β-actin. Data are showed as mean ± SEM of n = 3 or n = 5 
(VCAM1 mRNA), P*<0.05 and P**<0.01, P****<0.0001. One-way ANOVA with post-
hoc Dunnet´s post hoc. 
 
To determine whether the sEV miRNA and mRNA contents reflected 
inflammation-induced changes in levels in hCMEC/D3 cells, levels of miRNA-155 and 
of VCAM1 and ICAM1 mRNA were measured in cell extracts after treatment with 10 
ng/ml of TNFα and IFNγ. As expected, intracellular miRNA-155 levels were 6.40±0.56, 
P<0.0001 (n=3) higher in cells stimulated with 10 ng/ml when compared to untreated 
cells (Figure 3.11A). As shown in Figure 3.11, cytokine treatment significantly increased 
levels of VCAM1 and ICAM1 mRNA compared to untreated conditions (Figure 3.11A 
and 3.11B). Interestingly, the up-regulation of VCAM1 was 8 fold higher in the 
hCMEC/D3 cells than VCAM1 mRNA levels within the cargo of sEVs (28.9±0.28 
intracellularly and 2.87±0.77 within cytokine-sEVs) whereas ICAM1 levels were only 
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results suggested there was an enrichment of pro-inflammatory miRNA and mRNAs in 
sEVs that partially reflect the intracellular status of the secreting hCMEC/D3 cells. 
 
Figure 3.11. Effect of treatment with a combination of cytokines (TNFα and IFNγ) 
in hCMEC/D3 cells on transcript levels. hCMEC/D3 cells were treated with 10 ng/ml 
of TNFα and IFNγ and miRNA-155 and mRNA were analysed by RT-qPCR. Treatment 
with combination of cytokines led to increased levels of microRNA-155-5p (A), VCAM1 
(B) and ICAM1 mRNAs (C). Data are showed as mean±SEM of n = 3 of independent 






In this chapter, a systematic comparison of three well-established methods for the 
isolation of sEVs demonstrated that ultracentrifugation was the optimal method for 
isolation of cerebral endothelial sEVs. Characterisation of sEVs and L-EVs from 
cytokine-stimulated hCMEC/D3 cells identified differences in number of EVs and 
morphology. Finally, miRNA-155 as well as VCAM1 and ICAM1 mRNAs were shown 
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3.1.1. Size exclusion and precipitation method were outperformed by 
ultracentrifugation method for the isolation of sEVs based on 
sEV number and markers. 
 
Numerous studies have compared the different available methods for the 
separation of sEVs from CCM and/or biological fluids (Van Deun et al., 2014; Lane et 
al., 2015; Lobb et al., 2015; Taylor and Shah, 2015; Tang et al., 2017). However, great 
discrepancies in the selection of the method of isolation are observed across the literature, 
which makes assessing the reproducibility of a method difficult (Helwa et al., 2017). For 
these reasons, this study was initiated by comparing three well-established methods to 
determine an optimal technique that generated the greatest sEV recovery and purity from 
hCMEC/D3 cells. 
A greater number of sEVs were recovered from endothelial CCM using both 
precipitation-based and ultracentrifugation methods compared to the size exclusion 
method (qEVs). These results disagree with a published comparative study of qEVs and 
a precipitation-based method (ExoQuick), which showed that qEV performed better at 
recovering sEVs from CCM. However, differences among CCM pre-treatment as well as 
among precipitation-based methods might explain these differences in recovery (Lobb et 
al., 2015). The method from Exiqon (now part of Qiagen) was selected because this 
company had a published track record of generating products for the handling and 
analysis of miRNAs (Brunet-Vega et al., 2015). These commercial available kits rely on 
a PEG polymer with formulations that vary among the different manufacturers (García-
Romero et al., 2019). Interestingly, another study observed a better recovery of sEVs 
using non-commercial PEG-based precipitation kits when compared to size exclusion 
(Gámez-Valero et al., 2016). It is possible that the better performance of Exiqon may be 
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due to its unique PEG formulation that might be optimised for EV isolation. This 
formulation is not available to the general public.  
In the previous section, the two methods that recovered the highest yield of sEVs 
from the endothelial CCM (precipitation and ultracentrifugation methods) were selected. 
Next, the purity of the sample isolated by those two methods was studied. Although no 
significant difference in the amount of RNA recovered from each method was observed, 
the precipitation-based method carried a higher amount of protein per vesicle. It is well 
established that the higher the ratio protein content over sEV number is, the more likely  
that the method is co-isolating non-vesicular particles (Théry et al., 2018). Previous 
findings comparing different methods for the isolation of serum EVs showed that purity 
measured via band densitometry of soluble albumin protein of both Exiqon and 
ultracentrifugation was low in both cases (Buschmann et al., 2018). Given that 
performance of these methods relies on other factors such as CCM, EV population and 
user, confirmation of the purity of EVs was carried out by detecting the presence of 
markers for sEVs by Western blotting (Théry et al., 2018). All three EV markers (CD9, 
CD63 and HSP70) were present in sEVs isolated by both methods, however, there was a 
clear enrichment of all three markers in vesicles recovered by ultracentrifugation. This is 
in agreement with reports from other studies that reported that sEVs isolated using PEG-
based methods expressed fewer sEV protein markers (Lobb et al., 2015; Gheinani et al., 
2018). It is also possible that as equal loading was calculated by protein concentration, 
the additional protein may have masked the protein content of sEVs. 
Ultracentrifugation was the most common method used for the isolation of sEVs 
according to a world-wide survey (Gardiner, Di Vizio, et al., 2016). The recovery and 
purity of this method is very dependent of the parameters for centrifugation (temperature, 
rotor type, speed…) applied (Cvjetkovic, Lötvall and Lässer, 2014). The set-up carried in 
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this work was considered good to optimise the recovery of sEVs and the results showed 
that this method out-performed size exclusion and precipitation-based method. Therefore, 
size exclusion and precipitation were no longer used in the following experiments. 
 
3.2.6. Removal of pro-inflammatory cytokines after isolation of sEVs 
with ultracentrifugation 
 
Although ultracentrifugation was determined to provide the highest yield and 
purity in sEV isolation of the three methods studied, there was still a possibility that the 
samples were not pure enough for the downstream application. Other studies have 
reported that this method also isolates non-vesicular components such as albumin protein 
in serum derived sEVs (Tang et al., 2017). Although some residual TNFα and IFNγ were 
found in the sEV isolates, these concentrations were 10 times lower than the lowest dose 
reported to affect endothelial function (Cerutti et al., 2017). Thus, although there is no 
certainty that any biological effects induced by sEVs isolated from the CCM were not 
also influenced by residual pro-inflammatory cytokine contaminants, this influence is 
likely to be minimal.  
 
3.2.7. Endothelial cells secrete higher number of sEVs than L-EVs 
although both populations are heterogeneous 
 
Current methods for separation of EVs allow only partial purification of specific 
EV populations (Dozio and Sanchez, 2017). Thus, additional characterisation is needed 
to determine if the isolated EVs contained sEVs, L-EVs or a combination of both, as sEVs 
and L-EVs have been reported to have both overlapping and distinct biological effects 
(Théry et al., 2018). It was observed that hCMEC/D3 cells secreted a higher number of 
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sEVs than L-EVs. In another study using the same cell line and TNFα as stimulus, the 
authors reported that EV secretion was higher under inflammatory conditions, however 
they did not compare differences between sEV and L-EVs in terms of numbers (Dozio 
and Sanchez, 2017). For the current work, we will focus in investigating the role of sEVs 
in endothelial function. 
  
3.2.8. Morphology of sEVs by ultracentrifugation  
 
Observation of sEVs preparation using electronic microscopy is a requirement for 
the efficient characterisation of sEVs according to ISEV (Théry et al., 2018). Similarly 
to previously published reports, it was observed cup-shaped vesicle structures that are 
traditionally associated with sEVs (Théry et al., 2006). However, current evidence 
suggests that this morphology may be an artefact created by the technique for imaging 
sEVs (Raposo and Stoorvogel, 2013). Cryo-EM has proven that the most likely 
endogenous conformation of sEVs is spherical (Conde-Vancells et al., 2008). TEM also 
revealed some sEVs that had lost their membrane integrity. There is a high possibility this 
was due to the method of isolation because previous studies have shown that 
ultracentrifugation can damage some EVs during isolation (Helwa et al., 2017).  In 
summary, the morphology of sEVs represented the typical shape observed for sEVs 






3.2.9. Inflammation modulates secretion of sEVs by hCMEC/D3 cells. 
 
Modulators of inflammation such as cytokines have been reported to regulate 
secretion of sEVs in many different cell types (Sohda, Misumi and Oda, 2015; Podbielska 
et al., 2016; Wang et al., 2017). Most studies treat the secreting cells with one type of 
cytokines (Dozio and Sanchez, 2017). However, other studies have previously 
demonstrated a synergic effect of TNFα and IFNγ on brain endothelial function (Pan et 
al., 2011; Lopez-Ramirez et al., 2013; Reijerkerk et al., 2013). Therefore, how the 
treatment with a combination of these two cytokines affected the recovery of sEVs as 
well as their size distribution was investigated. Indeed, treatment with increasing doses 
of TNFα and IFNγ promoted a greater recovery of sEVs. Previous studies have suggested 
that TNFα increases the rate of vesicular formation in hCMEC/D3 cells, which might 
explain the increased number of sEVs observed. Only two other studies have attempted 
to characterise the sEVs isolated from hCMEC/D3 cells (Haqqani et al., 2013) and only 
one of them used an inflammatory stimulus such as TNFα (Dozio and Sanchez, 2017). 
However, TNFα has previously shown to increase sEV in HUVECs (Li et al., 2019). 
Indeed, results from this work confirmed that treatment of cytokines increased the number 
of sEVs recovered from hCMEC/D3 cells, as previously reported in other cell types 
(Podbielska et al., 2016; Tkach et al., 2017; Wang et al., 2017).  
Treatment with cytokines did not alter the size distribution of the sEVs, which is 
also in keeping with previous studies that demonstrated that treatment of hCMEC/D3 
cells with TNFα did not affect the size of the recovered sEVs (Dozio and Sanchez, 2017). 
However, it was noted that treatment with cytokines enriched for larger vesicles in 
cytokine-L-EVs when compared to quiescent-L-EVs represented by D90 of diameter 
size. A similar result was described by Yang and colleagues, who showed that LPS-
stimulated microglia released larger vesicles (also represented by D90) than naïve 
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microglia (Yang et al., 2018). In this article, vesicle number was not compared. However, 
it is tempting to speculate that although cytokine treatment may not increase the number 
of L-EVs released by hCMEC/D3 cells, a slight but significant increase into the secretion 
of larger vesicles might have a biological role in cell-to-cell communication in 
inflammation. Although for this work, focus was given to sEVs based on total number of 
isolated sEVs, future experiments to characterise L-EVs cargo and their role on BBB 
function will help to elucidate the role of L-EVs in inducing BBB dysfunction. 
 
3.2.10. Endothelial sEVs are enriched with pro-inflammatory miRNA-
155 and VCAM1 and ICAM1 mRNAs 
 
MiRNAs released from sEVs have been implicated in regulating 
immunomodulation (Balusu et al., 2016) and vascular function (Taverna et al., 2014) 
among other functions. Here, it was reported that miRNA-155 levels are enriched in the 
cargo of sEVs after treatment with pro-inflammatory cytokines. This miRNA was also 
increased intracellularly in treated hCMEC/D3 cells. However, miRNA fold change 
between control and cytokine-treated conditions was proportionally different between 
sEVs and hCMEC/D3 extracts. Some miRNAs are proposed to be actively exported by 
sEVs and that their physiological effects are dependent on the cellular context (de Jong 
et al., 2012; Djebali et al., 2012). Therefore, it is not surprising that these results differed 
from other published studies. For instance, mouse brain endothelial cells stimulated with 
a combination of inflammatory modulators (LPS and cytokines) released sEVs that were 
not enriched in miRNA-155 (Yamamoto et al., 2015). The specific up-regulation of 
miRNA-155 within the cargo of sEVs might suggest sEVs work as a vehicle for the 
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transmission of this microRNA to other target cells. In fact, cellular stress has been proven 
to be reflected in the RNA cargo of sEVs (de Jong et al., 2012) 
On the other hand, recent in-depth analysis of RNA species carried within sEVs 
and endothelial cells suggested that sEVs are enriched for long RNAs rather than short 
RNAs such as miRNAs (Pérez-Boza, Lion and Struman, 2018). Enrichment of miRNAs 
above other  RNA species is likely to be cell-specific (Sork et al., 2018). Nevertheless, 
specific modulation under cellular stress (e.g. TNFα) indicate that they are likely to play 
a role in cell function. Furthermore, it is important to acknowledge that other RNA 
molecules might be contributing to the function of sEVs (Chen et al., 2017; Ragni et al., 
2017; Pérez-Boza, Lion and Struman, 2018). Indeed, mRNAs encoding for adhesion 
molecules VCAM1 and ICAM1 were up-regulated in the cargo of sEVs upon treatment 
with combination of cytokines (TNFα and IFNγ). This is particularly interesting because 
both adhesion molecules have been involved in the pathogenesis of neuroinflammatory 
disorders (Lopes Pinheiro et al., 2016). In the next chapter, the role of sEVs modulating 











CHAPTER 4: Role of small extracellular vesicles on 
cerebrovascular function in inflammation 
 
4.1. Introduction 
In the previous chapter, it was observed that inflammation of BECs induced the 
release of sEVs containing pro-inflammatory vascular modulators such as miRNA-155 
and mRNAs for ICAM1 and VCAM1. Up-regulation of these three molecules has been 
linked to neuroinflammatory disorders such as MS (Alvarez, Cayrol and Prat, 2011; 
Lopez-Ramirez et al., 2014; Ortiz et al., 2014; Cerutti et al., 2016). Furthermore, sEVs 
have been previously described to promote inflammation in recipient peripheral 
endothelial, immune cells, brain pericytes and distant organs (for a review see Ramirez 
et al., 2018). Indeed, LPS-induced sEVs from the mouse brain endothelial cell line 
(b.End5) were shown to promote VEGFB expression in recipient pericytes (Yamamoto 
et al., 2015). On the other hand, quiescent BEC-derived sEVs were shown to decrease 
apoptosis by acceptor oligodendrocytes (Kurachi, Mikuni and Ishizaki, 2016). Currently 
little is known about the role of BEC-derived sEVs in modulating endothelial function in 
inflammation. Cerebrovascular dysfunction at the level of BECs can be measured by 
investigating the state of key endothelial properties such as elevated TEER, low 
paracellular permeability or controlled T cell transmigration (e.g. via leukocyte 
adhesion).  
The aim of the experiments in this chapter was to characterise the effect of sEVs 
isolated from TNFα- and IFNγ-activated hCMEC/D3 cells (cytokine-sEVs) on 
cerebrovascular function in comparison with untreated cells and/or cells treated with 
quiescent sEVs. In order to carry this work, the uptake of sEVs by different cells of the 
NVU was analysed by flow cytometry and confocal microscopy. The effect that sEVs 
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have on modulating TEER across BEC monolayers was investigated by ECIS. Then, 
whether treatment with sEVs induced leukocyte cell adhesion to brain endothelium was 
measured using an in-house flow-based method to analyse firm cell adhesion (Cerutti et 
al., 2016). Finally, a preliminary study on the molecular changes promoted by sEVs in 
acceptors cells was performed using RT-qPCR and western blotting. 
 
4.2. Results 
4.2.1. Uptake of endothelial sEVs by cells of the neurovascular unit 
To compare the uptake of cytokine- and quiescent endothelial sEVs by the three 
main cellular types of the NVU - endothelial cells, astrocytes and pericytes (Abbott, 
Adjanie A K Patabendige, et al., 2010) – the uptake of DiO-labelled sEVs by hCMEC/D3, 
HBMP and hA cell lines was assessed by flow cytometry. Uptake of quiescent sEVs by 
naïve hCMEC/D3 cells was 23±12 arbitrary units of median fluorescence (A.U.) 
compared to 6±1 A.U. for cytokine-sEVs (Figure 4.1.A). A similar pattern of uptake was 
observed by naïve astrocytes (the uptake of quiescent sEV was 112±54 A.U. and the 
uptake of cytokine sEVs was 53±21 A.U.) and pericytes (the uptake of quiescent sEVs 
was 30±6 A.U. and the uptake of cytokine sEVs was 11±2 A.U.). However, no 
statistically significant differences were observed among these groups (P>0.05, n=3). 
Given the intrinsic differences among cellular types (e.g. cell surface) which might have 
biased the comparison of the uptake among all three cell types, uptake of sEVs by NVU 
cells was normalised to the uptake of quiescent sEVs in each cell line. The uptake fold 
change for sEVs was 0.45±0.16 for BECs, 0.53±0.08 for astrocytes and 0.39±0.08 for 
pericytes. These ratios were not significantly different among the three cell lines (P>0.05, 
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n=3) (Figure 4.1.B) suggesting there is not a preference of uptake of endothelial sEVs by 
any of the three NVU cell types.  
 
Figure 4.1. Characterisation of the uptake of sEVs by cells of the neurovascular unit. 
Brain endothelial cells (BECs, hCMEC/D3 cells), pericytes (human brain pericytes) and 
astrocytes (human foetal cortical astrocytes) were cultured with 0.1 x 108 EVs/µl DIO-
labelled small EVs isolated from 10 ng/ml TNFα and IFNγ-treated hCMEC/D3 (cytokine-
sEVs) or quiescent hCMEC/D3 cells (quiescent sEVs). A) Flow cytometry analysis of 
sEVs uptake. B) Normalisation of data by cell type using ratio of median fluorescent 
intensity (MFI) of cytokine-sEVs MFI quiescent sEVs MFI. Data are shown as mean ± 
SEM, n = 3 of independent experiments; differences were assessed by two-way ANOVA 




4.2.2. Dose- and time- dependent uptake of cytokine-sEVs by 
hCMEC/D3 cells 
 
To study the temporal uptake of sEVs by BECs, naïve hCMEC/D3 cells were 
incubated with DiO-labelled cytokine-sEVs for 6, 24 and 48 h. Confocal microscopy 
showed a predominantly perinuclear localization of DiO dye within recipient cells (Figure 
4.2.A.). Uptake of cytokine-sEVs by hCMEC/D3 cells was qualitatively similar between 
24h and 48h of incubation, suggesting a level of saturation was achieved by 24 h. Based 
on these observations, a 24 h end-point was selected to carry out a dose response using 
flow cytometry. Quantification of the median fluorescence of BECs treated with DiO-
labelled cytokine-sEVs revealed that cellular uptake was dose-dependent (Figure 4.2.B). 
The uptake of 0.1x108 cytokine-sEVS/µl (90±13 A.U.) showed a non-significant increase 
in signal intensity compared to cells treated only with PBS (6±1 A.U.) (P>0.05). The 
fluorescent intensity was significantly higher in cells incubated with 0.5x108 and 1x108 
DiO-labelled cytokine-sEVs/µl compared to the PBS control (427±65 and 749±120 A.U., 
P<0.05 and P<0.001, respectively and n=3) (Figure 4.2.B). For the remainder of the 
study, treatment with 108 number of sEVs/µl for 24 h was selected to investigate their 







Figure 4.2. Characterisation of the uptake of cytokine-sEVs by naïve brain 
endothelium. (A) DIO-labelled small EVs (cytokine-sEVs) isolated from 10 ng/ml of 
TNFα and IFNy-treated hCMEC/D3 cells and incubated with human microvascular brain 
endothelial cells (hCMEC/D3) were imaged by confocal microscopy to analyse the 
uptake of 0.5x108 cytokine-sEVs/µl at different times (0, 6, 24 and 48h). (B) 
Quantification of flow cytometry of the median fluorescent intensity (MFI) of DIO-
labelled cytokine-sEVs (0.1, 0.5, 1x108 sEVs/µl) by naïve hCMEC/D3 cells for 24h. Data 
are showed as mean ± SEM (B, n = 3 independent experiments) *P < 0.05 and ****P < 
0.0001 or non-significant (N.S.). Differences were measured with one-way ANOVA and 




4.2.3. Effect of cytokine-sEVs on the TEER 
Loss of TEER is a well-known feature of CNS endothelial dysfunction and can be 
indirectly assessed by measuring the electrical impedance of the endothelial monolayer 
in vitro (Urdapilleta, Bellotti and Bonetto, 2006). First, the TEER of hCMEC/D3 cells 
under basal conditions or after treatment with a low dose of pro-inflammatory cytokines 
(1 ng/ml TNFα and IFNy) was investigated. Two days after seeding, naïve hCMEC/D3 
cells in culture reached a maximum TEER value of 3.53±0.03 Ω·cm2. Incubation with 1 
ng/ml of TNFα and IFNy significantly reduced the TEER of the endothelial monolayer 
in a time-dependent manner (Figure 4.3.A). TEER values for hCMEC/D3 monolayers 
under basal conditions started to decrease 24 hh after reaching confluence (Figure 4.3.A). 
For this reason, each time point of a treatment condition was normalised to their control 
time point of untreated cells. TEER values were then expressed as percentage of the 
treated condition (e.g. 1ng/ml TNFα and IFNγ) over untreated cells (Figure 4.3.B). 
Differences in TEER between naïve and cytokine-treated cells were analysed in 10 h 
periods (Figure 4.3.C). As mentioned above, treatment with 1 ng/ml TNFα and IFNγ 
significantly decreased TEER value over time and a biphasic decrease was observed. 
TEER rapidly decreased over the first 30 h of treatment, plateaued at 40 and further 
decreased at later times (Figure 4.3.C).  Hence, this method was used to analyse the effect 






Figure 4.3. Combination of TNFα and IFNγ affect hCMEC/D3 cells’ TEER. (A) 
Impedance values of untreated (control) hCMEC/D3 cells and those treated with 1 ng/ml 
of TNFα and IFNy were collected every 12 min intervals and transformed into 
transendothelial resistance (TEER) values. (B) Data wre transformed to percentage of 
treated vs. untreated cells at each time point. (C) Data were analysed at 10 h intervals 
using repeated measures two-way ANOVA with Tukey´s post hoc test. Data is shown as 
mean±SEM, n = 3 independent replicates and *P<0.0001 to control condition. 
 
Next, the effect of cytokine-sEVs on the TEER of naïve BECs was evaluated. 
After cells were grown to confluence, the hCMEC/D3 monolayers were cultured with 
increasing doses of cytokine-sEVs (0.1, 0.5, 1x108 sEVs/µl) during 60 h, which resulted 
in a dose-dependent decrease in TEER (Figure 4.4A). A maximum decrease in TEER to 
83±3% of that in control cells was observed over a 20 h incubation time with 108 cytokine-




In order to investigate whether the observed effect was specific to cytokine-sEVs, 
BECs were incubated with 0.5x108 sEVs/µl derived from either quiescent BECs or 
cytokine-treated BECs. Cytokine-sEVs decreased TEER similarly as reported above 
(Figure 4.4.A). Cells treated with quiescent sEVs had a small transient decrease in TEER 
10h after incubation (89.7±1.5 %, P<0.05 and n=3) whereas longer incubation times had 
no significant effect on TEER (Figure 4.4.B).  
 
Figure 4.4. Cytokine-sEVs but not quiescent sEVs decrease TEER. Trans-endothelial 
resistance (TEER) of hCMEC/D3 cells was calculated and data are shown as percentage 
of treated vs. untreated cells at each time point. (A) TEER values following incubation of 
hCMEC/D3 cells with increasing concentrations of cytokine-derived small EVs 
(cytokine-sEVs) (0.1, 0.5 and 1 x 108 sEVs/µl). (B) Comparison of the effect of 0.5 
sEVs/µl of cytokine-sEVs or quiescent sEVs on BECs TEER. Data are shown as mean ± 
SEM, n = 3 (B) and 4 (A) independent replicates. *P<0.05, **P<0.01, ***P<0.001, 
***P<0.0001 compared to untreated hCMEC/D3 cells, using repeated measures two-way 
ANOVA with Tukey´s multiple comparison test 
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4.2.4. Synergy between cytokine-sEVs and cytokines (TNFα and IFNγ) 
on TEER 
sEVs are likely to encounter other modulators of inflammation such as cytokines 
and chemokines when released into the blood stream. Therefore, whether cytokine-sEVs 
had any effect on already inflamed BECs was investigated. For this reason, hCMEC/D3 
cells were pre-activated with a low dose of combination of cytokines (1 ng/ml TNFα and 
IFNy overnight) and cultured with two different doses of cytokine-sEVs (either 0.1 or 
1x108 sEVs/µl) in the presence of TNFα and IFNy for up to 20 h (Figure 4.5.A). 
Treatment with 0.1x108 cytokine-sEVs/µl did not further decrease the effect of cytokine-
induced TEER during the course of the experiment when compared to hCMEC/D3 cells 
treated only with TNFα and IFNy. Indeed, TEER percentage change was 77.8±0.7% after 
20h of 0.1x108 cytokine-sEVs/ µl incubation TEER when compared to hCMEC/D3 cells 
treated only with pro-inflammatory cytokines (79.9±1.3%, P>0.05 and n=4) (Figure 
4.5.B). However, incubation with 1x108 cytokine-sEVs/µl together with TNFα and IFNy 
further decreased the TEER within 5 h after incubation (80.7±1.6 % for 
cytokine+cytokine-sEVs and 86.3±1.8 % for cells treated only with TNFα and IFNy at 
5h, P<0.01 and n=4). The observed effect was maintained over the full course of the 
experiment. Accordingly, TEER values were decreased to 71.9±1.9% of values of 
untreated cells in the presence of 108 cytokine-sEVs/ µl of cytokine-sEV (Figure 4.5.B) 
in comparison to 79.9±1.3% on hCMEC/D3 cells treated only with TNFα and IFNy 
(P<0.0001, n=4) (Figure 4.5.B). These results suggested that cytokine-sEVs are able to 
further decrease TEER under inflammatory conditions, which might have implication in 




Figure 4.5 Effect of cytokine-sEVs in combination with cytokines on TEER. (A) 
Diagram of the experimental set-up. hCMEC/D3 cells were pre-treated with 1ng/ml of 
TNFα and IFNy for 20h or left untreated (untreated cells/control, black line). The media 
of treated cells was replaced with the same dose of cytokines in the absence (TNFα and 
IFNy, blue line) or presence of cytokine-sEVs (0.1 or 1x108 sEVs/µl, green and red lines) 
for 20 h. (B) TEER values of cells pre-treated with TNFα and IFNy at 0, 5, 10, 15 and 
20h post-incubation with cytokine-sEVs. Data are shown as mean± SEM of the 
normalised TEER percentage of treated group over untreated cells, n=4 of independent 
replicates.  Differences are studied with repeated measures two-way ANOVA and 
Tukey´s post-hoc for multiple comparisons among all studied groups **P <0.01, ***P 





Next, the effect of cytokine-sEVs on modulating the recovery of pre-activated 
hCMEC/D3 cells from the cytokine treatment was studied (Figure 4.6.A). 
Following removal of TNFα and IFNγ, it was observed that TEER values started 
to increase, but values similar to untreated cells were not achieved over the time-
course of the experiment (TEER percentage change was 86.8±3.6 % for cells left 
with no post-treatment after 40 h of the pre-treatment). This suggested that longer 
times might be needed for hCMEC/D3 cells to recover from cytokine-induced 
loss of TEER. Incubation with 0.1x108 cytokine-sEVs/µl did not delay the 
recovery of TEER percentage change. Indeed, TEER percentage change was 
78.4±2.5 % after 40h treatment. Similarly, treatment with 1x108 cytokine-sEVs/µl 
failed to significantly delayed the recovery from the cytokine-induced loss of 
TEER in BECs. However, a non-significant trend was observed in those cells 
treated with the higher dose of cytokine-sEVs. For example, after 40h of the pre-
treatment, 108 sEVs/µl-incubated cells had a TEER percentage of 71.3±2.8 % of 
control (P=0.07, n=3) (Figure 4.6.B.). It is likely that further incubation time with 
this concentration of cytokine-sEVs would significantly delayed the recovery of 
hCMEC/D3 cells, hence, supporting the hypothesis that cytokine-sEVs modulate 




Figure 4.6. Effect of cytokine-sEVs on hCMEC/D3 cells recovery from cytokine 
treatment. (A) Diagram of the experimental set-up. hCMEC/D3 cells were pre-treated 
with 1 ng/ml of TNFα and IFNy for 20h or left untreated (untreated control, black line). 
The media of treated cells was replaced with fresh media without cytokines (positive 
control, orange line) or containing cytokine-sEVs (0.1 or 1x108 sEVs/µl, red and green 
lines). In last group, media was replaced with fresh media supplemented with 1ng/ml of 
TNFα and IFNy and used as negative control of cell recovery from cytokine effect (blue 
line) (B) TEER values of TNFα and IFNy pre-treated cells at 0 to 40h post-incubation 
with cytokine-sEVs. Data are shown as mean ± SEM of the normalised TEER percentage 
of treated group over untreated cells, n=3 of independent replicates.  Differences are 
studied as repeated measures two-way ANOVA with Tukey´s post-hoc for multiple 





4.2.5. Effect of cytokine-sEVs in leukocyte adhesion to brain 
endothelium 
As described above, T cell transmigration is also a main cause of endothelial 
dysfunction in neuroinflammation (Lopes Pinheiro et al., 2016). Leukocyte adhesion is a 
crucial step for the successful cell migration across the endothelium (Engelhardt and 
Ransohoff, 2012). Therefore, the effect of cytokine-sEVs on T cell adhesion to BECs was 
assessed using a flow-based assay. This system allows for the cells to be exposed to shear-
stress, which has been demonstrated to better mimic in vivo conditions (Uzarski, Scott 
and McFetridge, 2013; Cerutti et al., 2017).  
First, the effect that cytokine-sEVs had on modulating the adhesion of Jurkat T 
cells to hCMEC/D3 cells was studied. Fluorescent microscopy revealed bright spherical 
shapes corresponding to Jurkat T cells that were adhered to the hCMEC/D3 cell 
monolayer (spindle-shaped cells) (Figure 4.7.A). Under control conditions (no treated 
hCMEC/D3 cells), 51±8 Jurkat T cells/FOV (FOV, 640 × 480 μm) were adhered to 
hCMEC/D3 cells. Incubation with increasing doses of cytokine-sEVs amplified T cell 
adhesion to BECs in a dose-dependent manner (Figure 4.7.A). Indeed, treatment with 108 
cytokine-sEV/µl resulted in approximately 2 fold increase of Jukat T cell adhesion to 
BECs. A linear increase in cell adhesion was observed with a peak at 108 cytokine-sEV/µl 
of 96±10 Jurkat T cells/FOV (P<0.01, n=4) (Figure 4.7B). Combination of the low dose 
of cytokines (1 ng/ml TNFα and IFNγ for 24h) was used as a positive control of T cell 
adhesion. Unsurprisingly, treatment with 1 ng/ml of TNFα and IFNy significantly 
increased 4 times Jurkat T cell adhesion to brain endothelium (203±14 Jurkat T 




Figure 4.7. Dose-response of cytokine-sEVs on modulating Jurkat T cell adhesion to 
brain endothelium. (A) Representative brightfield (top) and fluorescent (FITC, bottom) 
images of Jurkat T cell adhesion under flow conditions (from left to right) in the absence 
(control), presence of cytokine-sEVs (cytokine-sEVs) at 0.1x108, 0.5x108 or 1x108  
cytokine-sEVs/µl or combination of cytokines (1ng/ml of TNFα+IFNγ). (B) 
Quantification of the number of firmly adhered T cells per field of view (FOV) following 
incubation with increasing doses of cytokine-sEVs for 24h. Data are shown as mean ± 
SEM and n = 4 of independent experiments. Differences were studied as repeated 
measures one-way ANOVA with Dunnet´s post-hoc for multiple comparisons to control 
with *P<0.05 and **P<0.01 and ***P < 0.001 or non-significant (N.S.) to 







Next, the kinetics of the cytokine-sEV-induced effect on T cell adhesion to BECs 
were investigated. Jurkat T cell adhesion to hCMEC/D3 cells after incubation with 108 
cytokine-sEVs/µl for 6, 24 and 48 h was measured (Figure 4.8.A). In accordance with the 
time-course of the previous TEER experiments (Figure 4.5), a rapid increase of T cell 
adhesion to BECs after 6 h of incubation was observed (Fig. 4.8A). Jurkat T cell adhesion 
to untreated brain endothelium was 27±5 Jurkat T cells/FOV whereas after 6h of 
incubation with cytokine-sEVs resulted in 96±10 Jurkat T cells/FOV (P<0.05, n=4) 
(Figure 4.8.B). Additional incubation time with cytokine-sEVs did not further increase 
the adhesion (Figure 4.8.B). Treatment of BECs with 1 ng/ml of TNFα and IFNy 
increased T cell adhesion by approximately twice as much as cytokine-sEVs (201±12 
Jurkat T cells/FOV, P<0.01, n=4) (Figure 4.8.B). These results demonstrated that 








Figure 4.8. Time-course effect of cytokine-sEVs in Jurkat T cell adhesion to brain 
endothelium. (A) Representative brightfield (top) and fluorescent (FITC, bottom) images 
of Jurkat T cell adhesion under flow conditions (from left to right) in the absence (0h), 
presence of 1x108 cytokine-derived small EVs (cytokine-sEVs)/µl after 6, 24 and 48h of 
incubation or combination of cytokines (1ng/ml of TNFα and IFNγ for 24h). Jurkat T 
cells appear as dark round-shaped cells whereas hCMEC/D3 cells appear as spindle-
shaped cells in brightfield images. Jurkat T cells are depicted as bright round-shaped cells 
at FITC images (B) Quantification of the number of firmly adhered T cells per field of 
view (FOV) following incubation with cytokine-sEVs at different times. Data are shown 
as mean ± SEM and n = 4 of independent experiments. Means were analysed using 
repeated measures one-way ANOVA with Dunnet´s post-hoc for multiple comparisons 







4.2.6. Effect of quiescent sEVs on leukocyte adhesion to hCMEC/D3 
cells 
 
To determine whether the effect of cytokine-sEV on adhesion of Jurkat T cells to 
hCMEC/D3 cells was specific to their inflammatory profile, the adhesion experiments 
were repeated with quiescent sEVs. hCMEC/D3 cells were exposed to the same 
concentration of sEVs (0.5x108 sEVs/µl) of either cytokine- or quiescent sEVs for 24 h 
prior to assessment of leukocyte adhesion (Figure 4.9.A). As observed previously, 
cytokine-sEVs increased firmly adhered Jurkat T cell number on endothelial monolayer 
as described in figure 4.8 (42±3 Jurkat T cells/FOV, P<0.05 and n=3) (Figure 4.9.B). 
Furthermore, incubation of hCMEC/D3 cells with quiescent sEVs did not increase 
leukocyte adhesion to brain endothelium. Quiescent-sEV-treated hCMEC/D3 cells 
showed 23±4 firmly adhered Jurkat T cells/FOV whereas untreated cells had 25±2 
adhered Jurkat T cells/FOV (Figure 4.9.B). These results confirmed that only cytokine-




Figure 4.9. Effect of quiescent-derived sEVs on Jurkat T cell adhesion to brain 
endothelium under basal conditions. (A) Representative brightfield (top) and 
fluorescent (FITC, bottom) images of Jurkat T cell adhesion under flow conditions (from 
left to right) in the absence (control), or presence of 0.5x108 quiescent hCMEC/D3 cell-
derived small EVs (quiescent sEVs)/µl or 0.5x108 cytokine-derived small EVs (cytokine-
sEVs)/µl after 24h of incubation. Jurkat T cells appeared as dark round-shaped cells 
whereas hCMEC/D3 cells appeared as spindle-shaped cells in brightfield images. Jurkat 
T cells are depicted as bright round-shaped cells at FITC images (B) Quantification of the 
number of firmly adhered T cells per field of view (FOV) following incubation with 
cytokine-sEVs or quiescent-sEVs. Data are shown as mean ± SEM and n=3 of 
independent experiments. Differences are studied as repeated measures one-way 
ANOVA with Dunnets´s post-hoc for multiple comparisons with **P<0.01 to 
untreated/control condition. Scale bar = 320µm. 
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4.2.7. Effect of quiescent sEVs on cytokine-induced leukocyte adhesion 
to brain endothelium 
It has been already reported that endothelial cell-derived quiescent EVs are able 
to suppress the inflammatory signal by inhibiting monocyte activation (Njock, Boudreau, 
et al., 2015). However, whether quiescent sEVs released by naïve hCMEC/D3 cells may 
be able to counteract the effects of cytokine-induced leukocyte adhesion to brain 
endothelium is still unknown. 
To test this hypothesis, hCMEC/D3 cells were cultured with a combination of 
cytokines (1 ng/ml of TNFα and IFNy) and quiescent-sEVs (0.5x108 sEVs/µl) for 24 h 
before Jurkat T cell adhesion was analysed (Figure 4.10 A). In accordance with the 
previous results, incubation of naïve hCMEC/D3 cells with quiescent-sEVs did not alter 
endothelial function. Indeed, the number of Jurkat T cells adhered to hCMEC/D3 cells 
(33±8 Jurkat T cells/FOV) was not significantly different from the number of T cells in 
untreated conditions (43±6 Jurkat T cells/FOV, P>0.05 and n=4) (Figure 4.10.B). 
However, a reduction of 20% on number of leukocytes were shown to be adhered when 
hCMEC/D3 cells were cultured with both TNFα/IFNy and quiescent-sEVs when 
compared to cytokine treatment by itself (cytokines = 164±9 Jurkat T cells/FOV vs. 
cytokines+quiescent sEVs = 133±8 Jurkat T cells/FOV, P=<0.01 and n=4) (Figure 
4.10.B). This result suggested that quiescent sEVs might play a role to balance the effect 




Figure 4.10. Effect of quiescent sEVs on Jurkat T cell adhesion to brain endothelium 
under inflamed conditions. (A) Representative brightfield (top) and fluorescent (FITC, 
bottom) images of Jurkat T cell adhesion under flow conditions. From left to right, 
representative images in the absence of cytokines and quiescent sEVs (control) or 
presence of 0.5x108 quiescent hCMEC/D3 cell-derived small EVs (quiescent sEVs)/µl. 
Cells treated with 1 ng/ml of TNFα and IFNy in the absence or presence of 0.5x108 
quiescent sEVs /µl after 24h of incubation. Jurkat T cells appear as round-shaped cells 
whereas hCMEC/D3 cells appear as spindle-shaped cells in brightfield images. Jurkat T 
cells are depicted as bright round-shaped cells at FITC images. (B) Quantification of the 
number of firmly adhered T cells per field of view (FOV) following incubation with 
combination of cytokines and/or quiescent-sEVs and/or left untreated. Data are shown as 
mean ± SEM and n = 4. Repeated measures two-way ANOVA with Tukey´s post hoc and 
**P<0.01 and NS = no significant to control (cell treated with without quiescent sEVs) 
condition. Scale bar = 320µm. 
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4.2.8. Effect of cytokine-sEVs and quiescent sEVs on miRNA and 
mRNA levels in recipient hCMEC/D3 cells  
 
Previous studies have demonstrated that the molecular cargo carried within EVs 
can be transferred to the recipient cells, driving phenotypic changes (Valadi et al., 2007).  
Alternatively, EVs can induce changes in gene expression in the acceptor cells instead. 
Therefore, the impact of sEVs on the expression profile of selected inflammation 
regulatory mRNAs and miRNAs of recipient BECs was assessed.  
hCMEC/D3 cells were cultured with both cytokine- and quiescent sEVs for 24 h 
prior to RNA extraction. In the context of miRNAs, levels of miRNA-155 were 
significantly up-regulated in hCMEC/D3 cells after incubation with cytokine-sEVs 
(1.45±0.07 fold change, P<0.05 and n=3) (Figure 4.11.A). On the other hand, expression 
of the anti-inflammatory miRNA-126-3p was not altered following sEV treatment 
(1.01±0.13, P>0.05, n=3) (Figure 4.11A). MiRNA-24 was measured as a control of a 
miRNA, whose expression is not altered by TNFα and IFNγ treatment in hCMEC/D3 
cells. As expected, quiescent sEVs did not alter the expression levels of any of the before-
mentioned miRNAs (Figure 4.11.A) 
Levels of mRNAs related to BEC inflammation were also investigated. Both 
ICAM1 and VCAM1 mRNA were up-regulated after cytokine-sEVs incubation for 24h. 
This up-regulation was small but significant (1.55±0.19 ICAM1 fold change, and 
1.45±0.08 VCAM1 fold change with P<0.01 and P<0.01 respectively), n=3 (Figure 
4.11.C). Levels of mRNAs for the tight junctional protein CLDN5 and OCLN were not 
changed following incubation with sEVs. In accordance with the results of the miRNA 
analysis, incubation of hCMEC/D3 cells with quiescent sEVs did not change endogenous 




Figure 4.11. Endothelial sEVs induce pro-inflammatory markers in recipient 
hCMEC/D3 cells. (A) qPCR of levels of microRNAs: miRNA-155-5p, miRNA-126-5p 
and miRNA-24 after treatment with cytokine-derived small EVs (cytokine-sEVs) or 
quiescent sEVs. Relative levels were normalised to the reference gene, small nuclear 
RNA U6. (B) Measurement of mRNA levels by qPCR after incubation of hCMEC/D3 
cells with cytokine-sEVs or quiescent-sEVs of intracellular adhesion molecules 1 
(ICAM1), vascular cell adhesion molecule 1 (VCAM1), occludin (OCLN) and claudin-5 
(CLDN5) mRNAs. Data are shown as mean±SEM, n=3 of independent experiments. 
One-wat ANOVA followed by Dunnet´s post-hoc test *P<0.05 in comparison to 
untreated cell levels. 
 
4.2.9. Protein expression is regulated by cytokine-sEVs in hCMEC/D3 
cells 
 
To determine whether the changes in mRNA levels observed in hCMEC/D3 cells 
following incubation with cytokine-sEVs resulted in corresponding changes in protein 
expression, the levels of key proteins involved in either leukocyte adhesion to BECs or 
TEER were investigated by Western blotting (Figure 4.12.A). 
Immunoblotting using primary antibodies against ICAM1 and VCAM1 revealed 
detectable levels of ICAM1 and VCAM1 under basal conditions in hCMEC/D3 cells 
(Figure 4.12.A). Normalisation of protein band intensity to a control confirmed that 
protein levels of ICAM1 and VCAM1 were significantly up-regulated in recipient BECs 
after incubation with cytokine-sEVs (1.66±0.19 and 5.06±0.96 relative to untreated 




CLDN5, both tight junctional proteins were detectable in hCMEC/D3 cells (Figure 
4.12.A). However, quantification of band densitometry of these proteins revealed that 
treatment with cytokine-sEVs did not alter the total levels of CLDN5 and OCLDN 
proteins in recipient hCMEC/D3 cells. (Figure 4.12 B).   
 
Figure 4.12. Cytokine-sEVs induce expression of pro-inflammatory adhesion 
molecules in recipient hCMEC/D3 cells. (A) Immunoblot of cytokine-sEV-treated or 
untreated (control) hCMEC/D3 cells for adhesion molecules, ICAM1 and VCAM1, tight 
junction related protein, OCLDN and CLDN5 and internal control GADPH. (D) Band 
densitometry was measured, normalised by GAPDH and expressed as ratio of cytokine-
sEV treated vs untreated hCMEC/D3 cells.  Data are shown as mean ± SEM, n = 3 of 





4.2.10. Role of VCAM1 and ICAM1 in leukocyte adhesion to BECs 
induced by cytokine-sEVs. 
To confirm the role of VCAM1 and ICAM1 proteins in modulating T cell 
adhesion to brain endothelium (Lopes Pinheiro et al., 2016), blocking antibodies against 
ICAM1 and VCAM1 alone or in combination were incubated with recipient hCMEC/D3 
cells for 1h prior T cell adhesion assays. Incubation with non-specific mouse IgG 
antibodies was used as control for blocking antibodies. IgG antibody treatment resulted 
in no differences in the number of T cells adhered to BECs in comparison to non-antibody 
treated cells. Then, blocking ICAM1 failed to prevent cytokine-sEV-induced T cell 
adhesion to brain endothelium compared to IgG-treated hCMEC/D3 cells (93±22% and 
103±7 fold change respectively, n=4) (Figure 4.13 A). However, blocking VCAM1 
partially blocked T cell adhesion to BECs (32±11%, P<0.05 and n=4). Furthermore, 
blocking VCAM1 and ICAM1 simultaneously completely prevented the effect of 




Figure 4.13. Effect of VCAM1 and ICAM1 in cytokine-sEV-induced Jurkat T cell 
adhesion to BECs (A) Representative images of Jurkat T cell adhesion (round points in FITC 
images and bright points in brightfiled images) to hCMEC/D3 (spindle-shaped cells in brightfield 
images). Prior to T cell adhesion assay, cells were treated from left to right images with mouse 
IgG control, 30 µg/ml ICAM1 antibody, 30 µg/ml VCAM1 antibody or combination of 30 µg/ml 
ICAM1 and VCAM1 antibodies. (B) Cell adhesion was quantified in eight to ten field of view 
(FOV 640 × 480 μm) and expressed as percentage of number of Jurkat T cell adhered to cytokine-
sEV treated hCMEC/D3 cells. Data are shown as mean ± SEM (n=4), one-way ANOVA 











Findings from these experiments indicated that treatment of BECs with sEVs induced 
cerebrovascular dysfunction by reducing trans-endothelial electrical resistance and by 
increasing leukocyte adhesion to brain endothelium. These results also suggested that 
sEVs derived from cytokine-treated BECs act as a novel pro-inflammatory regulator by 
modulating protein and RNA expression (miRNA-155, VCAM1 and ICAM1) in recipient 
naïve endothelial cells whereas quiescent sEVs decreased cytokine-induced T cell 
adhesion to BECs. 
4.3.1. Non-specific uptake of sEVs by cells of the neurovascular unit 
Few studies have compared the uptake of sEVs by different cells of the NVU.  For 
example, Ramirez and colleagues showed qualitative uptake of sEVs by astrocytes, 
pericytes and brain endothelial cells (Ramirez et al., 2018). Accordingly, in this project, 
the uptake of sEVs was detected in the three main cell types of the NVU. Although not 
significant, uptake of sEVs tended to be higher in astrocytes than pericytes and BECs. 
Astrocytes have a larger cell surface that might have biased the uptake of sEVs. On the 
other hand, normalised uptake of cytokine-sEVs was shown be similar for all three 
cellular types. These results suggested that uptake of sEVs is not enhanced during 
inflammation. Indeed, uptake of cytokine-sEVs appeared to be decreased in comparison 
to quiescent-sEV uptake. This result suggested a preference of uptake of quiescent sEVs 
by the cells of the NVU, which might be explained by differences in the route of vesicular 
uptake. However, little is known about the specific pathways involved in vesicular uptake 
and the different common methods for vesicular uptake have been proposed to modulate 
sEVs uptake by different cells types (Théry et al., 2018). Indeed, a recent study attempted 
to study the uptake of endothelial sEVS by endothelial cells using pharmaceutical 
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inhibitors of vesicular uptake (Banizs et al., 2018). The authors showed that sEV uptake 
was preferentially mediated by clathrin-dependent internalisation and to a lesser degree 
to micropinocytosis and caveolin-dependent internalisation (Banizs et al., 2018). 
Unfortunately, the receptors involved are not well understood. 
 The ISEV recommends to include both time- and dose- dependent experiments 
when evaluating both the function and uptake of sEVs by the acceptor cells (Théry et al., 
2018). In these experiments, the uptake of cytokine-sEVs by BECs was observed to be 
dependent on both time of incubation and concentration of EVs. These results were not 
surprising and the trend of uptake was in accordance with the general view of sEVs´ 
uptake. The staining pattern of DiO in cytokine-sEV-treated BECs was predominantly 
perinuclear. This is in accordance with a previous study where uptake of sEVs by 
HUVECs was evaluated (Gao et al., 2016; Durak-Kozica et al., 2018). However, little is 
known about the fate of sEVs once inside the acceptor cells (Mathieu, Thery 2019). 
Future experiments using double labelling for markers for different subcellular location 
such as the reticulum endoplasmatic (e.g. calnexin) will help to determine the fate of these 
sEVs after they have entered the BECs.  
4.3.2. Cytokine-derived sEVs reduce TEER 
sEVs derived from pro-inflammatory cytokine-activated cells have been 
previously shown to be capable of inducing cytokine-like effects in recipient cells (Buzas 
et al., 2014). However, most studies have investigated the role of sEV-mediated 
communication and their impact in vascular function using plasma- or serum-derived EVs 
(Marcos-Ramiro et al., 2014). As a result, these studies cannot differentiate EVs that 
originate from both vascular as well as non-vascular cells (e.g. immune cells) (Horstman 
et al., 2007). In contrast, this study focused on the specific role of BEC-derived sEVs and 
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supports the hypothesis that secretion of EVs by BECs modulates the susceptibility of 
naïve brain endothelial cells to inflammation-induced damage.  
Findings from experiments in this chapter suggested that pro-inflammatory 
cytokines (TNFα and IFNγ) rapidly decreased TEER in BECs, as previously reported in 
different studies (M Alejandro Lopez-Ramirez et al., 2016; Ni et al., 2017). Each time 
point was normalised to match an untreated control to account for a natural loss of TEER 
of  hCMEC/D3 during culture (Raymond et al., 2016). Cytokine-sEVs were also observed 
to decrease BEC resistance under basal conditions in a subtle manner. Whether this “fine-
tuning” leads to significant alteration in the transport of components across BECs is still 
unknown. However, it was noted that treatment with cytokine-sEVs caused a further 
decrease in the TEER of BECs under inflammatory conditions. This is especially relevant 
because during neuroinflammation, cells shed many pro-inflammatory mediators (e.g. 
cytokines, chemokines, EVs) into the blood that contribute to the activation of the 
endothelium (Tang et al., 2016). Therefore, it is likely that sEVs will interact and compete 
with many of these molecules in vivo. Szabó G et al showed that the combination of 
human monocyte-derived sEVs and TNFα have additive effects on the monocyte 
transcriptome (Szabó et al., 2014). The results from this study suggest that cytokine-sEVs 
may amplify cytokine-signalling in BECs, thereby contributing to the inflammatory 
response at the BBB.  
It is likely that the synergistic effect between sEVs and pro-inflammatory 
cytokines observed in the TEER experiments is due to the cytokines adhered to the 
surface of the sEVs (Kolowos et al., 2005) or both mediators enhancing signalling 
pathways such as NF-Kappa B (Szabó et al., 2014). sEVs can modulate cellular function 
by different mechanisms that involve EV protein- cell membrane´s protein interaction 
and/or release of EV cargo within the acceptor cell (van der Pol et al., 2012).  Several 
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studies have shown that endothelial-derived sEVs can influence recipient cell function 
towards activation or suppression of inflammatory genes via transmission of RNA cargo 
(e.g. mRNA and microRNAs) (Njock, Cheng, et al., 2015). It was observed that the 
molecular cargo contained within sEVs partially reflected the intracellular RNA profile 
of the donor cells, which is consistent with the current understanding that there is 
variability between levels of vesicular RNA and the secreting cells/tissue (Ragusa et al., 
2017).  
Only a trend for decreased levels were found in the mRNA of occludin, but no 
changes were observed at the protein level. It is very likely that changes in endothelial 
resistance might occur due to alterations in the expression or location of other proteins 
such as ZO-1 or VE-cadherin. A study using plasma-derived EVs from MS patients 
showed that the decreased TEER was caused by re-organization of the junctional 
complexes (Marcos-Ramiro et al., 2014). In this study, the effect on claudin-5 and 
occludin were evaluated given their importance in maintaining endothelial structure. 
However, future evaluations of other proteins might clarify the mechanism by which 
sEVs decreased the TEER of brain endothelium. 
4.3.3. Cytokine-sEVs increase leukocyte adhesion to BECs via VCAM1 
and ICAM1 
In particular, leukocyte adhesion to brain endothelium is a key step in the process 
for T cells to migrate into the brain (Lopes Pinheiro et al., 2016). Data strongly suggested 
that cytokine-sEV participate in this event by almost doubling the number of adherent 
leukocytes. Other studies have already shown that EVs can increase leukocyte adhesion 
to endothelium of other vascular beds (Tang et al., 2016; Wadey et al., 2019). Indeed, a 
recent study showed that EVs derived from HUVECs treated with TNFα, increased the 
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pro-inflammatory status of naïve HUVECS and human monocytic cells (THP-1), leading 
to an increase of monocyte adhesion and transmigration in vitro (Hosseinkhani et al., 
2018a). However, no study had evaluated this effect on BBB function. Interestingly, the 
degree to which cytokine-sEVs induced changes in BEC function was higher for 
leukocyte adhesion than trans-endothelial electrical resistance. Therefore, it can be 
speculated that cytokine-sEV might play a major role in modulating leukocyte adhesion 
to BECs under basal conditions than modulating BBB leakiness.  
 ICAM1 and VCAM1 protein and mRNA levels were up-regulated in recipient 
hCMEC/D3 cells after incubation with cytokine-sEVs. Similarly, another study 
evaluating the effect of primary aortic endothelial cell-derived sEVs shown this type of 
sEVs increased VCAM1 expression when cultured with VSMC, hence increasing 
leukocyte cell adhesion (Boyer et al., 2020). Furthermore, blocking VCAM1 but not 
ICAM1 with neutralizing antibodies (Lam et al., 2018) decreased T cell adhesion to 
BECs. This result was not unexpected since VCAM1 has been shown to play a crucial 
role in modulating leukocyte adhesion to endothelium (Lopes Pinheiro et al., 2016). It 
can be speculated that the contribution of ICAM1 to sEV-induced T cell adhesion is minor 
in comparison to VCAM1 given that ICAM1 protein levels in recipient cells were lower 
than VCAM1 after cytokine-sEV treatment. 
 
4.3.4. Cytokine-sEV-induced miRNA-155 expression in BECs 
Previous studies have reported that sEVs can transfer miRNA-155 and modulate 
the function of the recipient cells (Alexander et al., 2015). Furthermore, miRNA-155 is a 
widely accepted modulator of cellular inflammation and previous reports have 
demonstrated its relationship with brain endothelial function in inflammation (Lopez-
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Ramirez et al., 2014; Cerutti et al., 2016). Therefore, it is proposed that in 
neuroinflammation BECs increase miRNA-155 expression, which is packaged in 
associated with sEVs. MiRNA-155-enriched sEVs can spread a pro-inflammatory signal 
to other quiescent endothelial cells. However, the precise mechanism by which this 
miRNA-155-enriched sEVs mediates T cell adhesion and how blocking of miRNA-155 
may affect the observed phenotype remains to be elucidated. In addition, EVs are 
composed of many different molecules (protein, mRNA, microRNAs) that likely signal 
as whole to promote specific functions. The observed effects of cytokine induced-sEVs 
through miRNA-155-5p and VCAM1 and ICAM1 protein are most likely part of a larger 
combination of molecules, both vesicular and non-vesicular, orchestrating the activation 
of brain endothelium. 
 
4.3.5. Quiescent sEVs reduced T cell adhesion to inflamed BECs 
In this chapter, it has been consistently shown that quiescent EV had no effect on 
cerebrovascular function under basal conditions (regarding their effect on modulating the 
TEER and T cell adhesion to BECs). However, quiescent sEV decreased T cell adhesion 
in the presence of pro-inflammatory cytokines. These results are in agreement with a 
study from 2015, which observed that sEVs released from endothelial cells inhibited 
monocyte activation and decreased their transmigration in the presence of the systemic 
inflammatory stimulus LPS (Njock, Cheng, et al., 2015). Indeed, other reports have 
shown the beneficial effect of quiescent sEVs (Isola and Chen, 2016), especially those 
sEVs that help promoting tissue regeneration (Dorronsoro and Robbins, 2013) or 
angiogenesis (Salomon et al., 2013).  The mechanism of action by which sEVs may exert 
their effects on endothelia is unknown. One could speculate that since sEVs are packed 
with miRNAs, the release of anti-inflammatory miRNAs such as miR-126 and miR-146a, 
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whose anti-inflammatory role in brain endothelial cells has been previously described, 
could drive a protective phenotype (Wu, Cerutti, Miguel A Lopez-Ramirez, et al., 2015; 
Cerutti et al., 2017). However, alternative pathways might be involved such as protein-
protein interactions or induction of intracellular signalling pathways. Further experiments 
in evaluating the mechanism by which quiescent sEVs decrease cytokine-induced T cell 
adhesion to brain endothelium are needed, however, the present data support the concept 
that quiescent sEVs may play a protective role in neuroinflammation. 
Findings from the current study support a novel role for brain cytokine-sEVs in 
promoting and perpetuating endothelial dysfunction during inflammation. Our data 
suggested that this mechanism may be driven in part by the transmission of pro-
inflammatory modulators such as miRNA-155 as well as adhesion molecules, ICAM1 
and VCAM1 from the EVs to the recipient cells. In the next chapter, the mechanism of 













CHAPTER 5: Mechanism of miRNA-155-mediated T cell 
adhesion to brain endothelium 
 
5.1. Introduction 
In the previous Chapters, the mechanism by which cytokine-sEVs modulated the 
function of naïve BECs was investigated. Interestingly, the levels of miRNA-155 were 
up-regulated both in the cytokine-sEV cargo and intracellularly in the recipient BECs. In 
addition, cytokine-sEVs were able to up-regulate leukocyte adhesion to BECs. MiRNA-
155 has been previously shown to be a potent modulator of cerebrovascular function in 
inflammation (Lopez-Ramirez et al., 2014; Cerutti et al., 2016). Cerutti and colleagues 
described that miRNA-155 overexpression led to increased shear-resistant T cell adhesion 
to hCMEC/D3 cells. Leukocyte adhesion is a crucial step in the multi-step process of 
leukocytes migration into the brain (Lopes Pinheiro et al., 2016). This mechanism is 
tightly regulated by the temporal expression of surface molecules that modulate the 
adhesion of leukocytes to brain endothelium (Greenwood et al., 2011). MiRNA-155 
overexpression increases the expression of VCAM1 and ICAM1 in hCMEC/D3 cells 
(Cerutti et al., 2016). However, the mechanism(s) by which miRNA-155 increases the 
expression of these two adhesion molecules and affect leukocyte adhesion to BECs are 
still poorly understood.  
The aim of this chapter was to identify targets for miRNA-155 with the purpose of 
characterising the mechanism of action of miRNA-155-induced T cell adhesion to brain 
endothelium. In particular, whether overexpression of miRNA-155 led to leukocyte T cell 
adhesion to BECs was further investigated. Subsequently, identification of targets for 
miRNA-155 using preliminary proteomic data from a previous project was carried out 
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(Table 1, Annex 1). Top candidate proteins were further investigated and confirmation of 
their role in modulating leukocyte adhesion to BECs was studied. Finally, the relationship 
between the mRNA-miRNA-155 paired candidate was analysed by measuring mRNA 
and protein expression upon miRNA-155 overexpression. 
 
5.2. Results 
5.2.1. Effect of overexpression of endothelial miRNA-155 on T cell 
adhesion to BECs. 
 
To investigate the mechanism by which miRNA-155 mediates leukocyte adhesion 
to BECs, the consequences of miRNA-155 overexpression in hCMEC/D3 cells were 
characterised. To do so, the efficacy of SiportTM transfection with Cy3-labelled scrambled 
control was evaluated (Figure 5.1). Fluorescent microscopy revealed a strong Cy3 signal 
across the FOVs whereas a fluorescent signal was absent in the negative control cells 
(hCMEC/D3 cells culture with Cy3-labelled scrambled control without SiportTM 
treatment) (Figure 5.1.A). Flow cytometry confirmed that the fluorescent signalling was 
significantly higher in cells transfected with Cy3-oligonucleotides compared to controls 
(control hCMEC/D3 cells=5±1 %, Cy3+ hCMEC/D3 cells =96±2 %, P<0.001; n=3) 




Figure 5.1. Efficiency of transfection of hCMEC/D3 cells with SiportTM reagent. (A) 
Immunofluorescent images of hCMEC/D3 cells transfected with SiportTM containing 
Cy3-labelled oligonucleotides (Cy3-oligonucleotide) or Cy3-labelled oligonucleotide 
alone (negative control, NC). (B) Representative histogram of flow cytometry analysis of 
10,000 hCMEC/D3 cells transfected with Cy3-oligonucleotide (B in the graph) or NC (A 
in the graph). (C) Percentage of positive cells to NC was calculated and differences were 
compared by two-tails paired t-test, n=3 independent experiments, ***P<0.001. Scale 
bar=340µm. 
 
The kinetics of miRNA-155 overexpression using transient transfection of 
miRNA-155 mimic were then analysed at 0, 24 and 48 h post-transfection. RT-qPCR 
demonstrated that miRNA-155 was highly up-regulated at every time point when 
compared to scramble-transfected hCMEC/D3 cells (872±573, 1724±569 and 2308±1056 
relative miRNA-155 expression to scramble-transfected cells, P<0.0001, n=3, 
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respectively) (Figure 5.2). For subsequent experiments, 48 h end-point was used for 
remaining transfection experiments using miRNA-155 mimics. 
 
Figure 5.2. Levels of miRNA-155 after transfection of hCMEC/D3 cells. RT-qPCR 
analysis of miRNA-155 at 0, 24 and 48 h post-transfection with 30 nM of miRNA-155 
precursor. Small nuclear RNA U6 was used as housekeeping gene to normalised 
miRNA-155 expression values. Data are shown as mean±SEM, n=3 of independent 
experiments and ****P<0.0001. One-way ANOVA followed by post hoc test Dunnet´s 
multiple comparison test. 
 
Next, confirmation of the overexpression of miRNA-155 in hCMEC/D3 cells 
leading to increased leukocyte adhesion to brain endothelium was validated. As described 
in Chapters 2 and 4, CFMDA-labelled Jurkat T cells appeared as bright cells on top of 
spindle-shaped hCMEC/D3 cells (Figure 5.3.A). Under basal conditions (scramble-
transfected hCMEC/D3 cells), 47±6 Jurkat T cells/FOV were adhered to brain 
endothelium whereas overexpression of miRNA-155 led to 68±4 adhered cells/FOV 
(P<0.05 and n=5), which confirmed that miRNA-155 overexpression increased T cell 
adhesion to hCMEC/D3 cells (Figure 5.3.B).  
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Figure 5.3. Firmly Jurkat T cell adhesion to hCMEC/D3 cells after miRNA-155 
overexpression. (A) Representative brightfield (top) and fluorescent (FITC, bottom) 
images of Jurkat T cell adhesion (round-shaped cells) to hCMEC/D3 cells (spindle-
shaped cells) under flow conditions after transfection with scramble--oligonucleotide 
control (Scrambled, left panels) or pre-miRNA-155 oligonucleotide (pre-miRNA-155, 
right panels) with a 10x objective.  (B) Quantification of the number of firmly adhered T 
cells per field of view (FOV 640 × 480 μm) following transfection with scramble-
oligonucleotide control or pre-miRNA-155 oligonucleotide for 48 h.  Data are shown as 
mean ± SEM and n = 5 of independent experiments. Differences were evaluated with 
paired t-test with *P<0.05 to scramble-transfected control. Scale bar=340µm. 
 
 
Subsequently, impact of miRNA-155 overexpression on the expression of cell 
adhesion molecule, VCAM1, was investigated in hCMEC/D3 cells. RT-qPCR analysis 
revealed that VCAM1 mRNA levels were increased after miRNA-155 overexpression in 
hCMEC/D3 cells (2.77±0.43 relative VCAM1 expressione to scrambled-transfected cells 
1.04±0.18, P<0.05 and n=3) (Figure 5.4.A). In addition to the mRNA analysis, VCAM1 
protein expression showed clear increased levels in miRNA-155-overexpressing 
hCMEC/D3 cells (n=2) (Figure 5.4.B and 5.4.C). These results validated previous 
published data and confirmed the usefulness of this model in order to characterise the 




Figure 5.4. Overexpression of miRNA-155 increased VCAM1. (A) RT-qPCR analysis 
of vascular cell adhesion molecule 1 (VCAM1) mRNA after overexpression of miRNA-
155 in hCMEC/D3 cells for 48 h. mRNA levels were normalised to internal control, β-
actin mRNA. (B) Cropped image of two experiments of western blotting analysis of 
VCAM1 expression after transfection of hCMEC/D3 cells with miRNA-155 precursor 
(pre-miRNA-155) or scrambled control (scrambled). GAPDH was used a loading control. 
(C) Quatification of band densitometry of VCAM1 western blot with normalisation to 
loading control GAPDH and values showed as expression relative to values for the 
scrambled control transfected hCMEC/D3 cells. Data are shown as mean±SEM (A), n=3 
independent experiments and two technical replicates, *P<0.05 and n=2 independent 
experiments (B). Differences were measured with two-tailed paired t-test. 
 
5.2.2. Identification of mRNA targets for miRNA-155 
 
To identify the downstream gene targets of miRNA-155 that may participate in 
leukocyte adhesion, online microarray datasets generated by miRNA-155 overexpression 
in hCMEC/D3 cells were referenced (Geo accession GSE44694, platform GPL6883). In 
the original publication, the authors studied the effect of miRNA-155 modulating BBB 
permeability, therefore, no annotation was observed related to pathways involving 
leukocyte adhesion (Lopez-Ramirez et al., 2014).  
Given that the analysis of the microarray data did not result in the discovery of 
feasible candidates, identification of miRNA-155 targets was approached from a different 
angle. Preliminary analysis was conducted on proteomic data of miRNA-155-
overexpressing hCMEC/D3 cells generated by Dr. Arsalan Haqani (National Research 
Council of Canada, Human Health Therapeutics Portfolio, Canada) (n=1) (Annexe 1). 
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Proteins that were observed to be down-regulated by > 1 log2 fold change (97 proteins) 
were selected and compared to the list of predicted targets for miRNA-155 obtained from 
TargetScan (Figure 5.5.A). Indeed, six proteins showed at least one predicted site for 
binding of miRNA-155 according to TargetScan. The list of down-regulated proteins 
were also compared to the list of validated targets according to Tarbase and two mRNA 
targets were identified. Therefore, these two proteins have been previously shown to be 
targets of miRNA-155. Subsequently, a literature search was carried out on these 8 
proteins to identify links to endothelial function and/or regulation of immune response by 
using keywords of “endothelial”, “inflammation” or “leukocytes” in the National Center 
for Biotechnology Information (https://www.ncbi.nlm.nih.gov/). Only nuclear factor of 
activated T cells 5 (NFAT5), tight junction protein 1 (TJP1), REL proto-oncogene, NF-
kB subunit (REL) and WNK1 were cited in publications related to any of the before 
mentioned keywords.  
Figure 5.5. Analysis of proteins in miRNA-155 overexpressing hCMEC/D3 cells. (A) 
Venn diagram of down-regulated proteins upon miRNA-155 overexpression in 
hCMEC/D3 cells (proteomics), predicted targets of miRNA-155 by TargetScanHuman 
7.8 (TargetScan), validated list of miRNA-155 targets by Tarbase (Tarbase) and 
corresponding number of matched target with the proteomic analysis. (B)  Table 
summarising matched targets, log2 fold change (FC) to scrambled-transfected 
hCMEC/D3 cells, number of online database matches (targetScan or Tarbase) and 




Next, the expression of these four proteins was investigated at the mRNA level in 
murine brain cells using open-access data on single cell RNA-seq of murine brain cells 
(He et al., 2018). This database contained transcriptomic data on different groups of brain 
cells including pericytes (PC); smooth muscle cells (SMCs) either venular (veSMC), 
arteriolar (arSMC) or arterial (aSMC), microglia (MG), fibroblast-like type 1 or 2 (FPB1 
and FPB2, respectively), oligodendrocytes (OG) and endothelial cells (EC). ECs were 
grouped in 6 groups, three groups were identified as venous EC (vEC), capillary EC 
(capEC) or arterial EC (arEC), whereas there were three novel groups of ECs (EC1, EC2 
and EC3). Nfat5, tjp1 and wnk1 were abundantly expressed in the different clusters of 
ECs whereas rel expression was very low. Comparative analyses were not carried out, 
however, tjp1 seemed to show the highest level of expression among EC when compared 
to nfat5 and wnk1 (Figure 5.6).  Differential expression was observed in the other brain 






Figure 5.6. Expression of miRNA-155 target mRNAs in the mouse brain cells. 
Average expression of single cell RNA-seq provided by the open-access web dataset 
(http://betsholtzlab.org/VascularSingleCells/database.html, last accessed September 
2020) for different mouse brain cells to screen for the expression of nfat5 (A), tjp1 (B), 
rel (C) and wnk1 (D). Abbrevations: PC, pericytes; veSMC, arSMC and aSMC, venous, 
arteriolar and arterial smooth muscle cells, respectively; MG, microglia; FPB1, FPB2, 
fibroblast-like type 1 or 2; OG, oligodendrocytes; EC, endothelial cell; vEC, venous EC; 
capEC, capillary EC; aEC; arterial EC.  
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Subsequently, whether these proteins were expressed in human brain endothelial 
cells in vivo was investigated. For this purpose, open-access online database Human 
Protein Atlas (https://www.proteinatlas.org/; last accessed May 2020) and 
immunohistochemistry analysis of human cortex section were used (Figure 5.7.). The 
human protein atlas offered an estimation of the signal of the interrogated protein in 
endothelial, glial and neural cells. This information was collected and compared (Table 







Figure 5.7. Expression of miRNA-155 target proteins in the human cerebral cortex. 
(A) Immunohistochemestry analysis from The Human Protein Atlas 
(https://www.proteinatlas.org/) for NFAT5, TJP1, REL and WNK1. Staining is 
represented by brown signal. Scale bar is 50 µm. (B) Summary of expression of miRNA-
155 predicted target proteins in neural, glial and endothelial cells of the human cerebral 
cortex and proteomic analysis in hCMEC/D3 cells. Abbreviations: FC, fold change; BEC, 
brain endothelial cells; N/A, not applicable 
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TJP1 plays a role in BBB structure and permeability but there is currently no 
strong evidence to suggest it is involved in leukocyte transmigration into the brain 
(Reinhold and Rittner, 2017). Köchl R et al., (2016) proposed that deficiency of WNK1 
in leukocytes plays an important role modulating the adhesion of leukocytes to 
endothelial cells (Köchl et al., 2016). Furthermore, WNK1 is also a predicted target of 
the murine version of miRNA-155 (TargetScanMouse, 
http://www.targetscan.org/mmu_72/), which suggested that WNK1-miRNA-155 
interaction is conserved in the two species. Therefore, WNK1/miRNA-155 pair was 
selected for further investigation. 
5.2.3. Effect of WNK1 silencing on T cell adhesion to BECs 
 
To explore whether WNK1 played a role in modulating leukocyte adhesion to 
BECs, hCMEC/D3 cells were transiently transfected with siRNAs against WNK1 mRNA 
to decrease the levels of WNK1. Efficiency of WNK1 silencing was analysed from the 
expression of WNK1 protein and mRNA in transfected hCMEC/D3 cells (Figure 8). 
Firstly, testing of several antibodies for WNK1 by western blotting resulted in several 
unspecific bands. Furthermore, immunostaining revealed majority nuclear staining of 
WNK1, which is a cytoplasmic protein (data not shown). These different antibodies were 
discarded, finally, a new antibody against WNK1 yielded specific staining of WNK1 
confirmed by cytoplasmic signal intensity (Figure 5.A.). Immunostaining of WNK1 
demonstrated the loss of WNK1 staining on WNK1-siRNA transfected hCMEC/D3 cells 
(Figure 5.8.A). Upon transfection, WNK1 signal dropped to 49±8% of pixel intensity 
when compared to scrambled-transfected hCMEC/D3 cells (P<0.05, n=3) (Figure 5.8.B). 
RT-qPCR confirmed a significant decrease in the levels of WNK1 mRNA to 0.31±0.04 
(P<0.01, n=3) in WNK1-siRNA transfected hCMEC/D3 cells relative to levels of WNK1 










Figure 5.8. WNK1 silencing in hCMEC/D3 cells was demonstrated at the RNA and 
protein level. (A) Immunocytochemistry of hCMEC/D3 cells transfected with WNK1 
siRNA or scrambled control. The green channel represents WNK1 signal whereas the 
blue channel represents nuclear staining (DAPI). Scale bar = 75 µm (B) Quantification of 
the fluorescent staining of transfected hCMEC/D3 cells on 10 random images and 
normalized WNK1 signal by number of cells per image. (C) RT-qPCR analysis of WNK1 
expression after WNK1 siRNA transfection of hCMEC/D3 cells. Levels of WNK1 were 
normalized to internal control β-actin mRNA. Data are shown as mean±SEM, n=3 
independent experiments, differences were quantified by paired-t test with P*<0.05 to 




























































Subsequently, whether silencing WNK1 in hCMEC/D3 cells affected leukocyte 
adhesion to BECs was investigated (Figure 5.9.A). Under basal conditions (hCMEC/D3 
cells transfected with scrambled siRNA), 58±7 Jurkat T cells/FOV adhered to scrambled 
transfected hCMEC/D3 cells. Knockdown of WNK1 significantly increased the number 
of firmly Jurkat T cells adhered to hCMEC/D3 cells (74±7 Jurkat T cells/FOV, P<0.0001 
and n=7) (Figure 5.9.B). Under inflammatory conditions (1 ng/ml TNFα and IFNy for 24 
h) (Figure 5.9.C), 271±8 Jurkat T cells/FOV adhered to scramble-transfected hCMEC/D3 
cells (Figure 5.9.C). Deficiency of WNK1 in hCMEC/D3 cells did not alter the overall 
number of firmly adhered Jurkat T cells to cytokine-treated hCMEC/D3 cells compared 
to scramble-transfected hCMEC/D3 cells (290±17 number of firmly adhered Jurkat T 
cells/FOV for WNK1 siRNA-transfected cells, P>0.05 and n=3) (Figure 5.9.D). These 
results suggested that WNK1 played a role in modulating leukocyte adhesion to BECs 
only under basal conditions whereas stimulation with pro-inflammatory cytokines might 












Figure 5.9. WNK1 deficiency increased firmly leukocyte adhesion to hCMEC/D3 
cells after under basal conditions. (A) Representative brightfield (top) and fluorescent 
(FITC, bottom) images of Jurkat T cell adhesion (round-shaped cells) to hCMEC/D3 cells 
(spindle-shaped cells) under flow conditions after transfection with scrambled control 
(Scrambled, left panels) or WNK1 siRNA (WNK1 siRNA, right panels) under basal 
conditions.  (B) Quantification of the number of firmly adhered T cells per field of view 
(FOV) following transfection with scrambled control or WNK1 siRNA oligonucleotide 
for 48h under basal conditions. (C) Representative brightfield (top) and fluorescent 
(FITC, bottom) images of Jurkat T cell adhesion (round-shaped cells) to hCMEC/D3 cells 
(spindle-shaped cells) under flow conditions after transfection with scrambled control 
(Scrambled, left panels) or WNK1 siRNA (WNK1 siRNA, right panels) under 
inflammatory conditions (1ng/ml TNFα and IFNγ for 24h prior leukocyte adhesion was 
measured). (D) Quantification of the number of firmly adhered T cells per field of view 
following transfection with scrambled control or WNK1 siRNA for 48h under 
inflammatory conditions. Data are shown as mean±SEM and n=7 (A) and n=3 (B) 
independent experiments. ****P<0.0001 to scrambled control. Differences were 
assessed using a paired, two-tailed t-test. 




5.2.4. WNK1 expression is not modulated by overexpression of 
miRNA-155 in hCMEC/D3 cells 
 
In order to study whether WNK1 expression is modulated by miRNA-155, 
hCMEC/D3 cells were transfected with miRNA-155 mimic and levels of WNK1 were 
measured by qPCR and immunohistochemistry (Figure 5.10). Overexpression of 
miRNA-155 in hCMEC/D3 cells did not alter WNK1 mRNA expression (0.92±0.24 
expression levels of WNK1 relative to scrambled oligonucleotide-transfected cells) 
(Figure 5.10.A). Furthermore, analysis of WNK1 protein expression by 
immunohistochemistry revealed levels of the WNK1 protein were unchanged following 
miRNA-155 siRNA transfection in hCMEC/D3 cells when compared to scrambled-
transfected cells (Figure 5.10.C). Indeed, quantification of pixel intensity confirmed that 
WNK1 was unaltered upon silencing WNK1 in hCMEC/D3 cells (n=3). These results 
suggested that overexpression of miRNA-155 with miRNA-155 mimic did not modulate 
the expression of WNK1. Hence, this questioned whether WNK1 is an actual target of 











Figure 5.10. Overexpression of miRNA-155 did not alter WNK1 levels in 
hCMEC/D3 cells. (A) RT-qPCR analysis of WNK1 expression after WNK1 siRNA 
transfection of hCMEC/D3 cells. Levels of WNK1 were normalised to internal control β-
actin mRNA. (B) Immuno-cytochemistry of hCMEC/D3 cells transfected with WNK1 
siRNA or scrambled control. Green channel represents WNK1 signal whereas blue 
channel represents nuclear staining (DAPI). Scale bar = 75 µm (C) Quantification of the 
fluorescent staining of transfected hCMEC/D3 cells on 5-10 random images and 
normalized WNK1 signal by number of cells per image. Data are shown as mean±SEM, 
n=3 independent experiments, differences were quantified by paired-t test with P*<0.05 








In this chapter, the mechanism by which miRNA-155 mediated leukocyte 
adhesion to brain endothelium was investigated. WNK1 was identified as a possible target 
of miRNA-155 and it was confirmed that silencing of WNK1 led to increased leukocyte 
adhesion to BECs. However, the stable expression of WNK1 following overexpression 
of miRNA-155 suggested that WNK1 is not likely to be regulated by miRNA-155 
overexpression in human BECs. 
5.3.3. Efficient transfection of hCMEC/D3 cells with miRNA-155 
precursor 
 
Transfection of hCMEC/D3 cells with miRNA modulators has been previously 
characterised (Lopez-Ramirez et al., 2014; Cerutti et al., 2016). Similar to previous 
reports, transfection with pre-miRNA-155 resulted in high expression of miRNA-155 in 
the hCMEC/D3 cells (Lopez-Ramirez et al., 2014). Overexpression of miRNA-155 
subsequently led to increased adhesion of T cells to brain endothelia. These results were 
in accordance with Cerutti et al., (2016), who demonstrated a role for miRNA-155 in 
stimulating leukocyte adhesion to brain endothelium. However, results from the current 
experiments differed from this earlier report on absolute numbers as they were higher 
number of firmly adhered T cells to BECs. It is possible that these differences might be 
due to user variability as well as cell lot. Furthermore, it was confirmed that miRNA-155 
increased levels of VCAM1, one of the two proteins suggested to be involved in miRNA-
155-induced T cell adhesion to brain endothelium (Cerutti et al., 2016). Cerutti et al 
(2016) previously showed the linked between levels of miRNA-155 and VCAM1 
expression, which was confirmed in the current experiments. Therefore, this model and 
transfection method were robust and consistent with the previous literature. 
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5.3.4. Identification of miRNA-155 targets from existing microarray 
dataset 
 
Previous analysis of published microarray data on miRNA-155 overexpressing 
BECs identified a list of possible candidates that can be modulated by miRNA-155 
(Lopez-Ramirez et al., 2014). However, none of the predicted genes were known to be 
involved in leukocyte adhesion to the endothelium. Interestingly, Cerutti et al., showed 
that silencing miRNA-155 under inflammatory conditions had a stronger effect in 
modulating leukocyte adhesion than silencing under basal conditions (Cerutti et al., 
2016). It is likely that a complex network of miRNA-155 targets might be modulated 
upon inflammation. Therefore, it is possible that target identification for key players at 
the mRNA level modulating leukocyte adhesion might be more evident if they were to be 
studied under a pro-inflammatory scenario. Alternatively, miRNAs can also modulate 
protein levels without altering total mRNA levels (Cottrell, Szczesny and Djuranovic, 
2017). For this reason, it is also feasible that miRNA-155-induced leukocyte adhesion 
had no direct effect at the mRNA level. 
5.3.5. WNK1 is a possible modulator of leukocyte adhesion to BECs 
 
Proteomic analysis of miRNA-155-overexpressing hCMEC/D3 cells identified 8 
candidate proteins that were either predicted or validated targets of miRNA-155. Only 
four of these candidates were related to inflammation, endothelial cells and/or leukocytes 
mechanisms by different research papers. Single-cell RNA-seq data showed that nfat5, 
wnk1 and tjp1 were expressed in murine brain endothelial cells. However, both NFAT5 
and REL were observed not to be expressed in the human tissue section of cerebral cortex 
according to the Human Protein Atlas (www.proteinatlas.org). These differences might 
be due to species-specific expression (murine and human) or simply than NFAT5 protein 
expression is not high enough to be detected in brain endothelium. This latest approach 
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would be in disagreement with a recent study. Indeed, authors identified the inflammatory 
role of NFAT5 in BECs (Wu, Cerutti, Miguel A Lopez-Ramirez, et al., 2015) and showed 
that inhibition of NFAT5 decreased leukocyte adhesion to BECs. Furthermore, NFAT5 
is a transcription factor that  has been shown to have a protective role in oxygen-glucose-
serum deprived astrocytes (Xia et al., 2017). Accordingly, NFAT5 expression was 
detectable in glial cells. REL is a crucial protein for NFKappaBeta activation, a major 
transcription factor that regulates many inflammatory pathways (Wulczyn, Krappmann 
and Scheidereit, 1996). Under pro-inflammatory conditions REL has been shown to be 
up-regulated  (Tian, Nowak and Brasier, 2005). For this reason, it was hypothesised that 
under miRNA-155-induced status REL should have been up-regulated as well, however, 
proteomic analysis suggested otherwise. It is possible that down-regulation of REL in 
hCMEC/D3 cells might be a compensatory mechanism to cope with miRNA-155-induced 
inflammatory status. These two proteins were not further investigated because 1) no 
detection in cortical brain endothelial cells and 2) weak link on promoting T cell adhesion 
upon down-regulation. Then, it was confirmed that TJP1 was expressed in endothelial 
cells of human tissue sections of the cerebral cortex. TJP1 has been extensively 
characterised as a key protein for brain endothelium structure and function (Reinhold and 
Rittner, 2017). However, little is known about its possible link to leukocyte adhesion to 
brain endothelium. 
WNK1 was identified as a possible candidate for miRNA-155. WNK1 is a kinase 
protein that is mainly responsible for mediating the signalling of ion co-transporter whose 
main function has been linked to water balance in the kidney (Shekarabi et al., 2017). 
Interestingly, a recent report has showed that WNK1 is relevant in immune function 
(Köchl et al., 2016). In this research, the authors demonstrated that upon silencing in T 
cells, WNK1 increased T cell adhesion to endothelial cells but decreased their migration, 
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suggesting a fine-tune expression of WNK1 in order to respond to the cellular 
requirements. MiRNAs have been previously described as fine-tune regulators of gene 
expression (Zhang et al., 2012), thus, likely modulators of WNK1 expression. Results 
from the current study demonstrated that silencing WNK1 in hCMEC/D3 cells increased 
number of T cells adhered to brain endothelial cells under basal conditions. However, this 
phenotype was not replicated under inflammatory conditions. It is feasible that the 
mechanism by which WNK1-mediated T cell adhesion to BECs is saturated by the 
stimulation of BECs with TNFα and IFNγ, hence no further effect can be observed upon 
inhibition of WNK1 under inflammatory conditions. To understand these differences of 
T cell adhesion regulation by WNK1, the molecular players involved in WNK1-induced 
endothelial dysfunction are required. WNK1 has been proposed to control endothelial cell 
proliferation and angiogenesis mediated by OSR1 and SPAK1, two well-known targets 
of WNK1 (Dbouk et al., 2014). However, it is difficult to speculate the mechanism by 
which WNK1 might be mediating leukocyte adhesion, hence, future proteomic analysis 
of WNK1-deficient cells would be important to understand this phenotype.  
MiRNA-155 has been extensively studied for playing major roles in T cell 
function (Faraoni et al., 2009). MiRNA-155 showed a highly conserved binding site in 
the 3’ UTR of WNK1. For this reason, modulation of WNK1 expression might be partly 
controlled by miRNA-155. However, these results showed that overexpression of miRNA 
had no effect on mRNA or protein WNK levels. As mentioned previously, there is still a 
possibility where under basal conditions, the effect of miRNA-155 in WNK1 expression 
is undetectable. Furthermore, the proteomic analysis was based on only one sample for 
the screening. Hence, future experiment will include analysis of WNK1 expression under 




CHAPTER 6: Investigating the unexpected polydipsia in 
aged miRNA-155 deficient mice  
 
6.1. Introduction 
In the previous chapters, the mechanism by which sEVs and miRNA-155 affected 
cerebrovascular function in the context of inflammation was investigated. Initially, in vivo 
experiments were planned to evaluate the in vitro findings described in Chapter 4 and 5. 
Hence, a mouse model where miRNA-155 was knocked out (KO) (Lopez-Ramirez et al., 
2014) was maintained in the lab facilities. This model was used by other lab members to 
evaluate BBB function during healthy ageing. It was observed that there were no 
significant differences in BBB permeability and tight junction expression (unpublished 
data). However, over the course of the colony maintenance and ageing, it was noted that 
aged female miRNA-155 KO mice developed an unexpected increase in water intake 
compared to the WT mice. This phenotype has not been previously described in the 
literature of miRNA-155 KO mice, for this reason, a systematic analysis of this phenotype 
and a molecular characterisation was designed to be a side project of this thesis. 
An increase in the rate of water intake is commonly known as polydipsia (Ball, 2007). 
The physiology of polydipsia is related to changes in the water balance and/or thirst 
(Knepper, Kwon and Nielsen, 2015). Polydipsia is often associated with diabetes mellitus, 
diabetes insipidus, psychogenic thirst as well as rare syndromes affecting the kidney 
function (Makaryus and McFarlane, 2006; Ball, 2007; Aznar Rodríguez et al., 2012).  
Diabetes mellitus is characterised by a deregulation of the glucose levels and is often 
associated with polydipsia, polyuria (increase urine secretion) and weight loss among 
other symptoms (Aznar Rodríguez et al., 2012). Therefore, diagnosis of diabetes mellitus 
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that may be associated with an increased water intake can be achieved by measuring 
fasting blood glucose levels  (Aznar Rodríguez et al., 2012). 
Diabetes insipidus is the most common cause of polydipsia (Makaryus and 
McFarlane, 2006). Whereas diabetes mellitus is the consequence of a deregulation of the 
glucose-insulin system, diabetes insipidus is caused by a deregulation of the arginine 
vasopressin hormone (AVP), also known as antidiuretic hormone (Robertson, 1995; 
Valtin, 1995). Diabetes insipidus is considered “central” when the AVP production in the 
hypothalamus is impaired or if the pituitary gland fails to secrete it into the blood stream. 
Therefore, reduced levels of AVP in the blood will lead to compensatory mechanisms 
involving blood pressure, osmo-receptors and eventually increased thirst (Ball, 2007; 
Knepper, Kwon and Nielsen, 2015). “Nephrogenic” diabetes insipidus is caused when the 
production and secretion of AVP is normal but this hormone fails to activate its receptor 
in the kidney, likely due to renal dysfunction (Bichet, 2006). Diagnosis of both diabetes 
insipidus and its subtypes is achieved by measuring AVP levels in blood as well as 
performing a water deprivation test in combination with injection of desmopressin, an 
analogue of the AVP (Robinson, 1976). 
AVP is synthesised in the large magnocellular neurons situated in the hypothalamus. 
This region overlaps with the synthesis area for oxytocin. This molecule is a neuropeptide 
closely related to AVP. Oxytocin and AVP differ by only two amino acids located at 
position 3 and 8. Both oxytocin and AVP have functions closely related to social 
behaviour (Baribeau and Anagnostou, 2015). Water homeostasis can also be regulated by 
AVP-independent mechanism involving oxytocin (Cheng, Chu and Chow, 2009). 
Psychogenic thirst is a rare condition resulted in the deregulation of pathways 
involved in water intake independently from AVP. Pathological conditions such as brain 
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cancer or vascular dysfunction can lead to polydipsia (Ball, 2007). Diagnosis is normally 
achieved after eliminating the most common causes of polydipsia (Makaryus and 
McFarlane, 2006). 
      Another reason for  increased water intake may be associated with kidney 
malfunction, independently of AVP signalling (Ball, 2007). There are well-known 
mutations in the ion co-transporters that have been reported to lead to increased 
polydipsia. Bartter´s syndrome is the most common condition associated with co-
transporter dysfunction and can be sub-classified according to the mutations in different 
genes e.g. Na-K-2Cl symporter (SLC12A1 or NKCC2 gene)  or thick ascending limb K+ 
channel (ROMK or KCNJ1 gene) (Fulchiero and Seo-Mayer, 2019).  
         A putative role for miRNA-155 in regulating water balance has not been 
demonstrated previously. There is evidence that deficiency of this miRNA can lead to 
higher levels of angiotensin II type 1 receptor resulting in vascular constriction and higher 
blood pressure (DuPont et al., 2016). However, this mechanism would not explain 
increased water intake. Therefore, these preliminary observations suggest that there might 
be novel pathways by which miRNA-155 regulates water intake. 
           In this chapter, a systematic study investigating the physiological attributes (water 
and diet intake, weight and urine specific gravity) of both male and female miRNA-155 
KO mice and WT at different months of age (3, 6, 12 and 18) was carried out. 
Furthermore, aged female mice (18 month-old) were used to further investigate the 
aetiology of the observed physiological attributes. Finally, a systematic comparison 
between traditional miRNA-155 KO mice and newly generated miRNA-155 KO mouse 
obtained by cross-breeding the in-house WT mouse strain with miRNA-155 KO mice 
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was carried out to determine whether or not spontaneous genetic mutations may have 
arisen that might have explained the observations made. 
6.2. Results 
6.2.1. Genotype of miRNA-155 KO and WT mice 
 
To ensure the model has not lost the deletion of miRNA-155, both miRNA-155 
KO and WT mice were genotype by PCR. Imaging of resolved gels showed two distinct 
bands (Figure 6.1). WT mice showed a single band around 450 bp (predicted size was 
465 bp) whereas miRNA-155 KO mice presented a higher amplicon sized band. Indeed, 
the identified band was approximately 550 bp (predicted size for the amplicon of miRNA-
155 primers was 600 bp) (Figure 6.1). Therefore, this results confirmed that miRNA-155 
KO mice carried the mutated miRNA-155 gene. A systematic study was carried out to 
determine weight, water and diet intake as well as urine concentration 
 
Figure 6.1. Genotype of miRNA-155 KO mice. Representative image of genotyping 
miRNA-155 KO deletion by PCR. 2 to 7 wells are samples from miRNA-155 KO mouse 
whereas 8 to 12 are samples from wild-type (WT) mice. 
 





A systematic study was carried out to determine weight, water and diet intake as 
well as urine concentration in male and female WT and miRNA-155 KO mice over an 
18-month period. As expected, both WT and miRNA-155 KO male mice showed higher 
weight gain compared to female mice of both strains (Figure 6.2.A). Genotype did not 
affect body weight within the same sex (Fig. 6.2.A). Food intake over time did not differ 
among any groups at any time point studied. In fact, no differences were found in food 
intake percentage calculated from month 3 of the study (Figure 6.2.B). 
Mean daily water intake ranged between 2 to 4 ml per 25g of body weight for WT 
mice. These mice maintained constant fluid consumption across the study (Figure 6.1.C). 
Consistent water intake was also observed in male miRNA-155 KO mice. Although there 
was a trend for an increased gained water consumption at the later age of 15 and 18 
months (145% and 135%, respectively), this was no significant when compared to their 
aged-matched WT control (Figure 6.1.C). Female miRNA-155 KO mice showed the 
strongest increased of water intake amongst all groups studied. In fact, fluid consumption 
in this group was significantly higher than their age-matched control WT mice from 15 
month-old of age (P<0.001). This increase in water intake was also significantly higher 
in KO female mice compared to aged and genotype-matched male KO mice (Figure 
6.2.C). 
Urine concentration was analysed by measuring urine specific gravity every three 
months. Neither female nor male WT mice showed any changes in urine specific gravity 
at any point of the study. However, both female and male miRNA-155 KO mice showed 
a decreased in their urine specific gravity with age (Figure 6.1.D). Male miRNA-155 KO 
mice showed significant differences in urine specific gravity at late age of 18 months old 
(P<0.0001), whereas this effect was observed from 12 months of age for female miRNA-




Figure 6.1. Systematic study of physiological parameters of miRNA-155 KO and WT mice. (A) Weight of miRNA-155 knock-out (KO) and 
wild type (WT) mice (female and male) from 3 to 18 months old (n= 8 (mate WT), 10 (male and female miRNA-155 KO) and 13 (female WT) 
different mice). (B) Gained diet intake percentage of miRNA-155 KO and WT mice (female and male) from 3 to 18 months old (n = 3 (male WT 
and miRNA-155 KO) and 4 (female WT and miRNA-155 KO) cages). (C) Gained water intake percentage of miRNA-155 KO and WT mice 
(female and male) from 3 to 18 months old (n = 3 (male WT and miRNA-155 KO) and 4 (female WT and miRNA-155 KO) cages). (D) Urine 
specific gravity percentage of microRNA-155 KO and (WT) mice (female and male) from 3 to 18 months old (n= 4 (male WT), 6 (male miRNA-
155 KO), 9 (female WT) and 11 (female miRNA-155 KO) different mice). Data are shown as mean ± SEM.  Differences were measured with two-
way anova and Tukey´s post-hoc test for multiple comparisons. *P<0.05, ***P<0.001, ****P<0.0001 to aged- and sex- matched WT mice. 
####P<0.0001 to age- and genotype-matched male mice. 
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6.2.3. Urine and serum analysis  
 
Based on the results described in section 6.2.1, remaining analysis were centred 
in female 18-month old mice in order to investigate the pathology underlying the observed 
phenotype.  
To further characterise the effect of polydipsia in both urine and blood, serum and 
urine was analysed by an external company (IDDTEX, Germany). Total concentrations 
of sodium, magnesium and chloride were found to be significantly decreased in urine 
isolated from female miRNA-155 KO mice (Table 6.1), whereas calcium and magnesium 
urine levels were not changed. Urine osmolality was also decreased in the samples from 
miRNA-155 KO mice when compared to WT mice. These results are in accordance with 













Table 6.1. Electrolyte and osmolality of urine samples from miRNA-155 KO and 
WT mice (n=5). 
 
Abbreviations: wild type (WT), microRNA (miRNA, knock-out (KO) 
Serum analysis resulted in no significant differences in any of the electrolytes 
analysed neither the osmolality of samples taken from female miRNA-155 KO mice were 










Table 6.2. Electrolyte and osmolality of serum samples taken from miRNA-155 KO 
and WT mice (n=5). 
 
Abbreviations: wild type (WT), microRNA (miRNA, knock-out (KO) 
 
6.2.4. Investigating mechanisms underlying the polydipsia and diluted 
urine observed in female miRNA-155 KO mice with age  
 
In the previous section, female miRNA-155 KO mice were observed to develop a 
strong phenotype characterised by an increased water intake and diluted urine (Figure 
6.2). This phenotype is associated with different pathologies that affect water balance 
(Valtin, 1995; Ball, 2007). Figure 6.3 shows the flowchart outlining the steps taken to 




Figure 6.3. Schematic diagram for diagnosing the pathology underlying mouse 
polydipsia and diluted urine.  
 
 
6.2.5. Levels of glucose in the plasma of fasting miRNA-155 KO and 
WT mice 
 
Diabetes mellitus is characterised by a loss of function or decreased levels of the 
insulin hormone, which results in an increased concentration of the glucose in plasma 
(Aznar Rodríguez et al., 2012). Mice were fasted for 8 h prior the collection of blood 
samples to ensure glucose differences were not affected by their food intake. 
Measurement of glucose levels in the plasma revealed that there were no significant 
differences between miRNA-155 KO and WT mice (Figure 6.4). Therefore, it was 




Figure 6.4. Glucose levels on miRNA-155 KO and WT mice after fasting. 
Quantification of glucose levels in blood of miRNA-155 KO and wild type (WT) mice 
after 8h of fasting. Data are shown as mean ± SEM, n = 4 of different mice. Differences 
were measured with unpaired two-tailed t-test.   NS: no significant. 
 
6.2.6. Effect of desmopressin challenge in miRNA-155 KO mice´s urine 
osmolality 
 
Diabetes insipidus is the most frequent cause of water balance disorders. There 
are two different type of diabetes insipidus, which are classified either as central due to 
dysfunction of the hypothalamus and/or the pituitary gland, or as nephrogenic because of 
an ineffective response in the kidney to AVP (Robinson, 1976). To investigate whether 
either of these mechanisms may be contributing to the observed polydipsia, mice were 
first administrated with DAVP and the osmolality of urine collected 2 and 4h post-
injection was compared to baseline values. In order to reduce the number of animals 
tested, this test was only carried on miRNA-155 KO mice. Measurement of urine 
osmolality of aged female miRNA-155 KO mice revealed a significant increase in 
osmolality after treatment with DDAVP (Figure 6.5). These results suggested that the 
kidneys were able to respond to DDAVP, hence, it is unlikely these mice were suffering 
from nephrogenic diabetes insipidus. Furthermore, urine osmolality of miRNA-155 KO 
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mice after DDAVP challenge was similar to previously reported urine osmolality of WT 
mice (between 1000 to 2000 (mosmol/kg)) (Roncal-Jimenez et al., 2017). 
 
Figure 6.5. Urine osmolality of miRNA-155 KO mice after injection with 
desmopressin Quantification of the urine osmolality of miRNA-155 KO before and after 
they were challenged with a desmopressin compound (0.04 µg/Kg). Samples were 
collected 2 and 4h after injection and pulled together for analysis of urine osmolality. 
Data are shown as mean ± SEM, n = 5 of independent replicates and un-paired two-tailed 
t-test.    
 
6.2.7. Levels of vasopressin in the hypothalamus and plasma between 
female miRNA-155 KO and WT mice 
 
AVP is produced in response to thirst stimulus in the hypothalamus and then 
transported to the pituitary gland and AVP is stored at the posterior lobe of the pituitary 
gland (Ooi, Tawadros and Escalona, 2004). When levels of circulating AVP drop, this 
hormone is release into the bloodstream and AVP concentration is restored (Knepper, 
Kwon and Nielsen, 2015). Therefore, concentrations of AVP in the hypothalamus and/or 
plasma of female miRNA-155 KO and WT mice were measured.  
RT-qPCR analysis of hypothalamic samples showed that relative expression of 
mRNA AVP was 1.1±0.2 in WT mice and 0.9±0.3 in miRNA-155 KO mice (P>0.05) 
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(Figure 6.5.A). Given that OXC and AVP are produced by similar neurons, OXC mRNA 
levels were also analysed. OXC mRNA levels were not changed between WT and 
miRNA-155 KO mice (WT = 1.1±0.2 vs. KO = 0.9±0.3 relative mRNA levels, P>0.05; 
n=5) (Figure 6.6.A). To determine whether the expression and localization of AVP 
protein was different between WT and KO mice, immunohistochemistry for AVP was 
carried out in the hypothalamus of fixed brain sections. Qualitative analysis of the staining 
showed no obvious differences in the number of positive neurons for AVP (Figure 6.6.B).  
 
Figure 6.6. Vasopressin levels are not altered in the hypothalamus of miRNA-155 
KO mice. (A) RT-qPCR analysis of vasopressin (AVP) and oxytocin (OXC) in 
hypothalamus samples isolated from miRNA-155 KO mice and wild type (WT) mice. 
Data are shown as mean±SEM, n=5 independent replicates, unpaired two-tailed t-test. (B) 
Immunohistochemistry images of DAB-staining for AVP in the hypothalamus of 
miRNA-155 KO (left) and WT (right) mice. N = 5 of different animals with different 




Production of AVP can occur normally and still have reduced levels of AVP in 
the circulation.  This might occur if the pituitary gland fails to secrete the AVP that is 
stored ready to be delivered into the circulation (Baribeau and Anagnostou, 2015). 
Therefore, plasma concentrations of AVP were measured by ELISA. In WT mice, AVP 
concentrations were 79.21±26.85 pg/ml whereas miRNA-155 KO mice showed 
55.18±19.87 pg/ml of AVP in plasma (P>0.05; n=5) (Figure 6.7).  
 
 
Figure 6.7. Levels of vasopressin in plasma are not changed between miRNA-155 
KO and WT mice. ELISA measurement of soluble vasopressin (AVP) in plasma 
isolated from miRNA-155 KO and wild type (WT) mice. Data are shown as mean ± 
SEM, n=5 of independent replicates, unpaired two-tailed t-test. 
 
Taken together, these results suggested that aged female miRNA-155 KO mice 
are unlikely to be suffering from central diabetes insipidus. 
 
6.2.8. Levels of ion co-transporter NKCC2, NCC and WNK1 mRNA in 
renal tissue of miRNA-155 KO and WT mice. 
 
Next, the expression of proteins involved in water transport in the kidney were 
analysed in female WT and miRNA-155 KO mice (Figure 6.8). Kidneys were extracted 



























and protein homogenates were produced from the renal cortex. Immunoblotting revealed 
(Figure 6.8.A) that levels of the Na-K-2Cl cotransporter (NKCC2) ion channel were 
significantly reduced in female miRNA-155 KO mice (WT= 1.00±0.14 and miRNA-155 
KO = 0.44±0.08 protein band densitometry ratio, P<0.01; n=4), whereas, Na-2Cl 
cotransporter (NCC) ion channel appeared unaltered (WT=1±0.15 and miRNA-155 












Figure 6.8. Levels of NKCC2 and NCC on cortical kidney.  Cropped image of an 
immunoblot from samples isolated from the cortex of the kidney of female miRNA-155 
KO (KO) or Wild Type (WT) mice. Antibodies used were against NKCC2, NCC and 
GADPH as internal control. (B) Quantification of protein expression on the immunoblot 
by band densitometry and normalized to expression of wildtype mice (WT). Data are 
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NKCC2 protein activity is regulated up-stream by a network of kinases and 
proteins that include WNK1 (Shekarabi et al., 2017). As described in Chapter 5, WNK1 
is a predicted target of murine-miRNA-155, hence, expression of kidney-specific WKN1 
(which shares the same 3’UTR as the long-isoform WNK1) was studied. RT-qPCR 
analysis revealed that miRNA-155 KO mice expressed higher levels of WNK1 mRNA in 
the renal cortex than WT mice (1.96±0.07 relative levels to WT, P<0.01; n=4). Due to 
the inefficiency of tested antibodies to detect WNK1 (as described in Chapter 5), protein 
expression was not measured. 
 
Figure 6.9. Levels of WNK1 mRNA in the cortex of the kidney of female mice. RT-
qPCR analysis of WNK1 mRNA (kidney-specific variant) in the cortex from kidneys 
isolated from female miRNA-155 KO (KO) or wild type (WT) mice. Β-actin mRNA 
was used a housekeeping gene. Data are shown as mean ± SEM, n = 4 independent 
replicates, unpaired two-tailed t-test. 
 
6.2.9. Effect of cross-breeding miRNA-155 KO mice on water intake  
 
The miRNA-155 KO mouse colony had been maintained in the facility for over 
20 breeding cycles. Half way through the study, the colony presented difficulties in 
breeding, hence, miRNA-155 KO mice were backcrossed with the in-house WT strain 
C57Bl/6J mice. After three breeding cycles, an Open University (OU) line of 
miRNA-155 KO WT 
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homozygous miRNA-155 KO mice was generated as confirmed by PCR (data not 
shown). The miRNA-155 OU KO mice were aged for 18 months and water intake was 
measured. Female miRNA-155 OU KO mice showed water intake of 3.5±0.6 ml of water 
per 25g body weight and WT mice drank 2.4±0.1 ml (P>0.05) (Figure 6.9). The new 
mouse line failed to replicate the phenotype observed in the original miRNA-155 KO 
mouse line (10.7±2.6 ml of water per body weight) (Figure 6.9). In light of the termination 
of the original breeding line and the discrepancy between the polydipsia in the original 
and OU KO strains, it was decided to conclude these phenotyping studies.  
 
Figure 6.10. Water intake of miRNA-155 KO, WT and new-bred miRNA-155 KO 
mice. Wild type (WT) and miRNA-155 KO mice were crossed to generate a new miRNA-
155 KO mouse line (miRNA-155 OU KO mice). (A) Example of genotyping gel for 
miRNA-155 OU KO homozygous (well 3,4, and 5), wild type (WT) (wells 7 and 11) and 
miRNA-155 OU KO heterozygous (wells 8, 9, 10 and 12). (B). Mice (WT, miRNA-155 
KO and miRNA-155 OU homozygous) were aged to 18 months and water intake was 
measured. Data are shown as mean±SEM and differences were asset by one-way anova 
with Tukey´s post-hoc for multiple comparison **P<0.01, n= 3 (WT), 4 (miRNA-155 
OU KO) and 2 (miRNA-155 KO).   
 
 
6.3.  Discussion 
In this chapter, a systematic longitudinal study of miRNA-155 KO mice identified 
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observed on these mice. Phenotypically, female miRNA-155 KO mice suffered from 
polydipsia, diluted urine as well as low levels of sodium, potassium and osmolality in 
urine. Mechanistically, levels of NKCC2 were decreased whereas WNK1 mRNA was 
increased in these mice. However, the phenotype observed might be due to a cause 
unrelated to the deficiency of miRNA-155 because the resulting mouse line from miRNA-
155 KO mice backcrossed with WT mice failed to manifest polydipsia. 
 
6.3.1. Diagnosing female miRNA-155 KO mice underlying condition 
As mentioned before, aged female miRNA-155 KO mice showed an increased 
water intake and lower urine specific gravity than their aged- and sex-matched WT mice. 
However, no differences in food intake and neither in body weight were found among all 
four studied groups.  
A literature search was carried to identify the most likely pathologies underlying 
the observed phenotype. Based on the results obtained in this chapter, diabetes mellitus 
and both types of diabetes insipidus were unlikely to be the cause of the underlying female 
miRNA-155 KO mice´s polydipsia. Instead, these mice showed decreased levels of renal 
ion exchanger NKCC2 protein, which has been previously implicated in the kidney 
disorder, Bartter syndrome (Fulchiero and Seo-Mayer, 2019). Indeed, inactivating 
mutations in NKCC2 are of clinical relevance in Bartter Syndrome type 1 (Jeck et al., 
2005). In mice, a recent study demonstrated that loss of NKCC2 activity led to Bartter-
like phenotype, which included decreased levels of plasma K+ and higher plasma pH 
(Rieg et al., 2013). Interestingly, the serum analysis in this chapter showed a trend for 
down-regulated levels of serum K+ in the aged female miRNA-155 KO mice. It is fair to 
mention that this study was performed in only four different mice, whereas the differences 
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reported by Rieg and colleagues were observed in a cohort of 9-10 mice per group (Rieg 
et al., 2013). Therefore, the analysis of an increased number of mice might help elucidate 
whether the levels of serum K+ were changed in the aged female miRNA-155 KO mouse 
model. Furthermore, active reabsorption of NaCl by NKCC2 is a necessary step for the 
process of urine secretion mediated by nephrons (for a review see (Castrop and Schießl, 
2014)). Therefore, defective NKCC2 is a crucial step in the polyuria observed in Bartter´s 
syndrome type 1. Indeed, deficiency of NKCC2 leads to severe polydipsia and short 
survival rate of mice (Takahashi et al., 2000). These results suggested that the low 
expression of NKCC2 in the aged female miRNA-155 KO mice was likely to be 
responsible for the low concentrated urine, hence, the polydipsia too. 
Many proteins are involved in the regulation of the expression and activity of 
NKCC2. Among these, WNK1 has been previously shown to control reabsorption of 
sodium in the kidney (Liu et al., 2011). WNK1 has several isoforms, being a short one 
specifically expressed in the kidney together with the long (full) isoforms (Shekarabi et 
al., 2017). Overexpression of kidney-specific WNK1 (KS-WNK1) was shown to 
decrease the expression and phosphorylation of NKCC2 (Liu et al., 2011). In the current 
experiments, WNK1 mRNA was observed to be increased upon deletion of miRNA-155 
in the kidney. However, confirmation of changes in WNK1 at the protein levels will still 
be needed to confirm the up-regulation of WNK1 by miRNA-155 deletion. As mentioned 
in Chapter 5, WNK1 is a predicted target of murine miRNA-155, therefore study of the 
miRNA-155/WNK1 mRNA binding would be necessary to validate this relationship. 
Interestingly, there are other proteins involved in NKCC2 activity (WNK3 and OSR) that 
were also predicted targets for mmu-miR-155-5p (as shown in TargetScan database, 
http://www.targetscan.org/mmu_72/ ; last accessed September 2020). So it could be 
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speculated that miRNA-155 might affect different key points in the signalling pathway to 
control ion cotransporters such as NKCC2 that will affect water balance. 
The effect of either sex or age was not further characterised in this piece of work, 
however, it is possible to speculate the contribution of these factors to the observed 
phenotype. Regarding age, no study has previously investigated the aging of miRNA-155 
KO mice in physiology. Only one study carried a systematic comparison of both young 
WT and miRNA-155 KO mice after 42 days post-weaning in normal healthy aging 
(Zhang et al., 2017). According to the results in this piece of work, authors observed no 
significant differences across groups (body weight, serum chemistry, liver function etc) 
(Zhang et al., 2017). The study of age-dependent polydipsia in  STR/N mouse model 
suggested a possible degeneration of kidneys including enlarged kidneys, renal lesions or 
loss of renal medulla function (Kutscher and Miller, 1974). STR/N mice do not show 
alterations on the AVP gene and the genetic cause of polydipsia is still poorly understood 
(Chu et al., 2015). Another report proposed that murine age-dependent polydipsia in 
STR/N mice might be caused due to reduced expression of renal AVP receptor, hence, 
affecting AQP2 levels (Tsumura et al., 2006). It was suggested that humoral factors might 
be involved in the upstream regulation of these genes. Given that deletion of nkcc2 is 
lethal (Takahashi et al., 2000), it is possible to speculate that physiological changes in 
aging might contribute to the development of the effect of polydipsia.   
Physiological data in this study showed that female miRNA-155 KO mice were 
affected to a greater extent by polydipsia than age-matched male miRNA-155 KO mice. 
It is possible to speculate that sex differences played a major role in the observed 
phenotype. These differences can include sex hormones such as testosterone and 
oestrogen. Indeed, oestrogen has previously shown to modulate body fluid in rodents 
(Somponpun, 2007). Oestrogen levels decrease with age in rodent (Gee, Flurkey and 
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Finch, 1983), hence, it might enhance the appearance of polydipsia in female aged 
miRNA-155 KO mice. Future analysis of sex hormones between miRNA-155 KO and 
WT mice would help to elucidate differences between these two models.  
 
6.3.2. Loss of polydipsia phenotype in new miRNA-155 KO mouse line 
 
MiRNA-155 KO mice was originally obtained from collaborators at Queen´s 
Mary in London. This strain was maintained in the facilities without any previous 
backcrossing with the in house WT mice. Following Jackson Lab guidelines 
(https://www.jax.org/ ) mice were kept inbred. As described above, lack of breeding in 
the miRNA-155 KO mice led to the generation of new miRNA-155 KO OU mice. 
Unfortunately, polydipsia was not observed in this new mouse line. Therefore, it is likely 
that the studied phenotype might have been caused by a miRNA-155-independent 
pathway and/or a combination of the loss of miR-155 with further genetic alterations 
There are previous reports of genetic drifts in inbred mouse lines that have been bred for 
a high number of breeding cycles (Brekke, Steele and Mulley, 2018). For instance, 
Cariappa and colleagues attributed a defect in B-cell development to the deficiency of 
Sialic acid acetyl esterase (Siae) gene in their genetic engineer mouse model (Cariappa et 
al., 2009). However, authors realised that this phenotype was caused by an inherited 
mutation in the dock2 gene. Indeed, siae-KO mice bred for 13 generations did not exhibit 
the attributed phenotype on defective B-cell development (Zeldovich, 2017). Regarding 
miRNA-155 KO mice, it is likely that an inherited mutation from the vendor mouse line 
was indeed the cause of the observed phenotype. It is also possible that accumulation of 
sporadic mutations has affected some of the key processes involved in water balance. The 
relationship between WNK1 and miRNA-155 in this chapter might be serendipity and 
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unrelated to the observed phenotype. However, a future comparative study might help to 
identify which genes differed among different mouse lines that were responsible for the 
underlying polydipsia and diluted urine. This future data might help to unravel and 
discover novel genes involved in water balance 
Regardless the implications in water balance, this miRNA-155 KO mouse model has been 
previously used to study BBB function and miRNA biology. For this reason, both the 
miRNA-155 KO WT mouse models will be useful tool to translate some of the findings 
described in the previous chapters. Here there´s a list of experiments using these models. 
For Chapter 3 and 4 
Induce systemic inflammation (either with pro-inflammatory cytokines or LPS) on 
miRNA-155 KO and WT mice, then collect plasma and/or serum and isolate mouse-
derived cytokine-sEVs. Subsequently, the following experiments are carried out: 
a) Isolate RNA and measure miRNA-155, VCAM1 and ICAM1 mRNA expression 
by RT-qPCR to study whether plasma/serum-derived sEVs showed a pro-
inflammatory profile similar to the one described in Chapter 6. 
b) Treat mouse brain endothelial cells with plasma/serum-derived sEVs (either 
quiescent or cytokine-sEVs) and analyse both the induced effect on these cells by 
cell-based assay (e.g. T cell adhesion assays) and measuring molecular changes 
(expression of cytokine-sEV-induced miRNA and ICAM1/VCAM1 protein). 
c) Similar experiment to b using miRNA-155 KO-derived sEVs will help to study 
the role of miRNA-155 in cytokine-sEV-induced BEC dysfunction. 
d) After a, b and c experiments have been successfully carried out, WT mouse can 
be treated with plasma/serum-derived cytokine-sEVs and quiescent sEVs to 
analyse their impact on BBB function. Firstly, fluorescently-stained sEVs should 
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be injected (intracarotid injection preferably) to evaluate they reach BECs in vivo. 
BECs can be isolated from microvessels and fluorescent analysed by flow 
cytometry. Once this process is being optimised, expression of miRNA-155, 
VCAM1 and ICAM1 can be measured by RT-qPCR. Other markers of induced 
systemic inflammation will include immunocytochemistry for VCAM1/ICAM1 
protein expression and microglia activation (e.g. Allograft inflammatory factor 1, 
iba1). 
For Chapter 5: 
Whether loss of miRNA-155 alters levels of WNK1 mRNA and/or protein in BECs in 
vivo can be studied with both miRNA-155 KO and WT mouse models. This analysis can 
be done both under naïve and inflamed conditions (treatment with LPS or pro-
inflammatory cytokines). Then, analysis of WNK1 expression can be achieved by 
a) RT-qPCR and western blot on BECs isolated from microvessels 
b) Immunocytochemistry of WNK1 on brain slides with co-localisation with 










CHAPTER 7: GENERAL DISCUSSION 
 
Neuroinflammatory disorders are characterised by an activated BBB that 
facilitates the extravasation of immune cells into the brain thereby contributing to disease 
progression  (Blanchette and Daneman, 2015). Recently, EVs have gained growing 
attention for their role in modulating the cellular status of the recipient cells in 
inflammation (Ciardiello et al., 2016). However, little is known about the contribution of 
endothelial EVs to BBB function (Ramirez et al., 2018). Therefore, the main aim of this 
thesis was to characterise EVs derived from BECs and investigate their impact on naïve 
BEC´s function in inflammation. Secondly, to identify whether miRNA-155 was relevant 
for EV function and study the mechanism by which miRNA-155 mediates leukocyte 
adhesion to brain endothelium as it has been previously described to modulate BBB 
function in inflammation (Cerutti et al., 2016). In parallel, given the unexpected 
polydipsia developed by female miRNA-155 KO mice, a systematic study of the 
physiology and the molecular mechanism(s) underlying this phenotype was carried out. 
The results described in this thesis have shown that: 
1) Upon TNFα and IFNγ treatment, hCMEC/D3 cells secreted higher number of 
sEVs than L-EVs. These sEVs carried pro-inflammatory modulators such as 
VCAM1 and ICAM1 mRNA and miRNA-155. 
2) Cytokine-sEVs led to decreased TEER and increased leukocyte adhesion to 
BECs. VCAM1, ICAM1 and miRNA-155 were also up-regulated in hCMEC/D3 
cells upon stimulation with cytokine-sEVs 
3) Quiescent sEVs had no effect on naïve BEC function. However, stimulation of 
inflamed BECs with quiescent sEVs decreased leukocyte adhesion to BECs. 
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4) WNK1 was identified as modulator of leukocyte adhesion to BECs. However, 
although it was a predicted target of miRNA-155, overexpression of miRNA-155 
via pre-miRNA-155 transient transfection did not alter WNK1 mRNA nor protein 
levels in brain endothelium. 
5) MiRNA-155 KO mice showed polydipsia and diluted urine as well as reduced 
NKCC2 levels and increased WNK1 mRNA level. However, the observed 
polydipsia was likely to be independent of the loss of miRNA-155. 
 
7.1. sEVs modulate neurovascular function in inflammation 
In recent years, there have been several reports suggesting that EVs play a role in 
modulating the immune response in physiology (Kalani, Tyagi and Tyagi, 2014) and 
pathology (Howitt and Hill, 2016; Kalluri, 2016). In particular, special attention has been 
given to the mechanisms by which EVs modulate inflammation in the CNS (Li et al., 
2018) and specifically, how they might affect cells of the NVU As described above, this 
work has advanced the understanding in the field of the BBB and how ECs communicate 
with each other by identifying a novel pathway of BEC dysfunction mediated by 
endothelial sEVs released from inflamed BECs (Figure 7.1). Specifically, this model 
contributes to the field of EV research in 1) investigating the specific effect of BEC-
derived EVs on cerebrovascular function, 2) supporting the vision that endothelial EVs 
promote endothelial dysfunction in inflammation regardless of their vascular bed of 
origin and 3) improving the understanding of the molecular players involved in 
endothelial EV-induced cerebrovascular dysfunction. Ultimately, this working model sets 
the basis and rationale for future investigations of sEVs in  models of neuroinflammation 




Figure 7.1. Summary of effect and mechanism of intercellular communication of brain endothelial cells via extracellular vesicles.1)  
hCMEC/D3  cells increase the secretion of  sEVs (cytokine-sEVs) upon treatment with TNFα and IFNγ; 2) Cytokine-sEVs carry higher levels of 
ICAM1, VCAM1 mRNAs and miRNA-155 than quiescent sEVs; 3) Cytokine-sEVs can be taken up by naïve brain endothelial cells (BECs) and 
4) increase the levels of miRNA-155, ICAM1, VCAM1 in the repicient cells; 4) Cytokine-sEVs reduce the value of TEER and 6) increased T cell 
adhesion to BECs; 7)  deficiency of WNK1 increased T cell adhesion to BECs, however whether WNK1 is modulated by miRNA-155 and relevant 
to cytokine-sEV-induced vascular dysfunction is still unknown.
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In the context of neuroinflammation, endothelial EVs have been previously shown to 
contribute to BBB dysfunction (for a review see (Ramirez et al., 2018)). However, most 
of these studies focused on 1) the effect of endothelial EVs on immune cells and other 
cells of the CNS (Yamamoto et al., 2015; Hosseinkhani et al., 2018, 2020; Ramirez et 
al., 2018) or 2) endothelial EVs from a heterogeneous mix of circulating endothelial EVs 
from the serum/plasma of patients with neuroinflammatory disorders (Marcos-Ramiro et 
al., 2014; Ramirez et al., 2018). Indeed, circulating endothelial EVs have been reported 
to promote vascular dysfunction in different neuroinflamamtory disorders and models 
including MS¡(Jy et al., 2004; Marcos-Ramiro et al., 2014). The results described in this 
piece of work highlighted how brain endothelial EVs also affected the function of naïve 
BECs. Hence, proposing EVs as a route to disseminate cytokine-like effects to not only 
immune cells but other naïve BECs as well. Indeed, cytokine-sEVs consistently induce 
BEC dysfunction as studied in Chapter 4. It is important to note that experiments in this 
study were carried out in an in vitro model of the BBB, hence, validation in vivo is 
necessary to confirm these findings. One possible experiment to demonstrate whether 
cytokine-sEVs promote endothelium activation would be the intracarotid delivery of 
cytokine-sEVs in mice and the analysis of their downstream impact in BEC function.  
Cell-to-cell communication between BECs might be particular relevant in the context 
of neuroinflammatory disorders, where pro-inflammatory cytokines are  increased in the 
circulation (Martins et al., 2011) and known to modulate cerebrovascular function (Lopes 
Pinheiro et al., 2016). Hence, release of cytokine-sEVs is enhanced but whether they are 
biologically functional or only a consequence of cell activation in vivo is still unknown. 
Data from Chapter 4 demonstrated that cytokine-sEVs were able to increase the effect of 
cytokine-loss of TEER, hence suggesting they might still be biologically functional even 
in the presence of pro-inflammatory cytokines in the blood. This working model is still 
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dependent on future in vitro (validation of the combined cytokine+cytokine-sEV effect 
on T cell adhesion and endothelial CAMs) and in vivo characterisation. 
As mentioned above, endothelial EVs can promote endothelial dysfunction during 
inflammation. This has been previously reported to be the case in other endothelial beds 
(Table 7.1) (Letsiou and Bauer, 2018). Indeed, TNFα-treated HUVECs-derived EVs 
increased the expression of pro-inflammatory cell adhesion ICAM1, hence, increasing 
monocyte transmigration (Hosseinkhani et al., 2018). Induction of a pro-inflammatory 
state by endothelial EVs has also been reported in pulmonary and aortic ECs (Curtis et 
al., 2009; Liu et al., 2017). Therefore, results from this piece of work contribute to the 
hypothesis that after an inflammatory stimulus, endothelial cells release EVs that can 
affect endothelial function in a similar way regardless of their vascular bed. This was 
already proposed by Ramirez et al. in an overview article on the field of EVs in the CNS 
(Ramirez et al., 2018). Most studies analysing the impact of endothelial EVs on EC 
function have been performed with L-EVs. Therefore, the work described in Chapters 3 
and 4 improves the field of research on sEVs modulating vascular function. Interestingly, 
it was noted that pro-inflammatory cytokines did not increase the number of L-EVs in 
Chapter 3. Given the broad literature on L-EVs (Table 7.1), it can be speculated that 
cytokine-L-EVs might still biologically functional despite their numbers not changing in 
inflammation. As described in Chapter 3, an increase in the larger percentile of cytokine-
L-EVs was observed in comparison to quiescent L-EVs. It is possible that the pro-
inflammatory stimulus induces the production of larger EVs without changing their total 
number but modulating their cargo as well. Hence, future analysis of the downstream 
impact of cytokine-L-EVs on endothelial function will help to elucidate their function in 


















Increased T cell adhesion, 
miRNA-155, ICAM1 and 
VCAM1 expression and 
decreased TEER 
Chapter 4 
HUVECS TNFα sEVs HUVECs 
Reduced tube formation, 
migration and increased 
apoptosis 
(Li et al., 
2019) 
HUVECS TNFα L-EVs HUVECs 
Induced expression of pro-
apoptotic molecules, 
ICAM1 and monocyte 
adhesion 
(Lee et al., 
2014) 
HAEC TNFα L-EVs HAEC 
Pro-inflammatory 
activation towards release 
of sICAM1 
(Curtis et al., 
2009) 
HPMECs TNFα L-EVs HPMECs 
Pro-inflammatory 
activation of ECs via NF-
KB pathway 
(Liu et al., 
2017) 
 
Abbreviations, HBMEC, human brain microvascular endothelial cells; HUVECs, human 
umbilical vein endothelial cells; HAEC, human aortic endothelial cells; HPMECs, human 
pulmonary microvascular endothelial cells; TNFα, tumour necrosis factor-α; IFNγ, interferon 
gamma; EV, extracellular vesicles; sEVs, small EVS; L-EVs, large EVs; ICAM1, intracellular 
cell adhesion molecule-1; VCAM1, vascular cell adhesion molecule 1; EC, endothelial cell. 
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Mechanistically, blocking of VCAM1 with neutralising antibodies significantly 
decreased cytokine-sEV-induced T cell adhesion whereas treatment with ICAM1 
neutralising antibodies did not prevent this phenotype (Chapter 4). Ligands for both 
VCAM1 and ICAM1 (VLA-4 and LFA-1, respectively) have been shown to mediate 
arrest of T cell in CNS vessels in inflammation in EAE models using intravital 
microscopy (Rossi et al., 2011). T cell migration into the CNS is a critical event in EAE 
and MS (Lopes Pinheiro et al., 2016). Interestingly the effect of blocking VLA-4 with 
antibodies led to a reduction of the onset of EAE whereas blocking LFA-1 had a minor 
impact on the development of EAE (Rossi et al., 2011). It is suggested that VLA-
4/VCAM1 play a key role in the pathogenesis of EAE (Rossi et al., 2011; Lopes Pinheiro 
et al., 2016). Therefore, it is possible to speculate whether cytokine-sEVs might play an 
important role in VCAM-1-driven diseases such as EAE in mice or MS in humans. 
The data produced in this work showed no changes into claudin-5 and occludin 
after stimulation with cytokine-sEVs. Therefore, it still remains unknown the mechanisms 
by which cytokine-sEVs affected TEER in BECs. Future transcriptomic and/or proteomic 
analysis of cytokine-sEV-treated BECs will be useful to dissect the mechanism of action 
involved. In parallel, staining of the main molecular players in endothelial cytoskeletal 
and TJ structure (such as ZO-1) would be beneficial to investigate the mechanism of 
action of sEVs on TEER. 
Among the different miRNAs studied, miRNA-155 was the only miRNA up-
regulated in the cargo of sEVs upon TNFα and IFNγ treatment (Chapter 3) and also after 
BECs were cultured with cytokine-sEVs (Chapter 4). MiRNA-155 levels have been 
widely described to be increased upon inflammation (O’Connell et al., 2007), in 
neuroinflammatory disorders (Devier, Lovera and Lukiw, 2015; Pogue and Lukiw, 2018) 
as well as linked to the modulation of the immune response (Wu and Chen, 2016) and 
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BBB function in inflammation (Lopez-Ramirez et al., 2014). Regarding the impact of 
sEVs-induced miRNA-155 on endothelial function, a small increase of expression of 
miRNA-155 was observed in the recipient BECs. However, the contribution of miRNA-
155 on sEV-induced BEC dysfunction still remains unknown. Future experiments 
involving modulation of miRNA-155 both in secreting and acceptor cells will help to 
elucidate the contribution of miRNA-155 to the total outcome of sEVs-induced 
phenotype in BECs. Given the highly heterogenous composition of sEVs and the low 
abundance of miRNAs per vesicle (Sork et al., 2018), it is very likely that miRNA-155 
might only partially contribute to the total outcome of the sEV-activated phenotype and 
that other molecular players (such as the already identified VCAM1) might have an input 
in modulating the observed phenotypes on target cells. sEVs are a whole package of 
information rather than a single signalling molecule, hence, future transcriptomic analysis 
of sEVs will reveal the different players involved in the pathogenesis of sEV-induced 
endothelial dysfunction. This experiment would be especially useful to identify novel 
signature of miRNAs/mRNAs involved in sEV-induced BEC dysfunction. 
On another note, how quiescent sEVs decreased the inflammatory effect of TNFα 
and IFNy in inducing leukocyte adhesion was described in this thesis (Chapter 4). This 
data are in accordance with the growing view that quiescent sEVs have a functional role 
in physiology (Isola and Chen, 2016). In the last years, researchers have reported that 
quiescent sEVs help to damp the inflammatory response (Njock, Cheng, et al., 2015), 
promote cell regeneration (Dorronsoro and Robbins, 2013) and angiogenesis (Salomon 
et al., 2013)  or decrease ischemic injury (Lai et al., 2010). Furthermore, there has been 
an increasing trend on studies evaluating the transfusion of blood from young donors to 
elderly individuals (Hofmann, 2018). This work has specially been characterised in mice 
where authors performed parabiosis procedure in a pair of young and old mice and 
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observed an improvement in restoring capability of muscle cells upon injury (Conboy et 
al., 2005). However, this approach is being questioned and there is no evidence than 
transfusion of blood from young to old patients improves patient survival (Edgren et al., 
2017). Nevertheless, these data stress the physiological role of sEVs, which might 
contribute to balance inflammation in brain endothelium. Future experiments analysing 
the role of quiescent sEVs modulating cerebrovascular function in inflammation in depth 
as well as the molecular mechanism involved will help elucidate the likelihood of this 
type of quiescent sEVS as a therapeutic tool. 
 
7.2. The interaction between miRNA-155 and WNK1 to modulate 
leukocyte adhesion to brain endothelium 
MiRNA-155 negatively regulates BBB function (paracellular permeability and T cell 
adhesion) and is associated with neurological pathologies (Lopez-Ramirez et al., 2014; 
Cerutti et al., 2016). The mechanism by which miRNA-155 increased T cell adhesion to 
BECs is largely unknown. In this work, miRNA-155 was shown to modulate leukocyte 
adhesion to BECs and WNK1 was identified as a possible target for miRNA-155. 
However, overexpression of miRNA-155 by pre-miRNA-155 transient transfection did 
not affect the levels of WNK1. The most likely conclusion is that WNK1 expression is 
not modulated by miRNA-155. However, analysis of binding sites between miRNA-155 
and WNK1 by luciferase assay and expression upon miRNA-155 inhibition might be 
useful to confirm this conclusion. There is still the unknown of the mechanism by which 
miRNA-155 modulates T cell adhesion to BECs. Future approaches could include a 
systematic analysis of the protein profile of hCMEC/D3 cells upon miRNA-155 
modulation to identified novel candidates for modulators of leukocyte adhesion to BECs.  
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Although the results of this study suggested that miRNA-155 did not regulate WNK1 
expression, WNK1 silencing led to increased T cell adhesion in brain endothelium. This 
is interesting because WNK1 function in endothelial cells is still largely unknown. Main 
focus of research has been given to the role of WNK1 in regulating angiogenesis and 
development. Conditioned deletion of endothelial wnk1 in mice led to smaller and 
collapsed vessels in the heart embryo (Xie et al., 2009). Endothelial WNK1 has also been 
linked to tumour cell proliferation and angiogenesis in hepatocarcinoma (Sie et al., 2020). 
Here, it was shown a novel function where loss of WNK1 in BECs led to increased 
leukocyte adhesion. This in accordance to an earlier report where WNK1 was proposed 
to be a negative regulator of adhesion in leukocytes. In this report, the authors suggested 
that the WNK1-repression of leukocyte adhesion is mediated via RAP1-induced LFA-1 
clustering (Köchl et al., 2016). However, activation of endothelial RAP1 is known to 
inhibit the NFκB pathway, hence, leading to decreased levels of VCAM1 and ICAM1 
(Ohmura et al., 2017). Therefore, it is likely that the mechanism by which endothelial 
WNK1 modulates the leukocyte adhesion to BECs is RAP1-independent. Proteomic 
analysis of WNK1 partners and affected molecules will help to elucidate how WNK1 
affect T cell adhesion. Identification of the molecular signalling by which WNK1 affects 
T cell adhesion on BECs will help to identify novel therapeutic targets to treat brain 
inflammation.  
Here, WNK1 is proposed as a potential modulator of leukocyte adhesion to BECs. 
Whether WNK1 expression might be modulated by sEVs remains unknown. Preliminary 
screening showed that WNK1 mRNA levels were down-regulated upon stimulation of 
hCMEC/D3 cells with cytokine-sEVs (data not shown). For this reason, it is likely that 
WNK1 might contribute to the sEV-induced leukocyte adhesion (Figure 7.1). Future 
analysis of WNK1 expression as well as artificial overexpression of WNK1 upon sEV 
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treatment might help elucidate this pathway. However, future characterisation will also 
help to elucidate whether vesicular miRNA-155 affects sEV-induced T cell adhesion via 
down-regulation of WNK1 or other signalling proteins (Figure 7.1). 
 
7.3. MiRNA-155 KO mouse model showing polydipsia as novel tool 
for the identification of new molecular players in the modulation of 
water balance 
 
A systematic study on miRNA-155 KO mice revealed that female aged miRNA-
155 KO mice developed polydipsia and presented more diluted urine (Chapter 6). Data 
suggested that these mice were not suffering from diabetes insipidus or diabetes mellitus. 
In fact, it was likely that phenotype was caused by a defect in kidney function. In this 
chapter, it was shown alterations at the levels of ion co-transporter, NKCC2, and its 
upstream regulator WNK1u. However, generation of new inbred miRNA-155 KO mouse 
line failed to replicate the observed phenotype. For this reason, it is likely that possibly 
both polydipsia and diluted urine observed in female aged miRNA-155 KO mice was 
caused by a miRNA-155 independent mechanism. 
Although these mice showed Bartter-like phenotype, the onset of the pathology 
was observed at a latter age. Batter syndrome is characterised by the loss of function of 
NKCC2 which leads to early development of water balance problems such as polyuria 
(Fulchiero and Seo-Mayer, 2019). Hence, it is likely that the mechanism by which 
NKCC2 is affected in this mouse model differs from classical Bartter Syndrome. This is 
especially relevant since the phenotype was strongly observed in female mice rather male 
mice. Future analysis of RNA and/or DNA sequencing will help to reveal differences of 
expression and/or intrinsic mutation developed in this polydipsia animal line that might 
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explained the phenotype. Therefore, the tissue collected from this model might be useful 
for the identification of novel genes, mutation and/or allele variations that are involved in 
water balance. Changes in the composition and volume of body fluids are critical factors 
in physiology and especially in the aging population. Discovery of novel molecules or 
mutations that might enhance the development of these disorders with age is of utmost 
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Table Annexe 1. List of down-regulated proteins upon miRNA-155 overexpression 





GPR172B Porcine endogenous retrovirus A receptor 2 -6.573499609 
GPC2 Glypican-2 -5.097038479 
IRAK1BP1 Interleukin-1 receptor-associated kinase 1-binding protein 1 -4.98602902 
SHISA6 Protein shisa-6 homolog -4.579812381 
COL5A3 Collagen alpha-3(V) chain -3.680521316 
SNAP47 Synaptosomal-associated protein 47 -3.559763293 
NF1 Neurofibromin -3.554077579 
ECSCR Endothelial cell-specific chemotaxis regulator -3.411596802 
TNKS Tankyrase-1 -2.940077139 
C7orf51 Uncharacterized protein C7orf51 -2.930906657 
C10orf113 Putative uncharacterized protein C10orf113 -2.610237205 
DSTYK Dual serine/threonine and tyrosine protein kinase -2.600620234 
KIAA1210 Uncharacterized protein KIAA1210 -2.550454558 
EPCAM Epithelial cell adhesion molecule -2.543137532 
SYNPO2 Synaptopodin-2 -2.528653089 
PDILT Protein disulfide-isomerase-like protein of the testis -2.483061619 
FAM177A1 Protein FAM177A1 -2.467761733 
SHMT1 Serine hydroxymethyltransferase, cytosolic -2.448859795 
SLC8A2 Sodium/calcium exchanger 2 -2.438917161 
ATP12A Potassium-transporting ATPase alpha chain 2 -2.287141484 
RAB32 Ras-related protein Rab-32 -2.246461 
BTBD11 Ankyrin repeat and BTB/POZ domain-containing protein BTBD11 -2.200011173 
NFAT5 Nuclear factor of activated T-cells 5 -2.185314653 
C20orf12 Ankyrin repeat-containing protein C20orf12 -2.082872757 
FAM149B1 Protein FAM149B1 -2.068396498 
ADAM19 Disintegrin and metalloproteinase domain-containing protein 19 -2.041798274 
VTCN1 V-set domain-containing T-cell activation inhibitor 1 -2.009195762 
PRR18 Proline-rich protein 18 -1.957308087 
PKD1L1 Polycystic kidney disease protein 1-like 1 -1.899347811 
CLMN Calmin -1.753753757 
XKR8 XK-related protein 8 -1.732026112 
TJP1 Tight junction protein ZO-1 -1.72866411 
KLK11 Kallikrein-11 -1.72742747 
ZNHIT6 Box C/D snoRNA protein 1 -1.718414934 
SCMH1 Polycomb protein SCMH1 -1.709655346 
SCARB1 Scavenger receptor class B member 1 -1.646674008 
RIMBP3 RIMS-binding protein 3A -1.611776888 
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NPTXR Neuronal pentraxin receptor -1.608556553 
KCNK17 Potassium channel subfamily K member 17 -1.598210699 
C12orf48 UPF0419 protein C12orf48 -1.596980353 
HSP90AA4P Putative heat shock protein HSP 90-alpha A4 -1.56543253 
MXRA5 Matrix-remodeling-associated protein 5 -1.538278321 
BBOX1 Gamma-butyrobetaine dioxygenase -1.526938002 
PCSK7 Proprotein convertase subtilisin/kexin type 7 -1.524728463 
SKT Sickle tail protein homolog -1.441177713 
C3orf49 Putative uncharacterized protein C3orf49 -1.435667216 
SNX27 Sorting nexin-27 -1.420500264 
PPP1R12C Protein phosphatase 1 regulatory subunit 12C -1.388785292 
SBF2 Myotubularin-related protein 13 -1.383145647 
ZNF516 Zinc finger protein 516 -1.35275685 
C12orf23 UPF0444 transmembrane protein C12orf23 -1.337560802 
FREM2 FRAS1-related extracellular matrix protein 2 -1.324441655 
PRSS48 Serine protease 48 -1.317423428 
EDRF1 Erythroid differentiation-related factor 1 -1.270618158 
GATA5 Transcription factor GATA-5 -1.259009753 
MKLN1 Muskelin -1.255582648 
DDX10 Probable ATP-dependent RNA helicase DDX10 -1.248722335 
SYT13 Synaptotagmin-13 -1.239740292 
CNTN1 Contactin-1 -1.237682211 
PCDHGC5 Protocadherin gamma-C5 -1.230589056 
RPS15A 40S ribosomal protein S15a -1.177520681 
CD38 ADP-ribosyl cyclase 1 -1.161149583 
RAET1E NKG2D ligand 4 -1.160918575 
WIZ Protein Wiz -1.157660849 
SMAP2 Stromal membrane-associated protein 2 -1.153242992 
NOTUM Protein notum homolog -1.152227137 
CCDC137 Coiled-coil domain-containing protein 137 -1.150178062 
GARNL3 GTPase-activating Rap/Ran-GAP domain-like protein 3 -1.137866833 
ACTN3 Alpha-actinin-3 -1.131040638 
BTNL8 Butyrophilin-like protein 8 -1.125649598 
INVS Inversin -1.124046593 
RBM15 Putative RNA-binding protein 15 -1.123632957 
NME2P1 Putative nucleoside diphosphate kinase -1.118370773 
HAGH Hydroxyacylglutathione hydrolase, mitochondrial -1.105376122 
SLC25A22 Mitochondrial glutamate carrier 1 -1.101444379 
ART5 Ecto-ADP-ribosyltransferase 5 -1.093989365 
MMP12 Macrophage metalloelastase -1.081724855 
SPACA3 Sperm acrosome membrane-associated protein 3 -1.079358343 
ACCN4 Amiloride-sensitive cation channel 4 -1.079260354 
LRRFIP2 Leucine-rich repeat flightless-interacting protein 2 -1.064664611 
PRDM16 PR domain zinc finger protein 16 -1.059781517 
TCF9 GC-rich sequence DNA-binding factor -1.04793267 
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OR52N5 Olfactory receptor 52N5 -1.046461165 
CRTC3 CREB-regulated transcription coactivator 3 -1.04338933 
AMT Aminomethyltransferase, mitochondrial -1.034334695 
REL Proto-oncogene c-Rel -1.031438749 
HMGN2 Non-histone chromosomal protein HMG-17 -1.025997705 
CHST2 Carbohydrate sulfotransferase 2 -1.025690969 
CCDC69 Coiled-coil domain-containing protein 69 -1.025340905 
EIF3I Eukaryotic translation initiation factor 3 subunit I -1.02233408 
AACS Acetoacetyl-CoA synthetase -1.021726301 
WNK1 Serine/threonine-protein kinase WNK1 -1.018683046 
REEP6 Receptor expression-enhancing protein 6 -1.016549682 
MOV10L1 Putative helicase Mov10l1 -1.002250891 
ARHGEF18 Rho guanine nucleotide exchange factor 18 -1.000863722 
 
 
